CN109942523B - 一类苯并呋喃及苯并呋喃香豆素衍生物及其制备方法和应用 - Google Patents
一类苯并呋喃及苯并呋喃香豆素衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- CN109942523B CN109942523B CN201711387365.4A CN201711387365A CN109942523B CN 109942523 B CN109942523 B CN 109942523B CN 201711387365 A CN201711387365 A CN 201711387365A CN 109942523 B CN109942523 B CN 109942523B
- Authority
- CN
- China
- Prior art keywords
- nmr
- compound
- preparation
- benzofuran
- cdcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 243
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 title claims abstract description 66
- -1 benzofuran coumarin derivatives Chemical class 0.000 title description 99
- 150000001875 compounds Chemical class 0.000 claims abstract description 244
- 201000008827 tuberculosis Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 12
- 101150091632 pks13 gene Proteins 0.000 claims abstract description 9
- 108010030975 Polyketide Synthases Proteins 0.000 claims abstract description 6
- 239000012634 fragment Substances 0.000 claims abstract description 6
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 claims abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229940123982 Cell wall synthesis inhibitor Drugs 0.000 claims description 2
- CFNMUZCFSDMZPQ-GHXNOFRVSA-N 7-[(z)-3-methyl-4-(4-methyl-5-oxo-2h-furan-2-yl)but-2-enoxy]chromen-2-one Chemical compound C=1C=C2C=CC(=O)OC2=CC=1OC/C=C(/C)CC1OC(=O)C(C)=C1 CFNMUZCFSDMZPQ-GHXNOFRVSA-N 0.000 claims 5
- 150000004775 coumarins Chemical class 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 229930016834 coumestan Chemical class 0.000 abstract description 24
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 13
- 230000015572 biosynthetic process Effects 0.000 abstract description 11
- 230000009471 action Effects 0.000 abstract description 9
- 210000002421 cell wall Anatomy 0.000 abstract description 9
- 238000003786 synthesis reaction Methods 0.000 abstract description 8
- 239000002253 acid Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 244000005700 microbiome Species 0.000 abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 233
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 190
- 239000012467 final product Substances 0.000 description 130
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 96
- 239000003153 chemical reaction reagent Substances 0.000 description 92
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 89
- 239000007858 starting material Substances 0.000 description 89
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 66
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 64
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 52
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 52
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 40
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
- 229910052757 nitrogen Inorganic materials 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 31
- 239000000243 solution Substances 0.000 description 31
- 238000005406 washing Methods 0.000 description 31
- LIQVEXOTZPWBDF-UHFFFAOYSA-N 1-benzofuran-3-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=COC2=C1 LIQVEXOTZPWBDF-UHFFFAOYSA-N 0.000 description 30
- 239000002904 solvent Substances 0.000 description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 27
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 26
- 239000003208 petroleum Substances 0.000 description 25
- 238000001035 drying Methods 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- 239000002994 raw material Substances 0.000 description 21
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
- 230000004224 protection Effects 0.000 description 20
- 125000000217 alkyl group Chemical group 0.000 description 19
- 238000010791 quenching Methods 0.000 description 19
- 230000000171 quenching effect Effects 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 18
- 238000010992 reflux Methods 0.000 description 18
- 229910052739 hydrogen Inorganic materials 0.000 description 17
- 239000001257 hydrogen Substances 0.000 description 17
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 16
- 238000004809 thin layer chromatography Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 15
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 14
- DWPLEOPKBWNPQV-UHFFFAOYSA-N 1-(2-methoxyphenyl)ethanone Chemical compound COC1=CC=CC=C1C(C)=O DWPLEOPKBWNPQV-UHFFFAOYSA-N 0.000 description 13
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 125000003545 alkoxy group Chemical group 0.000 description 13
- 239000012043 crude product Substances 0.000 description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 11
- 229910052736 halogen Inorganic materials 0.000 description 11
- 150000002367 halogens Chemical class 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 11
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- 239000005457 ice water Substances 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- KZMZPNIZGCMWGG-UHFFFAOYSA-N 1-(2-chlorophenyl)-2-methoxyethanone Chemical compound COCC(=O)C1=CC=CC=C1Cl KZMZPNIZGCMWGG-UHFFFAOYSA-N 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 9
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 9
- BENJFDPHDCGUAQ-UHFFFAOYSA-N 1-benzofuran-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=COC2=C1 BENJFDPHDCGUAQ-UHFFFAOYSA-N 0.000 description 8
- QXJDOADTRZGPJZ-UHFFFAOYSA-N 1-benzothiophene-3-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=CSC2=C1 QXJDOADTRZGPJZ-UHFFFAOYSA-N 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 125000001931 aliphatic group Chemical group 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 7
- ZDPAWHACYDRYIW-UHFFFAOYSA-N 1-(4-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(F)C=C1 ZDPAWHACYDRYIW-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 125000004430 oxygen atom Chemical group O* 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 125000004434 sulfur atom Chemical group 0.000 description 6
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 5
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 5
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- NCCTVAJNFXYWTM-UHFFFAOYSA-N 2-tert-butylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)(C)C1=CC(=O)C=CC1=O NCCTVAJNFXYWTM-UHFFFAOYSA-N 0.000 description 4
- KGWNRZLPXLBMPS-UHFFFAOYSA-N 2h-1,3-oxazine Chemical compound C1OC=CC=N1 KGWNRZLPXLBMPS-UHFFFAOYSA-N 0.000 description 4
- NTPLXRHDUXRPNE-UHFFFAOYSA-N 4-methoxyacetophenone Chemical compound COC1=CC=C(C(C)=O)C=C1 NTPLXRHDUXRPNE-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 4
- GKKZMYDNDDMXSE-UHFFFAOYSA-N Ethyl 3-oxo-3-phenylpropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=CC=C1 GKKZMYDNDDMXSE-UHFFFAOYSA-N 0.000 description 4
- CRZQGDNQQAALAY-UHFFFAOYSA-N Methyl benzeneacetate Chemical compound COC(=O)CC1=CC=CC=C1 CRZQGDNQQAALAY-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 4
- 230000002365 anti-tubercular Effects 0.000 description 4
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 4
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 description 4
- 229960003350 isoniazid Drugs 0.000 description 4
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 150000003141 primary amines Chemical class 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 150000003512 tertiary amines Chemical class 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- VQTDPCRSXHFMOL-UHFFFAOYSA-N 2,4-Dimethoxyacetophenone Chemical compound COC1=CC=C(C(C)=O)C(OC)=C1 VQTDPCRSXHFMOL-UHFFFAOYSA-N 0.000 description 3
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 3
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 3
- HUGPVFHLSSCVSM-UHFFFAOYSA-N 4-methylsulfonyl-2-nitrobenzaldehyde Chemical compound CS(=O)(=O)C1=CC=C(C=O)C([N+]([O-])=O)=C1 HUGPVFHLSSCVSM-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 150000001335 aliphatic alkanes Chemical group 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- SBTSVTLGWRLWOD-UHFFFAOYSA-L copper(ii) triflate Chemical compound [Cu+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F SBTSVTLGWRLWOD-UHFFFAOYSA-L 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- AJPPKGMEHMXPMC-UHFFFAOYSA-N methyl 2-(4-fluorophenyl)acetate Chemical compound COC(=O)CC1=CC=C(F)C=C1 AJPPKGMEHMXPMC-UHFFFAOYSA-N 0.000 description 3
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 3
- 229960002218 sodium chlorite Drugs 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 229940005561 1,4-benzoquinone Drugs 0.000 description 2
- FAXUIYJKGGUCBO-UHFFFAOYSA-N 1-(2,5-dimethoxyphenyl)ethanone Chemical compound COC1=CC=C(OC)C(C(C)=O)=C1 FAXUIYJKGGUCBO-UHFFFAOYSA-N 0.000 description 2
- OSBUMVWTNSHAAG-UHFFFAOYSA-N 1-(2-methoxy-4,5-dimethylphenyl)ethanone Chemical compound COC1=CC(C)=C(C)C=C1C(C)=O OSBUMVWTNSHAAG-UHFFFAOYSA-N 0.000 description 2
- FHIOYMGCAXTUGF-UHFFFAOYSA-N 1-(2-methoxy-5-methylphenyl)ethanone Chemical compound COC1=CC=C(C)C=C1C(C)=O FHIOYMGCAXTUGF-UHFFFAOYSA-N 0.000 description 2
- YOXBPWVWNQROBJ-UHFFFAOYSA-N 1-(4-fluoro-2-methoxyphenyl)ethanone Chemical compound COC1=CC(F)=CC=C1C(C)=O YOXBPWVWNQROBJ-UHFFFAOYSA-N 0.000 description 2
- SMYGXKPXKKOIED-UHFFFAOYSA-N 1-(5-hydroxy-2-methylsulfanyl-1-benzofuran-3-yl)ethanone Chemical compound CC(=O)C1=C(OC2=C1C=C(C=C2)O)SC SMYGXKPXKKOIED-UHFFFAOYSA-N 0.000 description 2
- HZIKQUPQHICAGZ-UHFFFAOYSA-N 2-(4-fluorophenyl)-5-hydroxy-1-benzofuran-3-carboxylic acid Chemical compound O1C2=CC=C(O)C=C2C(C(=O)O)=C1C1=CC=C(F)C=C1 HZIKQUPQHICAGZ-UHFFFAOYSA-N 0.000 description 2
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 2
- ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 2
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- VPXJSTOFWHBSEJ-UHFFFAOYSA-N 5h-quinolin-6-one Chemical compound C1=CN=C2C=CC(=O)CC2=C1 VPXJSTOFWHBSEJ-UHFFFAOYSA-N 0.000 description 2
- PJLHJVCEKHYUHV-UHFFFAOYSA-N 6-phenylpyran-2-one Chemical compound O1C(=O)C=CC=C1C1=CC=CC=C1 PJLHJVCEKHYUHV-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 2
- GVLQCEROENZYNW-UHFFFAOYSA-N CS(=O)(=O)C(=C(C(C)=O)C(C)=O)S(=O)(=O)C Chemical compound CS(=O)(=O)C(=C(C(C)=O)C(C)=O)S(=O)(=O)C GVLQCEROENZYNW-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 2
- 108700035964 Mycobacterium tuberculosis HsaD Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101100203604 Penicillium rubens (strain ATCC 28089 / DSM 1075 / NRRL 1951 / Wisconsin 54-1255) sorA gene Proteins 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000012996 alamarblue reagent Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- GRTGGSXWHGKRSB-UHFFFAOYSA-N dichloromethyl methyl ether Chemical compound COC(Cl)Cl GRTGGSXWHGKRSB-UHFFFAOYSA-N 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 2
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- WPFRDBXLDHXFKL-UHFFFAOYSA-N ethyl 2-(3-methylbutyl)-8-phenyl-1,3-dihydrofuro[3,2-f][1,3]benzoxazine-9-carboxylate Chemical compound CCOC(=O)c1c(oc2ccc3OCN(CCC(C)C)Cc3c12)c4ccccc4 WPFRDBXLDHXFKL-UHFFFAOYSA-N 0.000 description 2
- PCOIFIVNARQEPO-UHFFFAOYSA-N ethyl 2-(4-fluorophenyl)-5-hydroxy-1-benzofuran-3-carboxylate Chemical compound O1C2=CC=C(O)C=C2C(C(=O)OCC)=C1C1=CC=C(F)C=C1 PCOIFIVNARQEPO-UHFFFAOYSA-N 0.000 description 2
- FPCIXPPKPCWDCQ-UHFFFAOYSA-N ethyl 2-(cyclopropylmethyl)-8-(2-methoxy-5-methylphenyl)-1,3-dihydrofuro[3,2-f][1,3]benzoxazine-9-carboxylate Chemical compound CCOC(=O)c1c(oc2ccc3OCN(CC4CC4)Cc3c12)c5cc(C)ccc5OC FPCIXPPKPCWDCQ-UHFFFAOYSA-N 0.000 description 2
- JJFBILCBLXDEAP-UHFFFAOYSA-N ethyl 2-(cyclopropylmethyl)-8-phenyl-1,3-dihydrofuro[3,2-f][1,3]benzoxazine-9-carboxylate Chemical compound CCOC(=O)c1c(oc2ccc3OCN(CC4CC4)Cc3c12)c5ccccc5 JJFBILCBLXDEAP-UHFFFAOYSA-N 0.000 description 2
- YJKNHSOLAVSDIL-UHFFFAOYSA-N ethyl 2-cyclopropyl-8-phenyl-1,3-dihydrofuro[3,2-f][1,3]benzoxazine-9-carboxylate Chemical compound CCOC(=O)c1c(oc2ccc3OCN(Cc3c12)C4CC4)c5ccccc5 YJKNHSOLAVSDIL-UHFFFAOYSA-N 0.000 description 2
- SJUXLKYJKQBZLM-UHFFFAOYSA-N ethyl 3-(4-fluorophenyl)-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=C(F)C=C1 SJUXLKYJKQBZLM-UHFFFAOYSA-N 0.000 description 2
- ZZEJIZHZTDVNRS-UHFFFAOYSA-N ethyl 4-(4-methoxyphenyl)-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)CC1=CC=C(OC)C=C1 ZZEJIZHZTDVNRS-UHFFFAOYSA-N 0.000 description 2
- BFAOOZMVTRWJKF-UHFFFAOYSA-N ethyl 5-methoxy-2-phenyl-4-(piperidine-1-carbonyl)-1-benzofuran-3-carboxylate Chemical compound COC=1C=CC2=C(C(=C(O2)C2=CC=CC=C2)C(=O)OCC)C=1C(=O)N1CCCCC1 BFAOOZMVTRWJKF-UHFFFAOYSA-N 0.000 description 2
- VPPWBXBHAPIDFS-UHFFFAOYSA-N ethyl 5-methoxy-2-phenyl-6-(piperidine-1-carbonyl)-1-benzofuran-3-carboxylate Chemical compound COC=1C(=CC2=C(C(=C(O2)C2=CC=CC=C2)C(=O)OCC)C=1)C(=O)N1CCCCC1 VPPWBXBHAPIDFS-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 2
- 229960000203 propafenone Drugs 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- 239000000814 tuberculostatic agent Substances 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- KCDIOLSWKWRQKY-UHFFFAOYSA-N (2-methoxyphenyl)methyl 3-oxobutanoate Chemical compound COC1=CC=CC=C1COC(=O)CC(C)=O KCDIOLSWKWRQKY-UHFFFAOYSA-N 0.000 description 1
- KYZHKXMHJFOQPM-UHFFFAOYSA-N 1-(4-bromo-2-methoxyphenyl)ethanone Chemical compound COC1=CC(Br)=CC=C1C(C)=O KYZHKXMHJFOQPM-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- HHAISVSEJFEWBZ-UHFFFAOYSA-N 1-[4-(trifluoromethyl)phenyl]ethanone Chemical compound CC(=O)C1=CC=C(C(F)(F)F)C=C1 HHAISVSEJFEWBZ-UHFFFAOYSA-N 0.000 description 1
- DRBLTQNCQJXSNU-UHFFFAOYSA-N 1-benzothiophene-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CSC2=C1 DRBLTQNCQJXSNU-UHFFFAOYSA-N 0.000 description 1
- AIACLXROWHONEE-UHFFFAOYSA-N 2,3-dimethylcyclohexa-2,5-diene-1,4-dione Chemical group CC1=C(C)C(=O)C=CC1=O AIACLXROWHONEE-UHFFFAOYSA-N 0.000 description 1
- NNWUEBIEOFQMSS-UHFFFAOYSA-N 2-Methylpiperidine Chemical compound CC1CCCCN1 NNWUEBIEOFQMSS-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- XNHKTMIWQCNZST-UHFFFAOYSA-N 2-bromo-5-methoxybenzaldehyde Chemical compound COC1=CC=C(Br)C(C=O)=C1 XNHKTMIWQCNZST-UHFFFAOYSA-N 0.000 description 1
- PYEQXZOIQJWYAH-UHFFFAOYSA-N 2-bromocyclohexa-2,5-diene-1,4-dione Chemical compound BrC1=CC(=O)C=CC1=O PYEQXZOIQJWYAH-UHFFFAOYSA-N 0.000 description 1
- GGOUKXJLOUNPFF-UHFFFAOYSA-N 2-methoxy-1-(2-methylphenyl)ethanone Chemical compound COCC(=O)C1=CC=CC=C1C GGOUKXJLOUNPFF-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- GQOVTYSQMKNHAT-UHFFFAOYSA-N 2h-chromene-7-carboxamide Chemical compound C1=CCOC2=CC(C(=O)N)=CC=C21 GQOVTYSQMKNHAT-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- JEGMWWXJUXDNJN-UHFFFAOYSA-N 3-methylpiperidine Chemical compound CC1CCCNC1 JEGMWWXJUXDNJN-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- HRXZRAXKKNUKRF-UHFFFAOYSA-N 4-ethylaniline Chemical compound CCC1=CC=C(N)C=C1 HRXZRAXKKNUKRF-UHFFFAOYSA-N 0.000 description 1
- UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- CRRSIUBBUSEXIN-UHFFFAOYSA-N 5-hydroxy-2-phenyl-1-benzofuran-3-carboxylic acid Chemical compound O1C2=CC=C(O)C=C2C(C(=O)O)=C1C1=CC=CC=C1 CRRSIUBBUSEXIN-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- WOFAGNLBCJWEOE-UHFFFAOYSA-N Benzyl acetoacetate Chemical compound CC(=O)CC(=O)OCC1=CC=CC=C1 WOFAGNLBCJWEOE-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- GUSANBRNBREBPL-TZTIVRRBSA-N alpha-D-Ara-(1->5)-alpha-D-Ara-(1->3)-[alpha-D-Ara-(1->5)]-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->2)-[alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)-[alpha-D-Man-(1->2)]-alpha-D-Man-(1->6)-alpha-D-Man-(1->6)-alpha-D-Man Chemical compound OC[C@H]1O[C@H](OC[C@H]2O[C@H](O[C@H]3[C@H](O)[C@@H](OC[C@H]4O[C@H](OC[C@H]5O[C@H](O[C@H]6[C@@H](O)[C@H](O)[C@@H](CO[C@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]7O)O[C@@H]6OC[C@H]6O[C@H](OC[C@H]7O[C@H](OC[C@H]8O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H](O)[C@@H]7O)[C@@H](O[C@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)O[C@@H]3CO[C@H]3O[C@H](CO)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O GUSANBRNBREBPL-TZTIVRRBSA-N 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940124976 antitubercular drug Drugs 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 150000004982 aromatic amines Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940045803 cuprous chloride Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- CGULTTSJZGXDBD-NTMALXAHSA-N ethyl (z)-3-amino-3-phenylprop-2-enoate Chemical compound CCOC(=O)\C=C(/N)C1=CC=CC=C1 CGULTTSJZGXDBD-NTMALXAHSA-N 0.000 description 1
- GCGQCAKHYXBFSZ-UHFFFAOYSA-N ethyl 2-(2,4-dimethoxyphenyl)acetate Chemical compound CCOC(=O)CC1=CC=C(OC)C=C1OC GCGQCAKHYXBFSZ-UHFFFAOYSA-N 0.000 description 1
- RNNQUXSAPFQIOP-UHFFFAOYSA-N ethyl 2-(2,5-dimethoxyphenyl)acetate Chemical compound CCOC(=O)CC1=CC(OC)=CC=C1OC RNNQUXSAPFQIOP-UHFFFAOYSA-N 0.000 description 1
- YPIMSZIOKNFNEV-UHFFFAOYSA-N ethyl 2-(cyclopropylmethyl)-8-(4-methoxyphenyl)-1,3-dihydrofuro[3,2-f][1,3]benzoxazine-9-carboxylate Chemical compound CCOC(=O)c1c(oc2ccc3OCN(CC4CC4)Cc3c12)c5ccc(OC)cc5 YPIMSZIOKNFNEV-UHFFFAOYSA-N 0.000 description 1
- IJKGAETWIFHTMH-UHFFFAOYSA-N ethyl 2-(cyclopropylmethyl)-8-(4-methylphenyl)-1,3-dihydrofuro[3,2-f][1,3]benzoxazine-9-carboxylate Chemical compound CCOC(=O)c1c(oc2ccc3OCN(CC4CC4)Cc3c12)c5ccc(C)cc5 IJKGAETWIFHTMH-UHFFFAOYSA-N 0.000 description 1
- UTHZUODGIWFCOP-UHFFFAOYSA-N ethyl 4-(2-methoxyphenyl)-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)CC1=CC=CC=C1OC UTHZUODGIWFCOP-UHFFFAOYSA-N 0.000 description 1
- KBNNDJXTUQSJOF-UHFFFAOYSA-N ethyl 4-(3-methoxyphenyl)-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)CC1=CC=CC(OC)=C1 KBNNDJXTUQSJOF-UHFFFAOYSA-N 0.000 description 1
- PYZHPBAVFIBPMF-UHFFFAOYSA-N ethyl 5-hydroxy-2-(2-methoxyphenyl)-1-benzofuran-3-carboxylate Chemical compound O1C2=CC=C(O)C=C2C(C(=O)OCC)=C1C1=CC=CC=C1OC PYZHPBAVFIBPMF-UHFFFAOYSA-N 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229940127285 new chemical entity Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003129 oil well Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- XBXHCBLBYQEYTI-UHFFFAOYSA-N piperidin-4-ylmethanol Chemical compound OCC1CCNCC1 XBXHCBLBYQEYTI-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical class [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明公开了如式(I)、(II)、(III)、(IV)所示的苯并呋喃类及Coumestans衍生物及其制备方法,以及所述苯并呋喃类及Coumestans衍生物化合物在治疗耐多药性肺结核疾病中的应用。本发明所述苯并呋喃类及Coumestans衍生物是一类结构新颖,抑菌效果显著的抗结核杆菌化合物,它是以结核杆菌pks13基因片段编码的聚酮合酶为作用靶点,抑制微生物的生长繁殖,尤其是抑制结核分枝杆菌细胞壁中分枝菌酸的合成,在医药领域具有潜在的应用前景。
Description
技术领域
本发明涉及药物化学领域,具体涉及一类苯并呋喃及Coumestans衍生物的制备方法和应用。
背景技术
结核病是一种迄今为止仍在全球范围内维持高发病率和死亡率的传染病之一,根据世界卫生组织的调查报告,每年有约800万人感染肺结核,超过160万人死于此病,同时由于一线药物,如异烟肼、利福平、乙胺丁醇等的广泛使用,使得耐药性、广泛耐药性结核病例呈上升趋势,结核病和艾滋病共同感染现象也迅速蔓延,亟待一种新结构和新靶点的抗结核药物来扼制肺结核病情的扩散。
结核杆菌是导致结核病的病原体,属于结核分枝杆菌(Mycobacterium)属,与其他引起重大传染性疾病的病原体相比,结核杆菌最大的特点在于其具有独特的细胞结构——细胞壁,其细胞壁主要由肽聚糖、***甘露糖糖脂、***半乳聚糖、分枝菌酸及其它脂类构成。有关研究表明:结核杆菌的很多致病因素与其细胞壁的结构有着十分密切的关系,这种构造不仅能抵御人体内免疫***的攻击,还可抑制外来化合物对菌体的干扰,同时独特的细胞壁结构赋予了结核分枝杆菌对多种抗结核药物的耐药性。许多抗结核药物不易穿透细胞壁结构,大大削减了结核病治疗过程中的疗效,延长了治疗周期,加重了病患的负担。
分枝菌酸是一类2‐烷基,3‐羟基长链脂肪酸,它与结核杆菌细胞壁形成密切相关,参与结核杆菌的细胞壁形成,Pks13是分枝菌酸合成途径中重要的靶蛋白,也是抗结核药物研发中的一个新靶点。
发明内容
本发明提供了一种苯并呋喃及天然产物Coumestans衍生物新化学实体,及其制备方法,所述苯并呋喃及天然产物Coumestans衍生物是抗结核活性更强的靶标化合物,同时对其进行小鼠体内试验,实验表明,此类化合物具有良好的生物利用度和抑菌活性,为该类化合物进入临床研究奠定基础,为抗肺结核药物研究提供条件。
根据本发明,所述的苯并呋喃及Coumestans衍生物结构通式如下式(I)、(II)、(III)、(IV)所示:
本发明中,所述苯并呋喃及Coumestans衍生物其结构如式(I)所示:
其中,X为氮原子、氧原子或硫原子;
R1是氢、羟基、甲氧基、乙氧基、甲氧基乙基醚或酯;
其中,Ra可为三元至八元脂肪环,含N,O,S中杂原子的三元至八元脂肪环,有取代的三元至八元脂肪环如C1‐C4烷基、羟基烷基、胺烷基、甲氧基或三元至八元内酰胺,开链结构的伯胺结构基团(即),N‐单直链烷烃或环烷烃取代的仲胺结构基团(即/>),N,N-双直链烷烃或环烷烃取代的叔胺结构基团/>(其中Rb选自氢、C1-C8烷基或C3-C8的环烷基,Rc选自氢、C1-C8烷基或C3-C8的环烷基;其中Rb、Rc可以相同,也可以不同);/>
优选地,R2为C2~C8的环烷基结构基团(即),含杂原子C2‐C8环烷基(即),取代的C2‐C8环烷基为(即/>),链结构的伯胺结构基团(即/>),N‐单直链烷烃或环烷烃取代的仲胺结构基团(即/>如乙胺基、丙胺基、环丙胺基、环丙烷亚甲胺基、环戊胺基或环己基胺基),N,N-双直链烷烃或环烷烃取代的叔胺结构基团(即其中Ra选自氢、C1-C8烷基或C3-C8的环烷基,Rb选自氢、C1-C8烷基或C3-C8的环烷基(如N,N二丙基胺基);
Ra为三元至八元脂肪环,含N,O,S中杂原子的三元至八元脂肪环结构,有取代的三元至八元脂肪环,有C1‐C4烷基、羟基烷基、胺基烷基取代的含N、O、S杂原子的三元至八元脂肪环,开链结构的伯胺结构基团(即),N‐单直链烷烃或环烷烃取代的仲胺结构基团(即/>其中Rb为氢、C1-C8烷基或C3-C8的环烷基),N,N-双直链烷烃或环烷烃取代的叔胺结构基团/>(其中Rb选自氢、C1-C8烷基或C3-C8的环烷基;Rc选自氢、C1-C8烷基或C3-C8的环烷基;其中Rb、Rc可以相同,也可以不同);
R3为羟基、C1~C8烷基、C1~C8烷氧基、C3~C8环烷基、螺环基、桥环基、金刚烷、脂肪胺基或芳香胺基;其中R3为芳香胺基时,芳香环上可各自独立的为以下取代基:羟基、C1~C8烷基、C1~C8烷氧基、卤素、硝基、三氟甲基、巯基或胺基;
进一步优选地,R3为羟基、甲基、乙氧基、乙胺基、甲胺基、苯胺基、苄胺基或金刚烷胺基;
R4可为苯环、取代苯基、甲硫基或各种取代胺基,其中:
1.当R4为取代胺基时,可具体为:C2~C9的环胺基结构基团其中m=1‐8;含氮饱和杂环;开链结构的伯胺结构基团/>N‐单直链烷烃或环烷烃取代的仲胺结构基团N,N-双直链烷烃或环烷烃取代的叔胺结构基团/>其中Rb选自氢、C1-C8烷基或C3-C8的环烷基,Rc选自氢、C1-C8烷基或C3-C8的环烷基,Rb,Rc可以相同也可以不同;芳香胺基,其中芳香环上可各自独立的为以下取代基:羟基、C1~C8烷基、C1~C8烷氧基、卤素、硝基、三氟甲基、巯基或胺基;
2.当R4为取代苯基时,苯环上各取代基可各自独立的为以下取代基:卤素、羟基、C1~C8烷基、C1~C8烷氧基、硝基、三氟甲基、甲氧基、巯基、胺基、氰基、脂肪胺基或亚甲基哌啶基;具体优选基团参见下表1。
R5可为卤素、羟基、C1~C8烷基、C1~C8烷氧基、硝基、三氟甲基、甲氧基、巯基、胺基、氰基、亚甲基哌啶基或环己基酰胺基;具体优选基团参见下表1。
R6可为氢、卤素、羟基、烷基、硝基、氨基、三氟甲基、烷氧基或苯基;
本发明中,所述苯并呋喃及Coumestans衍生物其结构如式(II)所示
其中,X为氮原子、氧原子或硫原子;
R7可以是C2‐C5的直链烷基或C3‐C8环烷基;
R3可为羟基、烷基、烷氧基、芳香胺基或脂肪胺基;其中R3为芳香胺基时,芳香环上可各自独立的为以下取代基:羟基、烷基、烷氧基、卤素、硝基、三氟甲基或甲氧基;
R为芳香环,芳香环上各取代基可各自独立的为以下取代基:氢、卤素、羟基、烷基、硝基、氨基、三氟甲基、烷氧基、氰基、脂肪胺基或亚甲基哌啶基;
本发明中,所述苯并呋喃及Coumestans衍生物其结构如式(III)所示:
其中,R7可为C2~C5的直链烷基或C3‐C8环烷基;
X为氮原子、氧原子或硫原子;
Y为氮原子、氧原子或硫原子;
R为芳香环,芳香环上各取代基可各自独立的为以下取代基:氢、卤素、羟基、烷基、硝基、氨基、三氟甲基、烷氧基、氰基、脂肪胺基或亚甲基哌啶基;
本发明中,所述苯并呋喃及Coumestans衍生物其结构如式(IV)所示:
其中,X为氮原子、氧原子或硫原子;
Y为氮原子、氧原子或硫原子;
R6可为氢、卤素、羟基、烷基、硝基、氨基、三氟甲基、烷氧基或苯基;
R5可为氢、卤素、羟基、烷基、硝基、氨基、三氟甲基、烷氧基、N‐亚甲基哌啶或甲酰基环C4‐C7胺;
R1可为氢、羟基、甲氧基、乙氧基、甲氧基乙基醚或酯;
R2可为Ra和Rb各自独立的选自以下取代基:氢原子;链状烷烃;环烷烃;其中,Rc为C2‐C8环烷基,含杂原子N,O,S环烷基,烷基取代的环烷基,或C3‐C8内酰胺;/>其中,Rd为C2‐C8环烷基或/>Rf为C2‐C8环烷基,Re为链状烷烃或醚;
R为芳香环,芳香环上各取代基可各自独立的为以下取代基氢、卤素、羟基、烷基、硝基、氨基、三氟甲基、烷氧基或亚甲基哌啶基。
本发明中,所使用的各基团采用其在本领域中的常规意义。
本发明所述通式(I)(II)(III)(IV)苯并呋喃及Coumestans衍生物,按自行设计的代号S1~S132表示,具体包括表1~4所述的化合物:
表1
表2
表3
表4
本发明还提供了所述通式(I)、(II)、(III)、(IV)苯并呋喃及Coumestans衍生物的对映异构体、非对映异构体、外消旋体及其混合物,及其对应的盐。
本发明还提供了所述通式(I)、(II)、(III)、(IV)苯并呋喃及Coumestans衍生物及其中间体的制备方法。上述式(I)、(II)、(III)、(IV)化合物可通过以下步骤制得:
路线1
路线2
路线3
路线4
路线5
路线6
路线7
其中,路线1~7中所有基团的定义与所述结构通式(I)、(II)、(III)、(IV)中的定义相同,并优选为表1~4中所表示的优势基团,但不仅限于这些优势基团。
本发明还提供了包括所述通式(I)、(II)、(III)、(IV)化合物或其药学上可接受的盐的药物组合物,所述药物组合物还包括药物上可接受的载体,或可选地,还包含其它治疗成分。所述药物组合物可包含所述式(I)、(II)、(III)、(IV)化合物或其药学上可接受的盐的单一的活性成分或混合的活性成分。所述药物组合物可以以任何形式给药,包括口服,直肠给药,鼻腔给药,注射给药(包括皮下注射,肌肉注射,静脉注射)等。所述的药物组合物被配置成可注射流体、气雾剂、乳膏、凝胶剂、丸剂、胶囊剂、糖浆剂或透皮贴剂。
本发明中,所述药学上可接受的载体可以根据实际期望的给药途径(如口腔给药,或注射给药等)以任何形式存在。
本发明中,在制备口服剂型的组合物时,任何常见的化学介质可能被采用,如在制备液体口服制剂(包括悬浮液和溶液)时,可采用水、乙二醇、油、醇类、调味剂、防腐剂和着色剂等。在制备固体口服制剂(如粉剂,胶囊)时,可选用的载体如淀粉、糖、微晶纤维素、填充剂、造粒剂、润滑剂、粘合剂、裂解剂等。
本发明还提供了所述通式(I)、(II)、(III)、(IV)化合物、所述药物组合物在制备微生物的抑制剂中的应用。所述微生物包括:细菌、病毒、真菌以及一些小型的原生生物、显微藻类等;其中,所述细菌包括结核分枝杆菌,金黄色葡萄球菌,链球菌,肺炎球菌,大肠杆菌,枯草芽孢杆菌,乳酸菌等。本发明中,所述通式(I)、(II)、(III)、(IV)化合物、所述药物组合物用于抑制微生物的生长、繁殖。
本发明还提供了所述通式(I)、(II)、(III)、(IV)化合物、所述药物组合物在制备结核分枝杆菌细胞壁合成抑制剂中的应用。
本发明还提供了所述通式(I)、(II)、(III)、(IV)化合物、所述药物组合物在制备抑制结核分枝杆菌的生长和繁殖的药物中的应用。
本发明还提供了所述通式(I)、(II)、(III)、(IV)化合物、所述药物组合物在制备治疗与pks13基因片段编码的聚酮合酶作为靶点有关的疾病的药物中的应用。
本发明还提供了所述通式(I)、(II)、(III)、(IV)化合物、所述药物组合物在制备预防和/或治疗肺结核疾病、抗癌、抗病毒、抗内风湿、抗真菌、抗氧化性、抗炎、护肝、止血及降血压的药物中的应用;优选用于治疗耐多药性肺结核疾病的药物中的应用。
本发明中,所述癌症包括乳腺癌、结肠直肠癌、胰腺癌、肾癌、***癌、尿路上皮癌、食管癌、头颈癌、肝癌、间皮瘤、卡波济氏肉瘤、卵巢癌、软组织肉瘤、胶质瘤、黑素瘤、小细胞‐非小细胞肺癌、子宫内膜癌、基底细胞癌、泌尿道上皮移行细胞癌、子***、子宫内膜癌、胃癌、膀胱癌、子宫肉瘤、多发性骨髓瘤、软组织、骨肉瘤和胆管癌等。
本发明中,所述苯并呋喃及Coumestans衍生物以结核杆菌pks13基因片段编码的聚酮合酶为作用靶点,抑制结核分枝杆菌细胞壁中分枝菌酸的合成,从而抑制结核分枝杆菌生长,达到治疗结核病的效果。
本发明还提供了将所述通式(I)、(II)、(III)、(IV)化合物、所述药物组合物用于预防和/或治疗肺结核疾病、抗癌、抗病毒、抗内风湿、抗真菌、抗氧化性、抗炎、护肝、止血及降血压的方法,包括向有需要的个体中给予所述通式(I)、(II)、(III)、(IV)化合物、所述药物组合物。
本发明的有益效果在于,本发明制备的式(I)、(II)、(III)、(IV)苯并呋喃类及Coumestans衍生物是一类结构新颖,抑菌效果显著的结核分枝杆菌细胞壁抑制剂。
附图说明
图1为本发明化合物口服给药血清抑制滴定实验的相对荧光强度。
图2为本发明化合物口服给药或腹腔给药血清抑制滴定实验的相对荧光强度。
具体实施方式
结合以下具体实施例和附图,对本发明作进一步的详细说明。实施本发明的过程、条件、实验方法等,除以下专门提及的内容之外,均为本领域的普遍知识和公知常识,本发明没有特别限制内容。
实施例1 5‐羟基‐(4‐(1‐(4‐甲基哌嗪基))亚甲基)‐2‐苯基苯并呋喃‐3‐羧酸乙酯(化合物S1)的制备
1.1将3.45g碳酸二乙酯,0.87g氢化钠加入到15mL甲苯中,接着在氮气保护下向体系中缓慢滴加2.19g苯乙酮,110℃搅拌30min,反应完毕待冷至室温加入冰水,加入冰醋酸至体系中性,乙酸乙酯(50mL×3)萃取,分出有机层,饱和食盐水100ml洗涤,无水硫酸钠干燥,蒸去溶剂乙酸乙酯后粗品经快速柱层析(石油醚:乙酸乙酯=15:1)得苯甲酰乙酸乙酯(化合物1‐1);
1.2将1.38g苯甲酰乙酸乙酯,86.37mg三氟甲磺酸铜溶解于20mL甲苯中,氮气保护的条件下缓慢滴加1,4‐苯醌0.52g,加热回流10h,冷却至室温。NH4Cl淬灭,乙酸乙酯(50mL×3)萃取,分出有机层,饱和食盐水10ml洗涤,无水硫酸钠干燥,蒸去溶剂乙酸乙酯后所得粗产物用硅胶柱层析纯化(石油醚:乙酸乙酯=10:1)
得5‐羟基‐2‐苯基苯并呋喃‐3‐羧酸乙酯(化合物1‐2);
1.3将513.3mg化合物1‐2,37%aq甲醛,N‐甲基哌嗪溶解于10mL无水乙醇中,氮气保护下加热回流16h,乙酸乙酯(20mL×3)萃取,分出有机层,饱和食盐水5ml洗涤,无水硫酸钠干燥,蒸去溶剂乙酸乙酯后所得粗产物用硅胶柱层析纯化(石油醚:乙酸乙酯=10:1)得最终产物5‐羟基‐4‐(1‐亚甲基‐N‐甲基哌嗪)‐2‐苯基苯并呋喃‐3‐羧酸乙酯。1HNMR(400MHz,MeOD)δ7.82–7.64(m,2H),7.46(d,J=6.1Hz,3H),7.34(d,J=8.8Hz,1H),6.84(d,J=8.8Hz,1H),4.34(q,J=7.1Hz,2H),3.95(s,2H),2.57(br,8H),2.28(s,3H),1.27(t,J=7.1Hz,3H).13C NMR(101MHz,MeOD)δ167.6,157.8,155.4,149.7,131.1,130.8,129.6,128.7,127.0,115.8,114.3,111.9,111.8,62.7,56.2,55.8,53.0,45.9,14.3.HRMS(ESI)m/z:Calcd for C23H27N2O4(M+H)+395.1965;Found 395.1938.
实施例2 4‐(二丙基氨基)亚甲基‐5‐羟基‐2‐苯基苯并呋喃‐3‐羧酸乙酯(化合物S2)的制备
采用类似于实施例1的方法制备,不同之处在于以二丙胺代替N‐甲基哌嗪,其余所需原料,试剂以及制备方法与实施例1相同,得终产物。1H NMR(400MHz,CDCl3)δ7.78–7.72(m,2H),7.48–7.40(m,3H),7.31(d,J=8.8Hz,1H),6.85(d,J=8.8Hz,1H),4.35(q,J=7.1Hz,2H),4.06(s,2H),2.54(t,J=7.5Hz,4H),1.70–1.51(m,4H),1.29(t,J=7.2Hz,3H),0.91(t,J=7.4Hz,6H).13C NMR(101MHz,CDCl3)δ166.4,156.6,155.6,148.1,130.0,129.5,128.3,127.8,125.3,115.2,112.9,110.6,110.0,61.4,55.7,54.2,19.6,13.9,11.8.HRMS(ESI)m/z:Calcd forC24H30NO4(M+H)+396.2169;Found 396.2168.
实施例3 5‐羟基‐(4‐(1‐(4‐(羟甲基)哌啶基))亚甲基)‐2‐苯基苯并呋喃‐3‐羧酸乙酯(化合物S3)的制备
采用类似于实施例1的方法制备,不同之处在于以4‐羟甲基哌啶代替N‐甲基哌嗪,其余所需原料,试剂以及制备方法与实施例1相同,得终产物。1H NMR(400MHz,MeOD)δ7.73–7.67(m,2H),7.51–7.45(m,3H),7.39(d,J=8.9Hz,1H),6.88(d,J=8.9Hz,1H),4.33(q,J=7.1Hz,2H),4.16(s,2H),3.43(d,J=6.3Hz,2H),3.33–3.30(m,1H),3.19(d,J=11.9Hz,2H),2.45(t,J=11.3Hz,2H),1.84(d,J=13.0Hz,2H),1.70–1.56(m,1H),1.45–1.30(m,2H),1.23(t,J=7.1Hz,3H).13C NMR(101MHz,MeOD)δ167.6,159.3,156.1,149.7,131.2,130.9,129.5,129.2,127.2,115.8,112.7,112.5,111.4,67.3,64.3,62.7,56.5,53.8,38.9,29.1,14.2.HRMS(ESI)m/z:Calcd for C24H28NO5(M+H)+410.1962;Found410.1980.
实施例4 5‐羟基‐(4‐(1‐哌啶基)亚甲基)‐2‐甲硫基苯并呋喃‐3‐羧酸乙酯(化合物S4)的制备
4.1将4.2mL的10mmol/mL乙酰丙酮,11.04g无水碳酸钾加入到10mLDMF中,N2保护下室温搅拌30min。冰水浴下滴加2.2mL的20mmol/mL二硫化碳,室温搅拌1h,然后滴加2.28mg/mL碘甲烷2.74mL,过夜反应。冰水浴中析出固体,水洗过滤,得淡粉红色化合物3‐[双(甲基磺酰基)亚甲基]‐2,4‐戊二酮,下称化合物4‐1;
4.2将1.624g化合物16‐1,1.296g苯醌,46mg溴化铜加入到15mL乙腈中,氮气保护下滴加BF3·Et2O,室温反应5h。饱和NaCl溶液洗涤,NaHCO3溶液调节体系呈中性,过滤沉淀,得5‐羟基‐2‐(甲硫基)‐3‐乙酰基苯并呋喃,下称化合物4‐2;
4.3将45mg化合物4‐2,0.1mL37%aq甲醛,哌啶加入到2mL乙醇中,氮气保护下加热回流10h,反应毕,得白色固体终产物。1H NMR(400MHz,CDCl3/MeOD=4/1)δ7.37(d,J=8.8Hz,1H),6.85(d,J=8.8Hz,1H),4.62(s,2H),4.41(q,J=7.1Hz,2H),3.13(br,4H),2.68(s,3H),1.90–1.76(m,4H),1.75–1.61(m,2H),1.46(t,J=7.1Hz,3H).13C NMR(101MHz,CDCl3/MeOD=4/1)δ166.0,165.8,156.2,150.5,127.8,113.2,113.1,109.3,109.2,62.1,55.2,53.9,24.6,23.2,14.7,13.9.
实施例5 5‐羟基‐(4‐(1‐哌啶基)亚甲基)‐2‐(4‐(三氟甲基)苯基)苯并呋喃‐3‐羧酸乙酯(化合物S5)的制备
采用类似于实施例1的方法制备,不同之处在于以对三氟甲基苯乙酮代替苯乙酮,哌啶代替N‐甲基哌嗪,其余所需原料,试剂以及制备方法与实施例1相同,得终产物。1H NMR(400MHz,CDCl3/MeOD=3/1)δ7.87(d,J=8.2Hz,2H),7.73(d,J=8.3Hz,2H),7.33(d,J=8.9Hz,1H),6.84(d,J=8.9Hz,1H),4.37(q,J=7.1Hz,2H),3.95(s,2H),2.58(br,4H),1.70–1.61(m,4H),1.52(br,2H),1.29(t,J=7.1Hz,3H).13C NMR(101MHz,CDCl3/MeOD=3/1)δ167.4,156.6,155.9,149.8,134.7,134.7,133.3(q,JC-F=32.8Hz),129.3,126.5(q,JC-F=3.8Hz),125.4(q,JC-F=272.6Hz),117.0,113.7,112.9,112.2,63.1,58.6,55.0,26.9,25.0,14.6.HRMS(ESI)m/z:Calcd for C24H25F3NO4(M+H)+448.1730;Found 448.1748.
实施例6 5‐羟基‐2‐(4‐甲氧基苯基)‐(4‐(1‐哌啶基)亚甲基)苯并呋喃‐3‐羧酸乙酯(化合物S6)的制备
采用类似于实施例1的方法制备,不同之处在于以对甲氧基苯乙酮代替苯乙酮,哌啶代替N‐甲基哌嗪,其余所需原料,试剂以及制备方法与实施例1相同,得终产物。1H NMR(400MHz,MeOD)δ7.62(d,J=8.7Hz,2H),7.25(d,J=8.8Hz,1H),6.95(d,J=8.7Hz,2H),6.75(d,J=8.8Hz,1H),4.31(q,J=7.1Hz,2H),3.91(s,2H),3.80(s,3H),2.53(br,4H),1.67–1.55(m,4H),1.48(br,2H),1.26(t,J=7.1Hz,3H).13C NMR(101MHz,MeOD)δ167.8,162.3,158.2,156.2,149.2,130.4,126.9,123.4,115.5,114.9,113.3,111.7,110.1,62.6,58.3,55.8,54.8,26.8,24.9,14.4.HRMS(ESI)m/z:Calcd forC24H28NO5(M+H)+410.1962;Found410.1973.
实施例7 2‐(4‐氟苯基)‐5‐羟基‐(4‐(1‐哌啶基)亚甲基)苯并呋喃‐3‐羧酸乙酯(化合物S7)的制备
采用类似于实施例1的方法制备,不同之处在于以对氟苯乙酮代替苯乙酮,哌啶代替N‐甲基哌嗪,其余所需原料,试剂以及制备方法与实施例1相同,得终产物。1H NMR(400MHz,MeOD)δ7.75(dd,J=8.6,5.4Hz,2H),7.33(d,J=8.8Hz,1H),7.19(t,J=8.7Hz,2H),6.83(d,J=8.8Hz,1H),4.35(q,J=7.1Hz,2H),4.02(s,2H),2.64(br,4H),1.73–1.63(m,4H),1.54(br,2H),1.29(t,J=7.2Hz,3H).13C NMR(101MHz,MeOD)δ167.2,164.7(d,JC-F=249.8Hz),157.4,156.2,149.3,131.1(d,JC-F=8.5Hz),127.3(d,JC-F=3.3Hz),126.5,116.3(d,JC-F=22.2Hz),116.0,113.0,111.9,111.1,62.6,58.1,54.6,26.5,24.6,14.3.HRMS(ESI)m/z:Calcd for C23H25FNO4(M+H)+398.1762;Found 398.1778.
实施例8 2‐(2,4‐二甲氧基苯基)‐5‐羟基‐(4‐(1‐哌啶基)亚甲基)苯并呋喃‐3‐羧酸乙酯(化合物S8)的制备
采用类似于实施例1的方法制备,不同之处在于以2,4‐二甲氧基苯乙酮代替苯乙酮,哌啶代替N‐甲基哌嗪,其余所需原料,试剂以及制备方法与实施例1相同,得终产物。1HNMR(400MHz,MeOD)δ7.47(d,J=9.0Hz,1H),7.28(d,J=8.8Hz,1H),6.76(d,J=8.8Hz,1H),6.66–6.59(m,2H),4.18(q,J=7.1Hz,2H),4.11(s,2H),3.85(s,3H),3.77(s,3H),2.61(br,4H),1.72–1.62(m,4H),1.58–1.49(m,2H),1.12(t,J=7.1Hz,3H).13C NMR(101MHz,MeOD)δ167.8,164.0,159.6,157.4,156.4,149.5,132.0,126.6,115.2,113.7,113.4,112.6,111.8,106.2,99.3,62.0,58.1,56.0,55.9,54.7,26.8,24.9,14.3.HRMS(ESI)m/z:Calcd forC25H30NO6(M+H)+440.2068;Found 440.2079.
实施例9 2‐(4‐溴‐2‐甲氧基苯基)‐5‐羟基‐(4‐(1‐哌啶基)亚甲基)苯并呋喃‐3‐羧酸乙酯(化合物S9)的制备
采用类似于实施例1的方法制备,不同之处在于以4‐溴‐2‐甲氧基苯乙酮代替苯乙酮,哌啶代替N‐甲基哌嗪,其余所需原料,试剂以及制备方法与实施例1相同,得终产物。1HNMR(400MHz,CDCl3/MeOD=4/1)δ7.46(d,J=8.1Hz,1H),7.31(d,J=8.8Hz,1H),7.28–7.19(m,2H),6.82(d,J=8.8Hz,1H),4.22(q,J=7.1Hz,2H),4.12(s,2H),3.82(s,3H),2.63(br,4H),1.73–1.64(m,4H),1.55(br,2H),1.17(t,J=7.1Hz,3H).13C NMR(101MHz,CDCl3/MeOD=4/1)δ166.9,158.2,156.1,155.4,149.4,131.9,125.7,125.5,124.4,119.8,115.6,115.4,113.4,113.3,111.4,61.8,58.3,56.2,54.4,26.5,24.5,14.1.HRMS(ESI)m/z:CalcdforC24H27BrNO5(M+H)+488.1067;Found 488.1087.
实施例10 2‐(4‐氟‐2‐甲氧基苯基)‐5‐羟基‐(4‐(1‐哌啶基)亚甲基)苯并呋喃‐3‐羧酸乙酯化合物(S10)的制备
采用类似于实施例1的方法制备,不同之处在于以4‐氟‐2‐甲氧基苯乙酮代替苯乙酮,哌啶代替N‐甲基哌嗪,其余所需原料,试剂以及制备方法与实施例1相同,得终产物。1HNMR(400MHz,CDCl3)δ7.47(t,J=7.2Hz,1H),7.21(d,J=8.8Hz,1H),6.77(d,J=8.7Hz,1H),6.70(t,J=7.8Hz,1H),6.61(d,J=10.4Hz,1H),4.13(dd,J=13.5,6.6Hz,2H),4.03(s,2H),3.72(s,3H),2.58(br,4H),1.71–1.31(m,6H),1.07(t,J=6.8Hz,3H).13C NMR(101MHz,CDCl3)δ165.7,164.5(d,J=250.5Hz),158.3(d,J=10.2Hz),155.7,154.8,148.4,131.6(d,J=10.4Hz),124.8,116.1,114.9,112.6,112.3,110.5,107.3(d,J=21.8Hz),99.2(d,J=26.1Hz),60.7,57.9,55.7,53.8,25.9,23.9,13.9.HRMS(ESI)m/z:Calcd for(M+H)+428.1868;Found 428.1876.
实施例11 5‐羟基‐2‐(2‐甲氧基‐4,5‐二甲基苯基)‐(4‐(1‐哌啶基)亚甲基)苯并呋喃‐3‐羧酸乙酯(化合物S11)的制备
采用类似于实施例1的方法制备,不同之处在于以4,5‐二甲基‐2‐甲氧基苯乙酮代替苯乙酮,哌啶代替N‐甲基哌嗪,其余所需原料,试剂以及制备方法与实施例1相同,得终产物。1HNMR(400MHz,CDCl3)δ7.36(s,1H),7.28(d,J=8.9Hz,1H),6.82(d,J=8.8Hz,1H),6.74(s,1H),4.22(q,J=7.1Hz,2H),4.09(s,2H),3.76(s,3H),3.03–2.00(m,10H),1.74–1.46(m,6H),1.17(t,J=7.1Hz,3H).13C NMR(101MHz,CDCl3)δ166.2,155.5,155.5,154.8,148.3,139.8,131.0,128.5,125.1,116.9,114.5,112.5,112.4,111.8,110.5,60.7,57.8,55.5,53.8,25.9,24.0,20.3,18.7,13.9.HRMS(ESI)m/z:Calcd forC26H32NO5(M+H)+438.2275;Found 438.2282.
实施例12 1‐(2‐((环丙基甲基)氨基)‐5‐羟基‐(4‐(1‐哌啶基)亚甲基)苯并呋喃‐3‐(1‐乙基)酮(化合物S12)的制备
12.1将4.2mL的10mmol/mL乙酰丙酮,11.04g无水碳酸钾加入到10mLDMF中,N2保护下室温搅拌30min。冰水浴下滴加2.2mL的20mmol/mL二硫化碳,室温搅拌1h,然后滴加2.28mg/mL碘甲烷2.74mL,过夜反应。冰水浴中析出固体,水洗过滤,得淡粉红色化合物3‐[双(甲基磺酰基)亚甲基]‐2,4‐戊二酮,下称化合物12‐1;
12.2将1.624g化合物16‐1,1.296g苯醌,46mg溴化铜加入到15mL乙腈中,氮气保护下滴加BF3·Et2O,室温反应5h。饱和NaCl溶液洗涤,NaHCO3溶液调节体系呈中性,过滤沉淀,得5‐羟基‐2‐甲硫基‐3‐乙酰基苯并呋喃,下称化合物12‐2;
12.3将50mg化合物16‐2与96mg环丙甲基胺加入到5mL乙醇中,氮气保护下加热回流10h,减压浓缩,快速柱纯化,得化合物12‐3;
12.4将45mg化合物12‐3,0.1mL37%aq甲醛,69.6mg哌啶加入到2mL乙醇中,氮气保护下加热回流10h,反应毕,冷却析出淡黄色固体终产物50mg。1H NMR(400MHz,MeOD)δ6.99(s,1H),6.83(s,1H),3.69(s,2H),3.40(d,J=7.0Hz,2H),2.53(br,4H),2.43(s,3H),1.65(dd,J=11.0,5.5Hz,4H),1.52(d,J=4.8Hz,2H),1.16(s,1H),0.58(d,J=7.9Hz,2H),0.33(d,J=5.1Hz,2H).13C NMR(101MHz,MeOD)δ192.9,167.4,156.2,144.6,127.9,116.4,111.2,106.3,95.7,62.2,54.7,47.5,28.7,27.0,25.1,12.2,3.9.
实施例13 1‐(5‐羟基‐2‐(哌啶基)‐4‐(1‐哌啶基)亚甲基)苯并呋喃‐3‐(1‐乙基)酮(化合物S13)的制备
采用类似于实施例12的方法制备,不同之处在于以哌啶代替环丙甲基胺,其余所需原料,试剂以及制备方法与实施例12相同,得白色固体终产物。1H NMR(400MHz,CDCl3/MeOD=4/1)δ7.03(s,1H),6.94(s,1H),3.67(s,2H),3.55(br,4H),2.61–2.42(m,7H),1.71(br,6H),1.67–1.58(m,4H),1.51(br,2H).13C NMR(101MHz,CDCl3/MeOD=4/1)δ192.8,165.9,155.4,143.8,129.1,117.2,110.6,107.4,99.1,62.3,54.5,51.3,30.6,26.8,26.7,24.9,24.9.
实施例14 1‐(2‐(苄基氨基)‐5‐羟基‐4‐(1‐哌啶基)亚甲基)苯并呋喃‐3‐(1‐乙基)酮(化合物S14)的制备
采用类似于实施例12的方法制备,不同之处在于以苄胺代替环丙甲基胺,其余所需原料,试剂以及制备方法与实施例12相同,得终产物。1H NMR(400MHz,CDCl3/MeOD=4/1)δ7.44–7.19(m,5H),6.96(s,1H),6.85(s,1H),4.71(s,2H),3.68(s,2H),2.56(br,4H),2.45(s,3H),1.76–1.60(m,4H),1.52(br,2H).13C NMR(101MHz,CDCl3/MeOD=4/1)δ193.1,166.8,155.9,144.4,139.0,129.6,128.5,128.1,127.7,116.3,111.1,106.2,95.8,62.2,54.6,46.4,28.8,26.8,24.9.
实施例15 1‐(5‐羟基‐2‐吗啉基‐4‐(1‐哌啶基)亚甲基)苯并呋喃‐3‐(1‐乙基)酮(化合物S15)的制备
采用类似于实施例12的方法制备,不同之处在于以吗啉代替环丙甲基胺,其余所需原料,试剂以及制备方法与实施例12相同,得终产物。1H NMR(400MHz,MeOD)δ7.04(d,J=11.5Hz,2H),3.89–3.76(m,4H),3.71(s,2H),3.69–3.59(m,4H),2.62–2.47(m,7H),1.70–1.60(m,4H),1.59–1.50(m,2H).13C NMR(101MHz,MeOD)δ193.4,165.5,155.9,144.2,129.0,118.1,111.1,107.6,100.2,67.7,62.2,54.7,50.4,30.8,27.0,25.1.
实施例16 1‐(2‐(环己基氨基)‐5‐羟基‐4‐(1‐哌啶基)亚甲基)苯并呋喃‐3‐(1‐乙基)酮(化合物S16)的制备
采用类似于实施例12的方法制备,不同之处在于以环己胺代替环丙甲基胺,其余所需原料,试剂以及制备方法与实施例12相同,得终产物。1H NMR(400MHz,MeOD)δ6.98(s,1H),6.81(s,1H),3.81(br,1H),3.71(s,2H),2.58(br,4H),2.39(s,3H),2.01(s,2H),1.77(s,2H),1.70–1.59(m,4H),1.52(d,J=4.3Hz,2H),1.49–1.40(m,4H),1.35–1.20(m,2H).13CNMR(101MHz,MeOD)δ192.9,166.5,156.1,144.6,128.1,115.7,111.6,106.3,95.5,61.7,54.6,52.3,34.3,28.7,26.7,26.4,25.5,24.9.
实施例17(1‐(2‐(二丙基氨基)‐5‐羟基‐4‐(1‐哌啶基)亚甲基)苯并呋喃基)‐(3‐乙基)酮(化合物S17)的制备
采用类似于实施例12的方法制备,不同之处在于以二丙胺代替环丙甲基胺,其余所需原料,试剂以及制备方法与实施例12相同,得终产物。1H NMR(400MHz,MeOD)δ6.99(d,J=11.5Hz,2H),3.71(s,2H),3.55(t,4H),2.52(m,7H),1.64(dd,J=14.5,7.4Hz,8H),1.52(d,J=4.4Hz,2H),0.89(t,J=7.4Hz,6H).13C NMR(101MHz,MeOD)δ192.7,165.5,155.6,143.9,129.7,116.9,110.8,107.3,99.2,61.9,54.7,54.2,30.8,26.8,25.0,22.3,11.4.
实施例18 5‐羟基‐(4‐(1‐哌啶基)亚甲基)‐2‐吡咯烷基苯并呋喃‐(1‐乙基)‐3‐酮(化合物S18)的制备
采用类似于实施例12的方法制备,不同之处在于以四氢吡咯代替环丙甲基胺,其余所需原料,试剂以及制备方法与实施例12相同,得终产物。1H NMR(400MHz,CDCl3/MeOD=4/1)δ6.93(s,2H),3.72(s,2H),3.65(t,J=6.4Hz,4H),2.58(br,4H),2.47(s,3H),1.99(t,J=6.6Hz,4H),1.69–1.60(m,4H),1.52(br,2H).13C NMR(101MHz,CDCl3/MeOD=4/1)δ192.2,163.7,155.2,143.9,129.5,115.5,110.7,106.6,97.3,61.8,54.4,51.2,30.7,26.5,26.2,24.6.
实施例19 N‐乙基‐5‐羟基‐2‐苯基‐(4‐(1‐哌啶基)亚甲基)苯并呋喃‐3‐甲酰胺(化合物S19)的制备
采用类似于实施例1的方法制备,不同之处在于合成5‐羟基‐2‐苯基苯并呋喃‐3‐羧酸乙酯后的步骤:
19.1合成5‐羟基‐2‐苯基苯并呋喃‐3‐羧酸乙酯(后简称化合物19‐1)之后,将120mg化合物19‐1,24.2mg LiOH·H2O加入到8mL 1,4‐二氧六环,氮气保护室温过夜反应,盐酸调节pH至中性,乙酸乙酯(50mL×3)萃取,饱和NaCl洗,无水Na2SO4干燥,减压浓缩,加入二氯甲烷析出沉淀,过滤白色固体得5‐羟基‐2‐苯基苯并呋喃‐3‐羧酸(化合物19‐2)。
19.2将100mg化合物19‐2,21.8mg乙胺,98.0mg EDC·HCl,69.1mg 1‐羟基苯并***(HOBT)和79.1mg 3‐甲基吡啶溶于5mLDMF中,氮气保护下室温反应5h,NH4Cl淬灭,乙酸乙酯(50mL×3)萃取,5%盐酸溶液洗,饱和NaHCO3洗,饱和NaCl洗,无水Na2SO4干燥,减压浓缩后得粗品N‐乙基‐5‐羟基‐2‐苯基苯并呋喃‐3‐甲酰胺(化合物19‐3)不经纯化直接进行下一步。
19.3将113.3mg化合物19‐3,0.1mL 37%aq甲醛,哌啶溶解于10mL无水乙醇中,氮气保护下加热回流16h,乙酸乙酯(20mL×3)萃取,分出有机层,饱和食盐水5ml洗涤,无水硫酸钠干燥,蒸去溶剂乙酸乙酯后所得粗产物用硅胶柱层析纯化(石油醚:乙酸乙酯=10:1)得终产物N‐乙基‐5‐羟基‐2‐苯基‐4‐(哌啶‐1‐基甲基)苯并呋喃‐3‐甲酰胺60.8mg。1H NMR(400MHz,MeOD)δ7.81(d,J=8.0Hz,2H),7.58–7.29(m,4H),6.86(d,J=8.8Hz,1H),4.10(s,2H),3.42(q,J=7.3Hz,2H),2.83(s,4H),1.83–1.68(m,4H),1.59(s,2H),1.20(t,J=7.3Hz,3H).13C NMR(101MHz,MeOD)δ168.7,155.7,154.8,149.5,130.8,130.6,129.9,127.9,127.8,115.5,114.4,112.9,111.3,54.8,54.6,36.0,26.1,24.3,14.2.HRMS(ESI)m/z:Calcd for C23H27N2O3(M+H)+379.2025;Found 379.2016.
实施例20 N‐环丙基‐5‐羟基‐2‐苯基‐(4‐(1‐哌啶基)亚甲基)苯并呋喃‐3‐甲酰胺(化合物S20)的制备
采用类似于实施例19的方法制备,不同之处在于以环丙胺代替乙胺,其余所需原料,试剂以及制备方法与实施例19相同,得终产物。1H NMR(400MHz,MeOD)δ7.79–7.65(m,2H),7.56–7.40(m,4H),6.96(d,J=8.9Hz,1H),4.32(s,2H),3.12(s,4H),3.05–2.89(m,1H),1.91–1.75(m,4H),1.67(s,2H),0.90–0.68(m,2H),0.59–0.45(m,2H).13C NMR(101MHz,MeOD)δ169.9,156.2,155.5,149.6,131.0,130.5,129.8,128.3,128.3,115.2,114.3,113.9,109.1,54.3,54.1,25.1,24.2,23.4,5.8.HRMS(ESI)m/z:Calcd for C24H27N2O3(M+H)+391.2016;Found 391.2011.
实施例21 N‐金刚烷基‐5‐羟基‐2‐苯基‐(4‐(1‐哌啶基)亚甲基)苯并呋喃‐3‐甲酰胺(化合物S21)的制备
采用类似于实施例19的方法制备,不同之处在于以金刚烷胺代替乙胺,得终产物。1HNMR(400MHz,MeOD)δ7.84(d,J=7.3Hz,2H),7.53–7.44(m,3H),7.40(d,J=8.8Hz,1H),6.86(d,J=8.8Hz,1H),4.20(s,2H),2.88(br,4H),2.13(s,11H),1.66(s,10H).13C NMR(101MHz,CDCl3)δ164.4,153.9,151.1,146.9,128.6,128.1,127.6,125.6,125.1,114.0,113.5,111.1,109.5,56.0,53.0,51.7,40.2,35.3,28.4,24.7,22.9.HRMS(ESI)m/z:Calcd forC31H37N2O3(M+H)+485.2799;Found 485.2805.
实施例22 N‐苄基‐5‐羟基‐2‐苯基‐(4‐(1‐哌啶基)亚甲基)苯并呋喃‐3‐甲酰胺(化合物S22)的制备
采用类似于实施例19的方法制备,不同之处在于以其余所需原料,试剂以及制备方法与实施例19相同,得终产物。1H NMR(400MHz,CDCl3)δ7.65(d,J=3.5Hz,2H),7.34–7.10(m,8H),6.71(d,J=8.8Hz,1H),6.26(s,1H),4.51(d,J=5.9Hz,2H),3.75(s,2H),2.92–1.85(br,4H),1.63–1.26(m,6H).13C NMR(101MHz,CDCl3)δ165.2,154.1,151.7,146.9,136.3,128.4,128.1,127.8,127.7,127.4,126.7,125.6,124.9,114.0,112.0,111.1,109.5,56.1,52.6,43.3,24.8,22.8.HRMS(ESI)m/z:Calcd forC28H29N2O3(M+H)+441.2173;Found441.2188.
实施例23 5‐羟基‐N,2‐二苯基‐(4‐(1‐哌啶基)亚甲基)苯并呋喃‐3‐甲酰胺(化合物S23)的制备
采用类似于实施例19的方法制备,不同之处在于以苯胺代替乙胺,其余所需原料,试剂以及制备方法与实施例19相同,得终产物。1H NMR(400MHz,CDCl3)δ7.91(s,1H),7.73(d,J=6.5Hz,2H),7.49(d,J=7.4Hz,2H),7.33(d,J=8.3Hz,4H),7.19(s,1H),7.13(d,J=6.8Hz,1H),6.78(d,J=8.3Hz,1H),3.89(s,2H),2.79–2.25(br,4H),1.65–1.41(m,6H).13CNMR(101MHz,CDCl3)δ164.4,155.2,153.2,148.0,137.7,129.4,129.4,129.2,128.9,126.7,125.9,125.0,120.1,115.3,113.5,111.9,110.8,57.0,53.8,25.6,23.7.HRMS(ESI)m/z:Calcd for C27H27N2O3(M+H)+427.2016;Found 427.2029.
实施例24 4‐(((环丙基甲基)氨基)甲基)‐5‐羟基‐2‐(4‐甲氧基苯基)苯并呋喃‐3‐乙酸乙酯(化合物S24)的制备
采用类似于实施例58的方法制备,不同之处在于生成化合物S58后,0℃冰水浴条件下缓慢滴加mL 1mmol/mL的BBr3·DCM 2mL,滴加完毕室温搅拌5h,乙醇淬灭,减压浓缩除去溶剂,二氯甲烷(50mL×3)萃取,分离有机相减压浓缩,快速柱纯化(石油醚:乙酸乙酯=10:1)得终产物。1H NMR(400MHz,CDCl3)δ7.64(d,J=7.4Hz,2H),7.41(d,J=8.6Hz,1H),7.29(d,J=9.0Hz,1H),6.98(d,J=7.4Hz,2H),4.45(s,2H),4.31(q,J=6.8Hz,2H),3.88(s,3H),2.98(d,J=6.9Hz,2H),1.36–1.18(m,5H),0.86(d,J=6.5Hz,1H),0.66(d,J=6.8Hz,2H),0.39(s,2H).13C NMR(101MHz,CDCl3)δ167.0,161.4,161.2,154.3,148.9,130.9,126.2,122.1,118.0,113.6,113.5,110.5,108.3,61.9,55.4,52.4,44.0,13.8,8.3,4.2.
实施例25 5‐羟基‐2‐苯基‐(4‐(1‐哌啶基)亚甲基)‐1H‐吲哚‐3‐乙酸乙酯(化合物S25)的制备
25.1将原料苯甲酰乙酸乙酯与5.0eq的甲酸铵,5~6粒4A分子筛加入到乙醇中,氮气保护下加热回流10h,反应毕,硅藻土过滤,减压浓缩,乙酸乙酯(50mL×3)萃取,分出有机层,饱和NaCl溶液洗,无水Na2SO4干燥,快速柱层析(石油醚:乙酸乙酯=20:1)得乙基(Z)‐3‐氨基‐3‐苯基丙烯酸酯,下称化合物25‐1;
25.2化合物25‐1与1.0eq溴化锌加入到重蒸四氢呋喃溶剂中,滴加1.0eq苯醌的THF溶液,室温反应1h,NH4Cl淬灭,乙酸乙酯(50mL×3)萃取,分出有机层,饱和食盐水10ml洗涤,无水硫酸钠干燥,柱纯化(石油醚:乙酸乙酯=10:1)得乙基‐5‐羟基‐2‐苯基‐1H‐吲哚‐3‐羧酸,下称化合物25‐2;
25.3将化合物25‐2与5.0eq的CH2O,5.0eq的哌啶加入到乙醇溶剂中,氮气保护下加热回流3h,反应完毕,乙酸乙酯(50mL×3)萃取,分出有机层,饱和食盐水10ml洗涤,无水硫酸钠干燥,硅胶柱层析纯化(石油醚:乙酸乙酯=10:1)得终产物。1H NMR(400MHz,MeOD)δ7.48(d,J=6.8Hz,2H),7.40(m,3H),7.22(d,J=8.6Hz,1H),6.73(d,J=8.6Hz,1H),4.99(br,2H)4.17–4.09(m,4H),2.71–2.49(m,4H),1.69–1.45(m,6H),1.05(t,J=7.1Hz,3H).13CNMR(101MHz,MeOD)δ169.4,154.7,144.3,134.4,132.1,130.0,129.4,129.1,127.1,114.7,112.6,111.8,106.2,61.4,59.1,54.6,26.8,24.9,14.2.
实施例26 5‐羟基‐(4–(1‐(4‐甲基哌啶))亚甲基)‐2‐苯基‐1H‐吲哚‐3‐羧酸乙酯(化合物S26)的制备
采用类似于实施例25的方法制备,不同之处在于以对甲基哌啶代替哌啶,其余所需原料,试剂以及制备方法与实施例25相同,得终产物。
1H NMR(400MHz,MeOD)δ7.52–7.44(m,5H),7.41(d,J=8.7Hz,1H),6.92(d,J=8.7Hz,1H),4.73(s,1H),4.10(q,J=7.1Hz,2H),3.56(d,J=13.7Hz,1H),3.14(t,J=12.0Hz,1H),1.91(d,J=13.2Hz,1H),1.77(s,1H),1.51(s,1H),1.02(d,J=6.4Hz,1H),0.94(t,J=7.1Hz,3H)
实施例27 5‐羟基‐2‐苯基‐(4‐(1‐吡咯烷基)亚甲基)‐1H‐吲哚‐3‐羧酸乙酯(化合物S27)的制备
采用类似于实施例25的方法制备,不同之处在于以四氢吡咯代替哌啶,其余所需原料,试剂以及制备方法与实施例25相同,得终产物。1H NMR(400MHz,MeOD)δ7.51–7.45(m,5H),7.40(d,J=8.7Hz,1H),6.93(d,J=8.7Hz,1H),4.86(s,2H),4.10(q,J=7.1Hz,2H),3.50(t,J=6.8Hz,4H),2.16–2.11(m,4H),1.28(s,1H),0.94(t,J=7.1Hz,3H)13C NMR(101MHz,MeOD)δ168.93,153.83,147.86,134.85,132.50,130.53,129.82,129.00,128.26,115.77,113.58,108.61,111.08,105.56,61.26,54.65,52.17,24.05,13.96.
实施例28 2‐(4‐氟苯基)‐5‐羟基‐4‐(1‐哌啶基)亚甲基)‐1H‐吲哚‐3‐羧酸乙酯(化合物S28)的制备
采用类似于实施例25的方法制备,不同之处在于以对氟苯乙酮代替苯乙酮,其余所需原料,试剂以及制备方法与实施例25相同,得终产物。1H NMR(400MHz,DMSO)δ12.31(br,1H),7.59–7.52(m,2H),7.42(d,J=8.7Hz,1H),7.34(t,J=8.9Hz,2H),7.03(d,J=8.7Hz,1H),4.69(s,2H),4.05(q,J=7.1Hz,2H),3.15(br,4H),1.73(br,4H),1.54(br,2H),0.94(t,J=7.1Hz,4H).13C NMR(101MHz,MeOD)δ169.17(s),164.57(d,J=247.2Hz),154.55(s),146.74(s),132.74(d,J=8.4Hz),132.51(s),131.02(d,J=3.4Hz),128.48(s),116.06(s),115.91(d,J=22.0Hz),113.74(s),107.32(s),105.93(s),61.52(s),54.13(s),53.90(s),24.38(s),23.06(s),14.08(s).
实施例29 N‐乙基‐2‐(4‐氟苯基)‐5‐羟基‐4‐(哌啶‐1‐亚甲基)苯并呋喃‐3‐甲酰胺(化合物S29)的制备
29.1将1.5g 4‐氟苯甲酰乙酸乙酯,0.1g三氟甲磺酸铜溶于甲苯,0.59g苯醌溶于甲苯,氮气保护下逐滴加入体系,加热回流10h,反应完毕,饱和氯化铵淬灭,乙酸乙酯(50mL×3)萃取,分出有机层,饱和氯化钠溶液洗涤,无水硫酸钠干燥,除去乙酸乙酯后粗品经硅胶柱层析纯化(石油醚:乙酸乙酯=10:1)得(4‐氟苯基)‐5‐羟基苯并呋喃‐3‐羧酸乙酯(化合物29‐1);
29.2将710mg化合物29‐1,265mg氢氧化钾溶入7mL甲醇,加热回流反应5h,反应完毕,2N盐酸洗涤,乙酸乙酯(50mL×3)萃取,分出有机层,饱和氯化钠溶液洗涤,无水硫酸钠干燥,除去乙酸乙酯后用二氯甲烷打浆得粗品(4‐氟苯基)‐5‐羟基苯并呋喃‐3‐羧酸(化合物29‐2);
29.3将386.9mg化合物29‐2溶于N,N‐二甲基甲酰胺,加入0.4mL三乙胺,657.8mg2‐(7‐氧化苯并三氮唑)‐N,N,N’,N’,四甲基脲六氟磷酸酯(HATU),搅拌反应20min后,加入78.71mg乙胺,反应30min后,加入饱和氯化钠溶液,乙酸乙酯(30mL×3)萃取,水洗(30mL×3)除去二甲基甲酰胺,蒸去溶剂乙酸乙酯后所得粗产物用硅胶柱层析纯化(石油醚:乙酸乙酯=3:1)得N‐乙基‐2‐(4‐氟苯基)‐5‐羟基苯并呋喃‐3‐甲酰胺(化合物S29(化合物29‐3);
29.4将23.5mg化合物29‐3,31.86mg 37%甲醛,27.92mg哌啶溶于2mL乙醇中加热回流反应8h,反应毕,乙酸乙酯(20mL×3)萃取,无水硫酸钠干燥,除去乙酸乙酯后使用薄层层析硅胶板在石油醚:乙酸乙酯=1:1条件下纯化,得最终产物S29。1H NMR(400MHz,CDCl3)δ7.69(dd,J=8.7,5.3Hz,2H),7.20(d,J=8.9Hz,1H),7.04(t,J=8.7Hz,2H),6.72(d,J=8.8Hz,1H),6.01(t,J=5.5Hz,1H),3.79(s,2H),3.46–3.36(m,2H),2.19(m,4H),1.56(m,6H),1.14(t,J=7.2Hz,3H).13C NMR(101MHz,CDCl3)δ165.2(s),163.4,160.9(d,JC-F=248.7Hz),154.0(s),150.6(s),146.9(s),127.5(d,JC-F=8.3Hz),124.9(s),124.8(d,JC-F=3.3Hz),115.0,114.8(d,JC-F=21.8Hz),112.0(s),111.1(s),109.5(s),56.0(s),52.8(s),34.1(s),24.8(s),22.9(s),13.4(s).
实施例30 N‐环丙基‐2‐(4‐氟苯基)‐5‐羟基‐4‐(哌啶‐1‐亚甲基)苯并呋喃‐3‐甲酰胺(化合物S30)的制备
采用类似于实施例29的方法制备,不同之处在于以环丙胺代替乙胺,其余所需原料,试剂以及制备方法与实施例29相同,得最终产物。1H NMR(400MHz,MeOD)δ7.80(dd,J=8.7,5.3Hz,2H),7.32(d,J=8.8Hz,1H),7.24(t,J=8.7Hz,2H),6.79(d,J=8.8Hz,1H),3.91(s,2H),2.94(dt,J=11.1,3.7Hz,1H),2.58(m,4H),1.69–1.63(m,4H),1.56(m,2H),0.86–0.81(m,2H),0.57(m,2H).13C NMR(101MHz,MeOD)δ170.4(s),166.0,162.8(d,JC-F=242.3Hz),156.0(s),152.9(s),149.3(s),131.0(s),129.6(d,JC-F=8.4Hz),127.4(d),117.0(d,JC-F=22.1Hz),115.8(s),114.18(s),113.2(s),111.7(s),57.8(s),54.9(s),27.5(s),24.9(s),24.1(s),6.0(s).
实施例31 N‐乙基‐5‐羟基‐2‐(4‐甲氧基苯基)‐4‐(哌啶‐1‐亚甲基)苯并呋喃‐3‐甲酰胺(化合物S31)的制备
采用类似于实施例29的方法制备,不同之处在于以4‐甲氧基苯甲酰乙酸乙酯代替4‐氟苯甲酰乙酸乙酯,其余所需原料,试剂以及制备方法与实施例29相同,得最终产物。1HNMR(400MHz,MeOD)δ7.74(d,J=8.8Hz,2H),7.30(d,J=8.8Hz,1H),7.02(d,J=8.8Hz,2H),6.75(d,J=8.8Hz,1H),3.92(s,2H),3.85(s,3H),3.43(q,J=7.3Hz,2H),2.58(m,4H),1.66(m,4H),1.54(m,2H),1.23(t,J=7.3Hz,3H).13C NMR(101MHz,MeOD)δ169.2(s),162.1(s),155.8(s),154.1(s),149.1(s),128.9(s),127.8(s),123.5(s),115.3(s),115.1(s),113.0(s),111.5(s),57.8(s),55.9(s),54.9(s),36.0(s),26.9(s),25.0(s),14.4(s).
实施例32 N‐乙基‐5‐羟基‐2‐(2‐甲氧基苯基)‐4‐(哌啶‐1‐亚甲基)苯并呋喃‐3‐甲酰胺(化合物S32)的制备
采用类似于实施例29的方法制备,不同之处在于以2‐甲氧基苯甲酰乙酸乙酯代替4‐氟苯甲酰乙酸乙酯,其余所需原料,试剂以及制备方法与实施例29相同,得最终产物。1HNMR(400MHz,CDCl3)δ7.54(dd,J=7.6,1.2Hz,1H),7.41(dd,J=11.4,4.3Hz,1H),7.25(dd,J=8.5,4.4Hz,1H),7.04(t,J=7.5Hz,1H),6.97(d,J=8.3Hz,1H),6.80(d,J=8.8Hz,1H),6.00(s,1H),4.03(s,2H),3.83(s,3H),3.30(dd,J=13.2,7.1Hz,2H),3.02–2.02(m,4H),1.62(s,6H),1.01(t,J=7.2Hz,3H).13C NMR(101MHz,CDCl3)δ164.51(s),155.74(s),154.24(s),150.17(s),147.41(s),130.23(s),129.98(s),124.50(s),119.84(s),118.05(s),114.99(s),113.69(s),111.68(s),110.10(s),109.30(s),56.39(s),54.34(s),52.72(s),33.60(s),24.85(s),22.91(s),13.45(s).
实施例33 N‐乙基‐5‐甲氧基‐2‐苯基‐4‐(哌啶‐1‐亚甲基)苯并呋喃‐3‐甲酰胺(化合物S33)的制备
采用类似于实施例42的方法制备,不同之处在于得到化合物42‐1后,将42‐1,哌啶在1.5mL甲醇中搅拌10min后加入硼氢化钠,氯化镁,反应30min后乙酸乙酯(50mL×3)萃取,分出有机层,饱和氯化钠溶液洗涤,无水硫酸钠干燥,除去乙酸乙酯后粗品经硅胶柱层析纯化(石油醚:乙酸乙酯=3:1)得最终产物。1H NMR(400MHz,CDCl3)δ7.93(s,1H),7.62(s,1H),7.53(t,J=7.4Hz,1H),7.49(d,J=7.6Hz,1H)7.12(t,J=7.3Hz,1H),7.04(d,J=8.3Hz,1H),5.81(s,1H),4.25(s,2H),3.92(s,3H),3.85(s,3H),3.35(dd,J=7.3,5.8Hz,2H),2.98(m,4H),1.99–1.50(m,6H),1.03(t,J=7.3Hz,3H).13C NMR(101MHz,CDCl3)δ162.7(s),156.1(s),154.0(s),152.7(s),147.6(s),131.4(s),130.5(s),128.8(s),120.1(s),117.3(s),114.8(s),113.9(s),110.6(s),101.9(s),55.1(s),54.7(s),53.6(s),51.2(s),33.2(s),28.68(s),22.1(s),21.3(s),13.5(s).
实施例34 N‐乙基‐5‐甲氧基‐2‐苯基‐6‐(哌啶‐1‐亚甲基)苯并呋喃‐3‐甲酰胺(化合物S34)的制备
采用类似于实施例19的方法制备,不同之处在于19‐3后的步骤:
34.1化合物19‐3,加入氯仿使其溶解,加入二氯甲基甲醚,搅拌,滴加四氯化钛,室温下反应40分钟。反应毕,加水淬灭,用乙酸乙酯萃取,饱和氯化钠溶液洗去水,无水硫酸钠干燥,减压浓缩,抽油泵,得呈淡红色半固体的粗产品N‐乙基‐5‐甲氧基‐2‐苯基‐6‐甲酰基苯并呋喃‐3‐甲酰胺(下称34‐1)。
34.2将34-1溶于甲醇中,加入哌啶,醋酸,氰基硼氢化钠,室温下过夜。TLC检测至反应完全后,加乙酸乙酯萃取,饱和氯化钠溶液洗去水,无水硫酸钠干燥,减压浓缩,TLC纯化得最终产物。1H NMR(400MHz,MeOD)δ7.80–7.72(m,2H),7.65(s,1H),7.47–7.38(m,4H),4.25(s,2H),3.88(s,3H),3.38(q,J=7.3Hz,2H),3.07(s,4H),1.89–1.74(m,4H),1.58(s,2H),1.13(t,J=7.3Hz,3H).13C NMR(101MHz,MeOD)δ164.20(s),155.99(s),154.89(s),147.74(s),130.16(s),130.02(s),128.69(s),128.61(s),127.61(s),115.08(s),112.75(s),101.73(s).
实施例35 N‐乙基‐5‐甲氧基‐2‐(2‐甲氧基苯基)‐6‐(哌啶‐1‐亚甲基)苯并呋喃‐3‐甲酰胺(化合物S35)的制备
采用类似于实施例19,34的方法制备,不同之处在于以邻甲氧基苯乙酮代替苯乙酮,其余所需原料,试剂以及制备方法与实施例19,34相同,得终产物。1H NMR(400MHz,CDCl3)δ7.93(s,1H),7.62(s,1H),7.53(t,J=7.4Hz,1H),7.49(d,J=7.6Hz,1H)7.12(t,J=7.3Hz,1H),7.04(d,J=8.3Hz,1H),5.81(s,1H),4.25(s,2H),3.92(s,3H),3.85(s,3H),3.35(dd,J=7.3,5.8Hz,2H),2.98(m,4H),1.99–1.50(m,6H),1.03(t,J=7.3Hz,3H).13CNMR(101MHz,CDCl3)δ162.7(s),156.1(s),154.0(s),152.7(s),147.6(s),131.4(s),130.5(s),128.8(s),120.1(s),117.3(s),114.8(s),113.9(s),110.6(s),101.9(s),55.1(s),54.7(s),53.6(s),51.2(s),33.2(s),28.68(s),22.1(s),21.3(s),13.5(s).
实施例36 5‐羟基‐2‐苯基‐4‐(哌啶‐1‐亚甲基)苯并[b]噻吩‐3‐羧酸乙酯(化合物S36)的制备
采用类似于实施例37的方法制备,不同之处在于苯基乙酸甲酯代替4‐氟苯基乙酸甲酯,其余所需原料,试剂以及制备方法与实施例37相同,得最终产物。1H NMR(400MHz,CDCl3)δ7.58(d,J=8.7Hz,1H),7.52(d,J=5.5Hz,2H),7.40(d,J=5.6Hz,3H),6.94(d,J=8.7Hz,1H),4.25(q,J=7.1Hz,2H),3.87(s,2H),1.66(m,4H),1.25(m,6H),1.20(t,J=7.1Hz,3H).13C NMR(101MHz,CDCl3)δ167.2(s),156.3(s),144.3(s),135.4(s),132.6(s),129.6(s),127.8(s),127.7(s),127.5(s),124.4(s),120.8(s),115.5(s),112.9(s),60.7(s),57.5(s),52.9(s),28.7(s),24.7(s),22.9(s),12.9(s).
实施例37 2‐(4‐氟苯基)‐5‐羟基‐4‐(哌啶‐1‐亚甲基)苯并[b]噻吩‐3‐羧酸乙酯(化合物S37)的制备
采用类似于实施例39的方法制备,不同之处在于省略酯水解及酰化反应,其余所需原料,试剂以及制备方法与实施例39相同,得最终产物。1H NMR(400MHz,CDCl3)δ7.51(d,J=8.7Hz,1H),7.47–7.40(m,2H),7.03(t,J=8.6Hz,2H),6.87(d,J=8.7Hz,1H),4.18(q,J=7.1Hz,2H),3.79(s,2H),2.9-2.2(m,4H)1.59(m,6H),1.16(t,J=7.2Hz,3H).13C NMR(101MHz,MeOD)δ168.2(s),163.0(d,JC-F=249.3Hz),156.7(s),144.2(s),136.1(s),130.7(s),130.6(s),129.4(d,JC-F=3.4Hz),125.5(s),121.8(s),116.3(s),115.5(d,JC-F=21.8Hz),113.9(s),61.8(s),58.4(s),53.8(s),25.6(s),23.7(s),13.7(s).
实施例38 N‐乙基5‐羟基‐2‐苯基‐4‐(哌啶‐1‐亚甲基)苯并[b]噻吩‐3‐甲酰胺(化合物S38)的制备
采用类似于实施例39的方法制备,不同之处在于苯基乙酸甲酯代替4‐氟苯基乙酸甲酯,其余所需原料,试剂以及制备方法与实施例39相同,得最终产物。1H NMR(400MHz,CDCl3)δ8.71(s,1H),8.30(s,1H),7.69(d,J=7.5Hz,2H),7.39(s,1H),7.31(t,J=7.4Hz,2H),7.23(d,J=7.3Hz,1H),3.71(s,2H),3.53–3.45(m,2H),2.50(m,4H),1.60(m,4H),1.46(m,2H),1.23(t,J=7.3Hz,3H).
实施例39 N‐乙基‐2‐(4‐氟苯基)‐5‐羟基‐6‐(哌啶‐1‐亚甲基)苯并[b]噻吩‐3‐甲酰胺(化合物S39)的制备
39.1将8.53g 2‐溴‐5‐甲氧基苯甲醛,5.08g硫单质,10g4‐氟苯基乙酸甲酯和16.44g碳酸钾加入到70mL N,N‐二甲基甲酰胺中,氮气保护下在110℃持续反应11h,反应完毕旋蒸除去溶剂,二氯甲烷(50mL×3)萃取,分出有机层,饱和食盐水30ml洗涤,无水硫酸钠干燥,蒸去溶剂二氯甲烷后粗品经快速柱层析(石油醚:乙酸乙酯=15:1)得化合物39‐1;
39.2将化合物39‐1,0.9mL二氯甲基甲醚溶于无水三氯甲烷中,室温滴加1mL四氯化钛,反应30min,反应毕,饱和碳酸氢钠淬灭,硅藻土抽滤除去白色络合物,二氯甲烷(50mL×2)萃取,分出有机层,饱和食盐水30ml洗涤,无水硫酸钠干燥,快速柱层析(石油醚:乙酸乙酯=25:1)得化合物39‐2;
39.3将化合物39‐2265mg,251.1mg亚氯酸钠溶入10mL的二氧六环与水7:3的混合体系中,缓慢滴加7滴5%盐酸。反应完毕,饱和氯化铵缓冲pH,饱和亚硫酸钠淬灭,5%盐酸调节体系至弱酸性,二氯甲烷(30mL×3)萃取,分出有机层,饱和食盐水5ml洗涤,无水硫酸钠干燥,蒸去溶剂乙酸乙酯后所得粗产物用硅胶柱层析纯化(二氯甲烷:甲醇=50:1)得化合物39‐3;
39.4将110mg化合物39‐3溶于N,N‐二甲基甲酰胺,加入0.08mL三乙胺,130.8mg 2‐(7‐氧化苯并三氮唑)‐N,N,N’,N’,四甲基脲六氟磷酸酯(HATU),搅拌反应20min后,加入15.51mg乙胺,反应30min后,加入饱和氯化钠溶液,乙酸乙酯(30mL×3)萃取,水洗(30mL×3)除去二甲基甲酰胺,蒸去溶剂乙酸乙酯后所得粗产物用硅胶柱层析纯化(石油醚:乙酸乙酯=5:1)得化合物39‐4;
39.5将化合物39‐4101.4mg溶于5mL无水二氯甲烷,氮气保护下加入0.65mL三溴化硼室温反应,反应完毕,旋蒸除去溶剂,乙酸乙酯(20mL×3)萃取,分出有机层,饱和氯化钠溶液洗涤,无水硫酸钠干燥,蒸去溶剂二氯甲烷后粗品经快速柱层析(石油醚:乙酸乙酯=3:1)得化合物39‐5;
39.6将50mg化合物39‐5,90.07mg 37%甲醛,56.38mg哌啶于4mL乙醇中加热回流反应8h,反应毕,使用薄层层析硅胶板在石油醚:乙酸乙酯=1:1条件下纯化,得最终产物。1H NMR(400MHz,CDCl3)δ8.66(s,1H),8.37(s,1H),7.65(dd,J=8.6Hz,5.3Hz,2H),7.39(s,1H),7.00(t,J=8.6Hz,2H),3.72(s,2H),3.50(dd,J=7.3Hz,2H),2.44(m,4H),1.56(m,6H),1.23(t,J=7.3Hz,3H).13C NMR(101MHz,CDCl3)δ165.7(s),162.9,160.4(d,JC-F=246Hz)155.0(s),143.0(s),139.9(s),130.6(s),129.9(s),127.2(d,J=8.1Hz),123.2(s),121.1(s),119.1(s),114.8,114.6(d,JC-F=21.62Hz),113.(s),61.2(s),52.4(s),33.3(s),24.5(s),22.7(s),14.0(s).
实施例40 N‐环丙基‐2‐(4‐氟苯基)‐5‐羟基‐6‐(哌啶‐1‐亚甲基)苯并[b]噻吩‐3‐甲酰胺(化合物S40)的制备
采用类似于实施例39的方法制备,不同之处在于以环丙胺代替乙胺,其余所需原料,试剂以及制备方法与实施例39相同,得最终产物。1H NMR(400MHz,CDCl3)δ8.80(s,1H),8.63(s,1H),7.72(dd,J=8.6Hz,2H),7.47(s,1H),7.08(t,J=8.6Hz,2H),3.80(s,2H),2.99(dt,J=10.5,3.4Hz,1H),2.91–2.21(m,4H),1.69(m,6H),0.88(dd,J=6.7,12.1Hz,2H),0.66(dd,J=6.7,12.1Hz,2H).13C NMR(101MHz,CDCl3)δ167.5(s),162.5,160.4(d,JC-F=247.1Hz),155.3(s),143.2(s),139.9(s),130.6(s),129.9(s),127.2,127.1(d,JC-F=8.0Hz),121.2(s),114.9,114.7(d,JC-F=17.1Hz),61.2(s),52.47(s),28.64(s),24.50(s),22.65(s),21.66(s),5.67(s).
实施例41 N‐乙基‐2‐(4‐氟苯基)‐5‐羟基‐6‐(4‐甲基哌啶‐1‐亚甲基)苯并[b]噻吩‐3‐甲酰胺(化合物S41)的制备
采用类似于实施例39的方法制备,不同之处在于以对甲基哌啶代替哌啶,其余所需原料,试剂以及制备方法与实施例39相同,得最终产物。1H NMR(400MHz,CDCl3)δ8.72(s,1H),8.42(s,1H),7.72(dd,J=8.5,5.3Hz,2H),7.47(s,1H),7.08(t,J=8.6Hz,2H),3.82(s,2H),3.60–3.51(m,2H),3.02(d,J=11.3Hz,2H),2.19(t,J=11.4Hz,2H),1.73(d,J=12.9Hz,2H),1.48(s,1H),1.30(d,J=7.2Hz,3H),1.25(s,2H),0.98(d,J=6.4Hz,3H).13CNMR(101MHz,CDCl3)δ165.7(s),162.9,160.4(d,JC-F=245.2Hz),154.9(s),143.1(s),139.9(s),130.6(s),129.9(d,JC-F=3.4Hz),127.16(d,JC-F=8.1Hz),123.21(s),121.08(s),119.10(s),114.8,114.6(d,JC-F=21.6Hz),113.03(s),60.87(s),51.93(s),33.33(s),32.81(s),20.52(s),14.01(s).
实施例42 N‐乙基‐5‐甲氧基‐2‐苯基‐4‐(哌啶‐1‐羰基)苯并呋喃‐3‐甲酰胺(化合物S42)的制备
采用34‐1中间体,其后续制备方法如下:
42.1将34-1溶于二氧六环中,加入水,亚氯酸钠、氨基磺酸,室温下搅拌半小时。TLC检测至反应完全后,加硫代硫酸钠溶液淬灭,用盐酸溶液调pH为弱酸性,加乙酸乙酯萃取,饱和氯化钠溶液洗去水,无水硫酸钠干燥,减压浓缩,得淡黄色固体42-1。
42.2氮气保护下,将42-1、EDC·HCl、HOBT溶于DMF中,加吡啶、哌啶,室温下搅拌,过夜。TLC检测至反应完全后,加氯化铵溶液淬灭,乙酸乙酯萃取,有机相依次用5%的盐酸溶液、饱和碳酸氢钠溶液、饱和氯化钠溶液洗,无水硫酸钠干燥,减压浓缩,TLC纯化得最终产物。1H NMR(400MHz,CDCl3)δ7.95–7.85(m,1H),7.52–7.34(m,2H),6.96(d,J=9.0Hz,1H),6.24(s,1H),3.98–3.82(m,2H),3.64–3.51(m,1H),3.37–3.27(m,1H),3.26–3.16(m,1H),1.77–1.52(m,4H),1.27–1.20(m,3H).13C NMR(101MHz,CDCl3)δ165.38(s),164.05(s),154.85(s),151.93(s),148.90(s),129.67(s),129.45(s),128.79(s),127.21(s),124.91(s),117.75(s),113.44(s),111.68(s),110.02(s),57.18(s),48.15(s),42.47(s),35.19(s),26.17(s),25.55(s),24.77(s),14.39(s).
实施例43 N‐乙基‐5‐羟基‐2‐苯基‐4‐(哌啶‐1‐羰基)苯并呋喃‐3‐甲酰胺(化合物S43)的制备6‐47
采用化合物S42作为原料,其后续制备方法如下:
氮气保护,化合物S42加入二氯甲烷使其溶解,加入1M三溴化硼的二氯甲烷溶液,室温下搅拌,过夜。TLC检测反应完全后,加乙醇淬灭,减压浓缩,TLC纯化,得最终产物。1HNMR(400MHz,MeOD)δ7.77(d,J=7.1Hz,2H),7.43–7.24(m,4H),6.81(d,J=8.8Hz,1H),3.39–3.19(m,6H),1.71–1.47(m,6H),1.13(t,J=7.3Hz,3H).
实施例44 N‐乙基‐5‐甲氧基‐2‐苯基‐6‐(哌啶‐1‐羰基)苯并呋喃‐3‐甲酰胺(化合物S44)的制备
采用类似于实施例42的方法制备,所需原料,试剂以及制备方法与实施例42相同,得终产物。1H NMR(400MHz,CDCl3)δ7.80(dd,J=7.7,1.6Hz,2H),7.50–7.42(m,3H),7.36(s,1H),7.29(s,1H),6.04(s,1H),3.85(s,3H),3.71(m,2H),3.51–3.35(m,2H),3.23–3.08(m,2H),1.62(br,4H),1.44(br,2H),1.14(t,J=7.2Hz,3H).13C NMR(101MHz,CDCl3)δ166.09(s),162.64(s),154.62(s),151.62(s),147.21(s),129.08(s),128.25(s),127.88(s),127.83(s),127.26(s),123.64(s),112.04(s),109.10(s),101.38(s),55.09(s),46.99(s),41.64(s),33.49(s),25.27(s),24.63(s),23.59(s),13.48(s).
实施例45 N‐乙基‐5‐羟基‐2‐苯基‐6‐(哌啶‐1‐羰基)苯并呋喃‐3‐甲酰胺(化合物S45)的制备
采用类似于实施例43的方法制备,所需原料为化合物S44,其制备方法与实施例43相同,得终产物。1HNMR(400MHz,CDCl3)δ9.44(br,1H),7.99–7.81(m,2H),7.51–7.44(m,3H),7.36(s,1H),7.32(s,1H),5.92(br,1H),3.66(t,J=5.2Hz,4H),3.52–3.39(m,2H),1.77–1.63(m,6H),1.19(t,J=7.2Hz,3H).13C NMR(101MHz,CDCl3)δ170.62(s),163.50(s),157.43(s),154.77(s),146.93(s),131.05(s),130.38(s),129.27(s),128.89(s),128.33(s),116.34(s),112.97(s),110.43(s),108.16(s),47.09(s),34.82(s),26.26(s),24.68(s),14.80(s).
实施例46 5‐羟基‐2‐苯基‐4‐(哌啶‐1‐羰基)苯并呋喃‐3‐甲酸(化合物S46)的制备
采用化合物S47,用类似于实施例43的方法制备得终产物。1H NMR(400MHz,MeOD)δ7.88–7.79(m,2H),7.40–7.34(m,3H),7.30(d,J=8.8Hz,1H),6.82(d,J=8.8Hz,1H),3.27(s,4H),1.69-1.46(m,6H).
实施例47 5‐甲氧基‐2‐苯基‐4‐(哌啶‐1‐羰基)苯并呋喃‐3‐羧酸乙酯(化合物S47)的制备
采用中间体19‐1,用类似于实施例42的方法制备得终产物。1H NMR(400MHz,CDCl3)δ7.84–7.78(m,2H),7.48–7.41(m,4H),6.97(d,J=9.0Hz,1H),4.39–4.21(m,2H),4.05–3.95(m,1H),3.87(s,3H),3.59–3.48(m,1H),3.41–3.28(m,1H),3.23–3.11(m,1H),1.83–1.48(m,6H),1.26(t,J=7.1Hz,3H).13C NMR(101MHz,CDCl3)δ165.44(s),163.98(s),158.78(s),152.33(s),149.22(s),130.03(s),129.75(s),128.64(s),128.32(s),125.14(s),118.48(s),111.77(s),110.20(s),110.04(s),61.21(s),57.12(s),48.01(s),42.43(s),26.05(s),25.41(s),24.87(s),14.09(s).
实施例48 5‐羟基‐2‐苯基‐6‐(哌啶‐1‐羰基)苯并呋喃‐3‐甲酸(化合物S48)的制备
采用化合物S49,用类似于实施例43的方法制备得终产物。1H NMR(400MHz,MeOD)δ7.91(dd,J=6.4,2.9Hz,2H),7.46(s,1H),7.41–7.35(m,3H),7.32(s,1H),3.48(s,4H),1.67–1.44(m,6H).
实施例49 5‐甲氧基‐2‐苯基‐6‐(哌啶‐1‐羰基)苯并呋喃‐3‐羧酸乙酯(化合物S49)的制备
采用中间体19‐1,用类似于实施例42的方法制备得终产物。1H NMR(400MHz,CDCl3)δ7.98(dd,J=6.3,2.9Hz,2H),7.58(s,1H),7.52–7.45(m,3H),7.40(s,1H),4.40(q,J=7.1Hz,2H),3.92(s,3H),3.77(m,2H),3.21(d,J=4.5Hz,2H),1.67(s,6H),1.39(t,J=7.1Hz,3H).13C NMR(101MHz,CDCl3)δ167.18(s),163.99(s),162.12(s),153.03(s),148.36(s),130.52(s),129.69(s),129.64(s),128.58(s),128.19(s),124.85(s),110.39(s),109.00(s),103.75(s),60.84(s),56.18(s),48.20(s),42.83(s),26.48(s),25.79(s),24.77(s),14.32(s).
实施例50 2‐(4‐氟苯基)‐5‐甲氧基‐4‐(哌啶‐1‐羰基)苯并呋喃‐3‐羧酸乙酯(化合物S50)的制备
采用类似于实施例42的方法制备,不同之处在于以对氟苯乙酮代替苯乙酮,其余所需原料,试剂以及制备方法与实施例42相同,得终产物。1H NMR(400MHz,CDCl3)δ7.81(dd,J=8.7,5.4Hz,2H),7.42(d,J=9.0Hz,1H),7.12(t,J=8.6Hz,2H),6.95(d,J=9.0Hz,1H),4.38–4.20(m,2H),4.06–3.97(m,1H),3.85(s,3H),3.55–3.45(m,1H),3.33(dt,J=9.5,4.5Hz,1H),3.21–3.09(m,1H),1.62(m,6H),1.26(t,J=7.1Hz,3H).13C NMR(101MHz,CDCl3)δ165.35(s),164.92(s),163.72(s),162.42(s),157.92(s),152.36(s),149.07(s),130.81(d,J=8.6Hz),125.91(d,J=3.5Hz),124.98(s),118.51(s),115.54(s),115.32(s),111.69(s),110.02(s),61.16(s),57.00(s),47.94(s),42.35(s),25.97(s),25.35(s),24.80(s),14.08(s).
实施例51 2-(4-氟苯基)-5-羟基-4-(哌啶-1-羰基)苯并呋喃-3-羧酸乙酯(化合物S51)的制备
采用类似于实施例43的方法制备,化合物S50,其余所需原料,试剂以及制备方法与实施例43相同,得终产物。1HNMR(400MHz,CDCl3)δ7.97(dd,J=8.7,5.4Hz,2H),7.43(d,J=8.9Hz,1H),7.16(t,J=8.6Hz,2H),7.01(d,J=8.9Hz,1H),4.27(q,J=7.1Hz,2H),3.86(s,1H),3.12(dd,J=16.5,6.4Hz,2H),1.66–1.43(m,6H),1.30(d,J=7.1Hz,3H).
实施例52 2‐(4‐氟苯基)‐5‐甲氧基‐6‐(哌啶‐1‐羰基)苯并呋喃‐3‐羧酸乙酯(化合物S52)的制备
采用类似于实施例42的方法制备,不同之处在于以对氟苯乙酮代替苯乙酮,其余所需原料,试剂以及制备方法与实施例42相同,得终产物。1H NMR(400MHz,CDCl3)δ8.01(dd,J=7.0,5.6Hz,2H),7.56(s,1H),7.39(d,J=0.8Hz,1H),7.16(t,J=8.0Hz,2H),4.43–4.34(m,2H),3.90(s,3H),3.81(d,J=13.2Hz,1H),3.70(d,J=12.9Hz,1H),3.26–3.13(m,2H),1.65(s,4H),1.48(d,J=30.5Hz,2H),1.40(dd,J=7.0,6.2Hz,3H).13C NMR(101MHz,CDCl3)δ167.04(s),165.21(s),163.84(s),162.70(s),161.05(s),153.01(s),148.19(s),131.83(d,J=8.7Hz),128.38(s),125.74(d,J=3.2Hz),124.91(s),115.43(s),115.22(s),110.31(s),108.86(s),103.76(s),60.85(s),56.10(s),48.13(s),42.76(s),26.41(s),25.72(s),24.69(s),14.29(s).
实施例53 2‐(4‐氟苯基)‐5‐羟基‐6‐(哌啶‐1‐羰基)苯并呋喃‐3‐羧酸乙酯(化合物S53)的制备
采用类似于实施例43的方法制备,化合物S52,其余所需原料,试剂以及制备方法与实施例43相同,得终产物。1HNMR(400MHz,CDCl3)δ8.08(dd,J=8.8,5.4Hz,2H),7.62(s,1H),7.39(s,1H),7.18(t,J=8.7Hz,2H),4.42(q,J=7.1Hz,2H),3.71(m,4H),1.71(m,6H),1.43(t,J=7.1Hz,3H).
实施例54 N‐乙基‐2‐(4‐氟苯基)‐5‐羟基‐4‐(哌啶‐1‐羰基)苯并呋喃‐3‐甲酰胺(化合物S54)的制备
采用类似于实施例42和43的方法制备,不同之处在于以对氟苯乙酮代替苯乙酮,其余所需原料,试剂以及制备方法与实施例42和43相同,得终产物。1H NMR(400MHz,CDCl3)δ7.79(dd,J=8.8,5.3Hz,2H),7.28(s,1H),7.05(t,J=8.7Hz,2H),6.80(d,J=8.9Hz,1H),3.30(m,4H),1.59(m,6H),1.13(t,J=7.3Hz,3H).
实施例55 N‐乙基‐2‐(4‐氟苯基)‐5‐羟基‐6‐(哌啶‐1‐羰基)苯并呋喃‐3‐甲酰胺(化合物S55)的制备
采用类似于实施例42和43的方法制备,不同之处在于以对氟苯乙酮代替苯乙酮,其余所需原料,试剂以及制备方法与实施例42和43相同,得终产物。1H NMR(400MHz,CDCl3)δ9.49(s,1H),7.97(dd,J=8.8,5.4Hz,2H),7.34(s,1H),7.24(s,1H),7.16(t,J=8.6Hz,2H),5.99(s,1H),3.67(m,4H),3.48(p,J=7.2Hz,2H),1.73–1.65(m,6H),1.22(t,J=7.3Hz,3H).13C NMR(101MHz,CDCl3)δ170.53(s),163.42(s),156.78(s),154.83(s),146.74(s),130.80(s),130.46(d,J=8.6Hz),125.53(s),116.20(d,J=17.2Hz),115.90(s),112.68(s),110.50(s),107.86(s),34.89(s),29.83(s),26.25(s),24.66(s),14.90(s).
实施例56 N‐乙基‐5‐甲氧基‐2‐(2‐甲氧基苯基)‐6‐(哌啶‐1‐羰基)苯并呋喃‐3‐甲酰胺(化合物S56)的制备
采用类似于实施例42的方法制备,不同之处在于以邻甲氧基苯乙酮代替苯乙酮,其余所需原料,试剂以及制备方法与实施例42相同,得终产物。1HNMR(400MHz,CDCl3)δ7.59(s,1H),7.53(t,J=7.6Hz,1H),7.51(d,J=7.5Hz)7.35(s,1H),7.12(t,J=7.6Hz,1H),7.05(d,J=8.4Hz,1H),5.81(s,1H),3.90(s,3H),3.85(s,3H),3.81–3.69(m,2H),3.35(dd,J=18.9,6.3Hz,2H),3.19(dd,J=11.2,6.9Hz,2H),1.69–1.49(m,6H),1.03(t,J=7.3Hz,3H).13C NMR(101MHz,CDCl3)δ166.3(s),162.8(s),156.1(s),152.1(s),151.6(s),147.6(s),131.2(s),130.5(s),127.6(s),123.4(s),120.1(s),117.6(s),114.1(s),110.6(s),109.0(s),102.0(s),55.1(s),54.7(s),47.0(s),41.7(s),33.2(s),25.3(s),24.7(s),23.6(s),13.5(s).
实施例57 2‐(环丙基甲基)‐8‐苯基‐2,3‐二氢‐1H‐苯并呋喃并[4,5‐E][1,3]恶嗪‐9‐羧酸乙酯(化合物S57)的制备
采用类似于实施例1的方法制备,不同之处在于以伯胺环丙基甲胺代替N‐甲基哌嗪,其余所需原料,试剂以及制备方法与实施例1相同,得终产物。1H NMR(400MHz,MeOD)δ7.75–7.70(m,2H),7.49–7.43(m,3H),7.31(d,J=8.9Hz,1H),6.81(d,J=8.9Hz,1H),4.94(s,2H),4.43–4.29(m,4H),2.64(d,J=6.7Hz,2H),1.28(t,J=7.1Hz,3H),1.03–0.92(m,1H),0.60–0.51(m,2H),0.15(q,J=4.7Hz,2H).13C NMR(101MHz,MeOD)δ166.90(s),159.41(s),151.83(s),150.17(s),131.15(s),131.01(s),129.52(s),129.37(s),125.74(s),116.44(s),113.20(s),111.63(s),111.37(s),82.33(s),62.66(s),57.49(s),50.22(s),14.59(s),10.25(s),4.44(s).
实施例58 2‐(环丙基甲基)‐8‐(4‐甲氧基苯基)‐2,3‐二氢‐1H‐苯并呋喃并[4,5‐E][1,3]恶嗪‐9‐羧酸乙酯(化合物58)的制备
采用类似于实施例57的方法制备,不同之处在于以对甲氧基苯乙酮代替苯乙酮,其余所需原料,试剂以及制备方法与实施例57相同,得终产物。1H NMR(400MHz,CDCl3)δ7.74(d,J=8.8Hz,2H),7.26(d,J=8.8Hz,1H),6.97(d,J=8.8Hz,2H),6.77(d,J=8.9Hz,1H),4.99(s,2H),4.51–4.24(m,4H),3.86(s,3H),2.65(d,J=6.7Hz,2H),1.32(t,J=7.1Hz,3H),1.04–0.91(m,1H),0.56–0.51(m,2H),0.15(q,J=5.0Hz,2H).13C NMR(101MHz,CDCl3)δ165.4,160.7,158.1,150.5,148.3,129.8,124.7,122.3,114.7,113.7,112.1,110.1,108.9,81.3,61.2,56.2,55.3,49.2,14.0,9.5,3.5.HRMS(ESI)m/z:Calcd for(M+H)+408.1805;Found 408.1808.
实施例59乙基2‐环丙基‐8‐苯基‐2,3‐二氢‐1H‐苯并呋喃并[4,5‐E][1,3]恶嗪‐9‐羧酸乙酯(化合物S59)的制备
采用类似于实施例57的方法制备,不同之处在于以环丙胺代替环丙基甲胺,其余所需原料,试剂以及制备方法与实施例57相同,得终产物。1H NMR(400MHz,CDCl3)δ7.78(dd,J=6.3,1.6Hz,2H),7.50–7.43(m,3H),7.31(d,J=8.9Hz,1H),6.87(d,J=8.9Hz,1H),4.91(s,2H),4.44–4.31(m,4H),2.45–2.38(m,1H),1.31(t,J=7.1Hz,2H),0.58(d,J=4.8Hz,4H).13C NMR(101MHz,CDCl3)δ165.3,158.0,150.7,148.7,129.9,129.7,128.3,128.3,124.5,115.4,112.9,110.3,110.2,82.0,61.3,49.8,32.9,13.9,7.0.HRMS(ESI)m/z:Calcdfor(M+H)+364.1543;Found 364.1555.
实施例60 2‐(环丙基甲基)‐8‐(对甲苯基)‐2,3‐二氢‐1H‐苯并呋喃并[4,5‐E][1,3]恶嗪‐9‐羧酸乙酯(化合物S60)的制备。
采用类似于实施例57的方法制备,不同之处在于以对甲基苯乙酮代替苯乙酮,其余所需原料,试剂以及制备方法与实施例57相同,得终产物。1HNMR(400MHz,CDCl3)δ7.51(d,J=7.6Hz,1H),7.12(dd,J=19.3,12.3Hz,2H),6.63(d,J=8.8Hz,0H),4.83(s,1H),4.26–4.11(m,2H),2.49(d,J=6.4Hz,1H),2.27(d,J=13.6Hz,2H),1.19–1.10(m,1H),0.82(s,1H),0.38(d,J=7.3Hz,1H).13C NMR(101MHz,CDCl3)δ206.88,165.50,158.07,150.61,148.50,139.93,129.02,128.82,128.12,127.03,124.68,114.94,112.26,110.23,109.64,81.46,76.76,61.27,56.31,49.15,30.89,21.45,14.06,9.60,3.56.HRMS(ESI)m/z:Calcdfor(M+H)+392.1856;Found 392.1847.
实施例61 2‐(环丙基甲基)‐8‐(2‐甲氧基‐5‐甲基苯基)‐2,3‐二氢‐1H‐苯并呋喃并[4,5‐E][1,3]恶嗪‐9‐羧酸乙酯(化合物S61)的制备
采用类似于实施例57的方法制备,不同之处在于以1‐(2‐甲氧基‐5‐甲基苯基)乙酮代替苯乙酮,其余所需原料,试剂以及制备方法与实施例57相同,得终产物。1H NMR(400MHz,CDCl3)δ7.34(s,1H),7.23–7.08(m,2H),6.77(d,1H),6.71(d,1H),4.90(s,2H),4.22–4.08(m,2H),3.68(t,3H),2.58(d,2H),2.27(s,3H),1.08(t,3H),0.96–0.87(m,1H),0.45(d,2H),0.08(d,2H).13C NMR(101MHz,CDCl3)δ165.25,155.72,154.81,150.56,148.84,131.55,130.62,129.79,124.27,119.33,114.73,112.49,110.89,110.13,81.45,60.69,56.38,55.53,49.44,20.42,13.93,9.63,3.58,1.01,0.86.HRMS(ESI)m/z:Calcdfor(M+H)+422.1962,Found 422.1956.
实施例62 2‐(环丙基甲基)‐N,8‐二苯基‐2,3‐二氢‐1H‐苯并呋喃并[4,5‐E][1,3]恶嗪‐9‐甲酰胺(化合物S37)的制备
采用类似于实施例19的方法制备,不同之处在于以环丙基甲胺代替哌啶,以苯胺代替乙胺,其余所需原料,试剂以及制备方法与实施例19相同,得终产物。
1H NMR(400MHz,CDCl3)δ7.84(d,1H),7.51(d,J=7.6Hz,1H),7.48–7.45(m,1H),7.44(d,J=5.1Hz,1H),7.42(d,J=3.3Hz,1H),7.37(t,J=7.9Hz,1H),7.30(d,J=8.9Hz,1H),7.18(t,J=7.4Hz,1H),6.82(d,J=8.9Hz,1H),4.97(s,1H),4.37(s,1H),2.65(d,J=6.7Hz,1H),0.48(dt,J=7.8,5.1Hz,1H),0.12(dt,1H).13C NMR(101MHz,CDCl3)δ165.25,155.72,154.81,150.56,148.84,131.55,130.62,129.79,124.27,119.33,114.73,112.49,110.89,110.23,81.45,60.69,48.2,28.4,15.6,9.5,3.6.HRMS(ESI)m/z:Calcd for(M+H)+425.1860;Found425.1861.
实施例63 2‐(环丙基甲基)‐N‐(4‐甲基苯基)‐8‐苯基‐2,3‐二氢‐1H‐苯并呋喃并[4,5‐E][1,3]恶嗪‐9‐甲酰胺(化合物S63)的制备
采用类似于实施例62的方法制备,不同之处在于以对乙基苯胺代替乙胺,其余所需原料,试剂以及制备方法与实施例62相同,得终产物。1H NMR(400MHz,CDCl3)δ7.70(d,J=7.1Hz,2H),7.59(s,1H),7.35–7.25(m,5H),7.15(d,J=8.4Hz,1H),7.08(d,J=7.8Hz,2H),6.67(d,J=8.8Hz,1H),4.81(s,2H),4.22(s,2H),2.66–2.32(m,4H),1.16(m,4H),0.80(d,J=5.8Hz,2H),0.37(d,J=7.4Hz,2H).13C NMR(101MHz,CDCl3)δ163.5,153.3,150.4,148.5,141.2,135.1,129.5,129.2,128.9,128.5,126.8,125.1,120.4,115.2,113.7,112.3,110.1,81.7,56.4,48.2,28.4,15.6,9.5,3.6.HRMS(ESI)m/z:Calcd for C29H29N2O3(M+H)+453.2173;Found 453.2172.
实施例64 N‐(4‐氯苯基)‐2‐(环丙基甲基)‐8‐苯基‐2,3‐二氢‐1H‐苯并呋喃并[4,5‐E][1,3]恶嗪‐9‐甲酰胺(化合物S64)的制备
采用类似于实施例62的方法制备,不同之处在于以对氯苯胺代替乙胺,其余所需原料,试剂以及制备方法与实施例62相同,得终产物。1H NMR(400MHz,CDCl3)δ7.78(s,1H),7.65(s,2H),7.41–7.26(m,4H),7.14(d,J=8.4Hz,1H),6.93(s,2H),6.67(d,J=8.5Hz,1H),4.78(s,2H),4.18(s,2H),2.50(d,J=5.5Hz,2H),1.25–1.10(m,1H),0.80(s,2H),0.37(d,J=5.7Hz,2H).13C NMR(101MHz,CDCl3)δ163.25,153.35,150.54,147.78,137.20,129.67,129.24,129.02,126.98,125.07,120.08,115.32,113.85,113.70,112.39,110.23,81.78,56.45,48.26,9.56,3.56,0.94.
实施例65 2‐异戊基‐8‐苯基‐2,3‐二氢‐1H‐苯并呋喃并[4,5‐E][1,3]恶嗪‐9‐羧酸乙酯(化合物S65)的制备
采用类似于实施例57的方法制备,不同之处在于以异戊胺代替环丙基甲胺,其余所需原料,试剂以及制备方法与实施例57相同,得终产物。1H NMR(400MHz,CDCl3)δ7.71–7.66(m,2H),7.39–7.32(m,3H),7.20(d,J=8.9Hz,1H),6.74(d,J=8.9Hz,1H),4.80(s,2H),4.27(q,J=7.1Hz,2H),4.19(s,2H),2.68(t,J=7.56Hz,2H),1.56(dt,J=13.2,6.6Hz,1H),1.40(dd,J=14.9,7.1Hz,2H),1.21(t,J=7.1Hz,3H),0.82(d,J=6.6Hz,6H).13C NMR(101MHz,CDCl3)δ165.3,157.9,150.7,148.6,129.9,129.6,128.2,128.2,124.5,115.2,112.6,110.2,110.2,81.7,61.2,49.7,49.2,37.1,26.1,22.6,13.9.HRMS(ESI)m/z:Calcd for C24H28NO4(M+H)+394.2013;Found 394.2014.
实施例66 2‐环戊基‐8‐苯基‐2,3‐二氢‐1H‐苯并呋喃并[4,5‐E][1,3]恶嗪‐9‐羧酸(化合物S66)的制备
采用类似于实施例57的方法制备,不同之处在于以环戊胺代替环丙基甲胺,其余所需原料,试剂以及制备方法与实施例57相同,得终产物。1H NMR(400MHz,CDCl3)δ7.84–7.72(m,2H),7.50–7.42(m,3H),7.29(d,J=8.9Hz,1H),6.82(d,J=8.9Hz,1H),4.96(s,2H),4.49–4.22(m,4H),3.37–3.12(m,1H),2.11–1.84(m,2H),1.84–1.69(m,2H),1.65–1.46(m,4H),1.31(t,J=7.2Hz,3H).13C NMR(101MHz,CDCl3)δ165.4,157.8,151.2,148.6,129.9,129.7,128.3,128.2,124.4,115.1,112.7,110.2,110.2,81.1,61.3,59.8,48.0,31.5,23.7,14.0.
实施例67 2‐环丙基甲基‐N‐乙基‐8‐苯基‐2,3‐二氢‐1H‐苯并呋喃并[4,5‐E][1,3]恶嗪‐9‐甲酰胺(化合物S67)的制备
采用类似于实施例62的方法制备,不同之处在于以乙胺代替苯胺,其余所需原料,试剂以及制备方法与实施例62相同,得终产物。1H NMR(400MHz,CDCl3)δ7.70(d,J=7.3Hz,2H),7.39–7.29(m,3H),7.16(d,J=8.8Hz,1H),6.69(d,J=8.8Hz,1H),5.86(s,1H),4.87(s,2H),4.24(s,2H),3.44–3.34(m,2H),2.58(d,J=6.4Hz,2H),1.11(t,J=7.1Hz,3H),0.92–0.86(m,1H),0.46(d,J=7.3Hz,2H),0.08(s,2H).13C NMR(101MHz,CDCl3)δ164.5(s),151.9(s),149.3(s),147.5(s),128.4(s),128.3(s),127.8(s),125.8(s),124.1(s),113.9(s),112.6(s),111.3(s),109.1(s),80.7(s),55.5(s),46.9(s),33.9(s),13.3(s),8.6(s),2.6(s).
实施例68 9‐氯‐2‐(环丙基甲基)‐2,3‐二氢‐1H,13H‐色烯并[4',3':2,3]苯并呋喃并[4,5‐E][1,3]恶嗪‐13‐酮(化合物S68)的制备
采用类似于实施例1的方法制备,不同之处在于进行第一步合成时以2‐甲氧基‐5‐氯苯乙酮代替苯乙酮,合成5‐羟基‐2‐(2‐甲氧基‐5‐氯苯基)苯并呋喃‐3‐羧酸乙酯后,将其溶于DCM中,氮气保护,0℃冰水浴条件下缓慢滴加1mmol/mL的BBr3·DCM,滴加完毕室温搅拌5h,乙醇淬灭,另加5mL乙醇加热回流5h,减压浓缩除去溶剂,二氯甲烷(50mL×3)萃取,分离有机相减压浓缩,快速柱纯化(石油醚:乙酸乙酯=10:1)得化合物;之后与甲醛,环丙基甲胺在乙醇回流下反应得终产物。
1H NMR(400MHz,CDCl3)δ7.96(s,1H),7.52(d,J=8.4Hz,1H),7.40(m,2H),6.92(d,J=8.8Hz,1H),5.03(s,2H),4.83(s,2H),2.69(d,J=6.0Hz,2H),1.03(s,1H),0.56(d,J=6.3Hz,2H),0.15(s,2H).13C NMR(101MHz,CDCl3)δ158.0,156.5,151.0,150.7,149.2,130.7,129.1,120.3,120.2,117.6,116.1,113.5,112.6,109.6,106.2,81.0,55.4,48.9,8.5,2.6.HRMS(ESI)m/z:Calcd forC21H17ClNO4(M+H)+382.0841;Found 382.0862.
实施例69 9‐溴‐2‐(环丙基甲基)‐2,3‐二氢‐1H,13H‐色烯并[4',3':2,3]苯并呋喃并[4,5‐E][1,3]恶嗪‐13‐酮(化合物S69)的制备
采用类似于实施例68的方法制备,不同之处在于以2‐甲氧基‐5‐溴苯乙酮代替2‐甲氧基‐5‐氯苯乙酮,其余所需原料,试剂以及制备方法与实施例68相同,得终产物。1H NMR(400MHz,CDCl3)δ8.11(s,1H),7.65(d,J=8.3Hz,1H),7.36(dd,J=16.4,8.9Hz,2H),6.91(d,J=8.9Hz,1H),5.02(s,2H),4.82(s,2H),2.69(d,J=6.6Hz,2H),1.02(br,1H),0.56(d,J=7.2Hz,2H),0.15(d,J=4.2Hz,2H).13C NMR(101MHz,CDCl3)δ158.9,157.5,152.2,152.1,150.2,134.5,124.3,121.3,118.9,117.4,117.2,114.5,114.1,110.7,107.2,82.0,56.5,49.9,9.6,3.6.HRMS(ESI)m/z:Calcd forC21H17BrNO4(M+H)+426.0335;Found426.0321.
实施例70 9‐氟‐2‐(环丙基甲基)‐2,3‐二氢‐1H,13H‐色烯并[4',3':2,3]苯并呋喃并[4,5‐E][1,3]恶嗪‐13‐酮(化合物S70)的制备
采用类似于实施例68的方法制备,不同之处在于以2‐甲氧基‐5‐氟苯乙酮代替2‐甲氧基‐5‐氯苯乙酮,其余所需原料,试剂以及制备方法与实施例68相同,得终产物。1H NMR(400MHz,CDCl3)δ7.57(d,J=7.6Hz,1H),7.36(dd,J=9.0,4.1Hz,1H),7.31(d,J=8.9Hz,1H),7.23(d,J=8.3Hz,1H),6.84(d,J=8.9Hz,1H),4.95(s,2H),4.76(s,2H),2.61(d,J=6.6Hz,2H),1.01–0.91(m,1H),0.48(d,J=7.8Hz,2H),0.08(d,J=4.8Hz,2H).13C NMR(101MHz,CDCl3)δ159.1,158.4(d,JC-F=2.8Hz),156.7(d,JC-F=3.8Hz),151.0,149.2,148.6,120.4,118.3(d,JC-F=24.7Hz),117.9(d,JC-F=8.5Hz),116.1,113.5,112.2(d,JC-F=9.6Hz),109.6,106.5(d,JC-F=25.7Hz),106.2,81.0,55.4,48.9,8.5,2.6.HRMS(ESI)m/z:Calcd forC21H17FNO4(M+H)+366.1136;Found 366.1166.
实施例71 9‐甲基‐2‐(环丙基甲基)‐2,3‐二氢‐1H,13H‐色烯并[4',3':2,3]苯并呋喃并[4,5‐E][1,3]恶嗪‐13‐酮(化合物S71)的制备
采用类似于实施例68的方法制备,不同之处在于以1‐(2‐甲氧基‐5‐甲基苯基)乙酮代替2‐甲氧基‐5‐氯苯乙酮,其余所需原料,试剂以及制备方法与实施例68相同,得终产物。1H NMR(400MHz,CDCl3)δ7.76(s,1H),7.42–7.31(m,3H),6.88(d,J=8.9Hz,1H),5.02(s,2H),4.84(s,2H),2.69(d,J=6.6Hz,2H),2.47(s,3H),1.02(s,1H),0.55(d,J=7.6Hz,2H),0.15(d,J=4.6Hz,2H).13C NMR(101MHz,CDCl3)δ159.5,157.3,150.8,150.7,149.0,133.4,131.9,120.7,120.4,115.9,115.4,113.4,111.1,109.4,105.4,80.9,55.4,49.0,19.9,8.6,2.6.HRMS(ESI)m/z:Calcd for C22H19NNaO4(M+Na)+384.1206;Found 384.1214.
实施例72 9‐甲氧基‐2‐(环丙基甲基)‐2,3‐二氢‐1H,13H‐色烯并[4',3':2,3]苯并呋喃并[4,5‐E][1,3]恶嗪‐13‐酮(化合物S72)的制备
采用类似于实施例68的方法制备,不同之处在于以2,5‐二甲氧基苯乙酮代替2‐甲氧基‐5‐氯苯乙酮,其余所需原料,试剂以及制备方法与实施例68相同,得终产物。1H NMR(400MHz,CDCl3)δ7.37(m,3H),7.13(d,J=9.2Hz,1H),6.89(d,J=8.9Hz,1H),5.02(s,2H),4.84(s,2H),3.92(s,3H),2.69(d,J=6.7Hz,2H),1.13–0.95(m,1H),0.55(d,J=7.6Hz,2H),0.15(d,J=4.5Hz,2H).13C NMR(101MHz,CDCl3)δ159.3,157.2,155.2,150.8,149.0,147.1,120.7,119.2,117.4,115.6,113.5,111.7,109.4,105.7,102.2,80.9,55.4,54.9,49.0,8.6,2.6.HRMS(ESI)m/z:Calcd for C21H17BrNO4(M+H)+426.0335;Found 426.0327.
实施例73 9,10‐二甲基‐2‐(环丙基甲基)‐2,3‐二氢‐1H,13H‐色烯并[4',3':2,3]苯并呋喃并[4,5‐E][1,3]恶嗪‐13‐酮(化合物S73)的制备
采用类似于实施例68的方法制备,不同之处在于以4,5‐二甲基‐2‐甲氧基苯乙酮代替2‐甲氧基‐5‐氯苯乙酮,其余所需原料,试剂以及制备方法与实施例68相同,得终产物。1HNMR(400MHz,CDCl3)δ7.70(s,1H),7.35(d,J=8.8Hz,1H),7.23(s,1H),6.86(d,J=8.8Hz,1H),5.01(s,2H),4.84(s,2H),2.69(d,J=6.6Hz,2H),2.37(d,J=5.5Hz,6H),1.02(d,J=5.6Hz,1H),0.56(d,J=7.5Hz,2H),0.16(d,J=4.2Hz,2H).13C NMR(101MHz,CDCl3)δ159.8,157.5,151.1,150.8,148.8,141.0,132.5,120.8,120.7,116.6,115.1,113.3,109.4,109.0,104.7,80.9,55.4,49.1,19.5,18.3,8.6,2.6.HRMS(ESI)m/z:Calcd for(M+H)+376.1543;Found 376.1545.
实施例74 9,10‐二氯‐2‐(环丙基甲基)‐2,3‐二氢‐1H,13H‐色烯并[4',3':2,3]苯并呋喃并[4,5‐E][1,3]恶嗪13‐酮(化合物S74)的制备
采用类似于实施例68的方法制备,不同之处在于以2‐甲氧基‐4,5‐二氯苯乙酮代替2‐甲氧基‐5‐氯苯乙酮,其余所需原料,试剂以及制备方法与实施例68相同,得终产物。1HNMR(400MHz,CDCl3)δ8.06(s,1H),7.59(s,1H),7.39(d,J=9.0Hz,1H),6.93(d,J=8.9Hz,1H),5.02(s,2H),4.81(s,2H),2.68(d,J=6.6Hz,2H),1.07–0.97(m,1H),0.56(d,J=7.6Hz,2H),0.15(d,J=4.6Hz,2H).13C NMR(101MHz,CDCl3)δ158.4,157.1,152.2,151.6,150.3,135.9,129.0,122.6,121.3,119.2,117.4,114.5,112.2,110.7,107.2,82.0,56.5,49.9,9.6,3.6.HRMS(ESI)m/z:Calcd for C21H16Cl2NO4(M+H)+416.0451;Found416.0446.
实施例75 2‐(环丙基)‐10‐甲氧基‐2,3‐二氢‐1H,13H‐色烯并[4',3':2,3]苯并呋喃并[4,5‐E][1,3]恶嗪13酮(化合物S75)的制备
采用类似于实施例68的方法制备,不同之处在于以2,4‐二甲氧基苯乙酮代替2‐甲氧基‐5‐氯苯乙酮,其余所需原料,试剂以及制备方法与实施例68相同,得终产物。1H NMR(400MHz,CDCl3)δ7.87(d,J=8.7Hz,1H),7.34(d,J=8.9Hz,1H),7.03–6.91(m,2H),6.85(d,J=8.9Hz,1H),5.02(s,2H),4.84(s,2H),3.91(s,3H),2.69(d,J=6.6Hz,2H),1.11–0.96(m,1H),0.56(d,J=7.5Hz,2H),0.16(d,J=4.7Hz,2H).13C NMR(101MHz,CDCl3)δ163.0,161.1,158.4,155.4,151.8,149.7,122.8,121.8,115.8,114.2,113.1,110.3,105.8,104.0,101.0,81.9,56.4,55.8,50.0,9.6,3.6.HRMS(ESI)m/z:Calcd forC22H20NO5(M+H)+378.1336;Found 378.1333.
实施例76 2‐环己基‐2,3‐二氢‐1H,13H‐色烯并[4',3':2,3]苯并呋喃并[4,5‐E][1,3]恶嗪13酮(化合物S76)的制备
采用类似于实施例78的方法制备,不同之处在于以环己胺代替环丙基甲胺,其余所需原料,试剂以及制备方法与实施例78相同,得终产物。1H NMR(400MHz,CDCl3)δ7.99(d,J=7.7Hz,1H),7.58(t,J=7.8Hz,1H),7.46(d,J=8.3Hz,1H),7.38(t,J=8.3Hz,2H),6.88(d,J=8.8Hz,1H),5.04(s,2H),4.84(s,2H),2.75(t,J=10.6Hz,1H),2.01(d,J=11.2Hz,2H),1.76(d,J=12.0Hz,2H),1.43–1.08(m,6H).13C NMR(101MHz,CDCl3)δ160.4,158.2,153.5,152.8,150.0,131.8,124.5,121.8,121.2,117.2,116.8,116.0,112.6,110.3,106.6,80.4,59.2,47.1,31.6,25.9,25.6.HRMS(ESI)m/z:Calcd for(M+H)+376.1543;Found 376.1562.
实施例77 2‐环戊基‐2,3‐二氢‐1H,13H‐色烯并[4',3':2,3]苯并呋喃并[4,5‐E][1,3]恶嗪13酮(化合物S77)的制备
采用类似于实施例78的方法制备,不同之处在于以环戊胺代替环丙基甲胺,其余所需原料,试剂以及制备方法与实施例78相同,得终产物。1H NMR(400MHz,CDCl3)δ7.99(d,J=7.6Hz,1H),7.58(t,J=7.5Hz,1H),7.47(d,J=8.2Hz,1H),7.39(d,J=8.1Hz,2H),6.91(d,J=8.9Hz,1H),4.98(s,2H),4.83(s,2H),3.22(s,1H),1.99(s,2H),1.74(s,2H),1.56(s,4H).13C NMR(101MHz,CDCl3)δ160.4,158.1,153.5,152.4,150.1,131.8,124.5,121.8,121.5,117.2,116.5,114.8,112.5,110.4,106.6,81.7,60.1,49.0,31.4,23.7.HRMS(ESI)m/z:Calcd for C22H20NO4(M+H)+362.1387;Found 362.1400.
实施例78 2‐(环丙基甲基)‐2,3‐二氢‐1H,13H‐色烯并[4',3':2,3]苯并呋喃并[4,5‐E][1,3]恶嗪‐13‐酮(化合物S78)的制备
采用类似于实施例68的方法制备,不同之处在于以2‐甲氧基苯乙酮代替2‐甲氧基‐5‐氯苯乙酮,其余所需原料,试剂以及制备方法与实施例68相同,得终产物。1H NMR(400MHz,CDCl3)δ8.00(d,J=7.8Hz,1H),7.59(t,J=7.7Hz,1H),7.47(d,J=8.3Hz,1H),7.43–7.36(m,2H),6.90(d,J=8.9Hz,1H),5.03(s,2H),4.86(s,2H),2.70(d,J=6.6Hz,2H),1.09–0.97(m,1H),0.56(d,J=7.7Hz,2H),0.16(d,J=4.7Hz,2H).13C NMR(101MHz,CDCl3)δ160.4,158.0,153.6,151.9,150.1,131.8,124.6,121.8,121.7,117.2,116.6,114.4,112.6,110.6,106.5,82.0,56.5,50.0,9.6,3.6.HRMS(ESI)m/z:Calcd forC21H18NO4(M+H)+348.1230;Found 348.1252.
实施例79 8‐羟基‐7‐(哌啶‐1‐亚甲基)‐6H‐苯并呋喃[3,2‐c]苯并吡喃‐6‐酮(化合物S79)的制备
采用类似于实施例1的方法制备,不同之处在于进行第一步合成时以邻甲氧基苯乙酮代替苯乙酮,合成5‐羟基‐2‐(2‐甲氧基苯基)苯并呋喃‐3‐羧酸乙酯后,将化合物溶于DCM中,氮气保护,0℃冰水浴条件下缓慢滴加1mmol/mL的BBr3·DCM,滴加完毕室温搅拌5h,乙醇淬灭,另加5mL乙醇加热回流5h,减压浓缩除去溶剂,二氯甲烷(50mL×3)萃取,分离有机相减压浓缩,快速柱纯化(石油醚:乙酸乙酯=10:1)得中间体;之后与甲醛,哌啶回流反应,得终产物。1H NMR(400MHz,CDCl3/MeOD=4/1)δ7.92(d,J=7.6Hz,1H),7.61(t,J=7.7Hz,1H),7.45(d,J=8.9Hz,1H),7.42–7.36(m,2H),6.94(d,J=8.9Hz,1H),4.71(s,2H),2.96(br,4H),1.83–1.70(m,4H),1.61(br,2H).13C NMR(101MHz,CDCl3/MeOD=4/1)δ161.9,159.9,157.5,154.1,150.2,133.2,125.8,124.2,122.6,117.7,116.9,113.5,112.9,112.3,106.6,56.6,54.0,25.1,23.6.HRMS(ESI)m/z:Calcd for C21H20NO4(M+H)+350.1387;Found 350.1389.
实施例80 3‐溴‐8‐羟基‐7‐(哌啶‐1‐亚甲基)‐6H‐苯并呋喃[3,2‐c]苯并吡喃‐6‐酮(化合物S80)的制备
采用类似于实施例79的方法制备,不同之处在于以2‐甲氧基‐4‐溴苯乙酮代替邻甲氧基苯乙酮,其余所需原料,试剂以及制备方法与实施例79相同,得终产物。1H NMR(400MHz,CDCl3)δ7.87(d,J=8.4Hz,1H),7.66(s,1H),7.52(d,J=8.3Hz,1H),7.43(d,J=8.9Hz,1H),6.97(d,J=8.9Hz,1H),5.30(br,1H),4.66(s,2H),2.51(br,4H),1.67-1.49(m,6H).13C NMR(101MHz,CDCl3)δ160.0,157.7,157.5,153.5,149.5,128.0,125.7,122.8,122.4,120.3,116.8,114.9,111.6,111.1,106.2,58.4,53.6,25.8,23.9.HRMS(ESI)m/z:Calcd for(M+H)+428.0492;Found 428.0464.
实施例81 3‐氟‐8‐羟基‐7‐(哌啶‐1‐亚甲基)‐6H‐苯并呋喃[3,2‐c]苯并吡喃‐6‐酮(化合物S81)的制备
采用类似于实施例79的方法制备,不同之处在于以2‐甲氧基‐4‐氟苯乙酮代替邻甲氧基苯乙酮,其余所需原料,试剂以及制备方法与实施例79相同,得固体终产物。1H NMR(400MHz,CDCl3/MeOD=4/1)δ8.04(dd,J=8.4,6.1Hz,1H),7.44(d,J=8.9Hz,1H),7.25–7.14(m,2H),6.90(d,J=8.9Hz,1H),4.65(d,J=3.8Hz,2H),2.68(br,4H),1.71–1.61(m,4H),1.55(br,2H).13C NMR(101MHz,CDCl3/MeOD=4/1)δ165.4(d,JC-F=253.6Hz),161.3,159.2,158.1,155.2(d,JC-F=13.0Hz),150.1,124.4(d,JC-F=10.4Hz),123.1,117.1,114.9,113.7(d,JC-F=23.3Hz),112.0,110.0,105.5,105.1(d,JC-F=26.2Hz),58.8,54.1,26.2,24.3.HRMS(ESI)m/z:Calcd for C21H19FNO4(M+H)+368.1293;Found 368.1307.
实施例82 8‐羟基‐2‐甲基‐7‐(哌啶‐1‐亚甲基)‐6H‐苯并呋喃[3,2‐c]苯并吡喃‐6‐酮(化合物S82)的制备
采用类似于实施例79的方法制备,不同之处在于以5‐甲基‐2‐甲氧基‐苯乙酮代替邻甲氧基苯乙酮,其余所需原料,试剂以及制备方法与实施例79相同,得固体终产物。1HNMR(400MHz,CDCl3)δ9.47(br,1H),7.78(s,1H),7.47–7.30(m,3H),6.94(d,J=8.8Hz,1H),4.68(s,2H),3.18–2.29(m,7H),1.90–1.20(m,6H).13C NMR(101MHz,CDCl3)δ160.7,158.5,157.3,151.7,149.4,134.4,132.9,122.7,121.5,116.7,116.3,114.9,112.2,110.9,106.0,58.5,53.6,25.9,23.9,21.0.HRMS(ESI)m/z:Calcd for C22H22NO4(M+H)+364.1543,Found 364.1532.
实施例83 8‐羟基‐2‐甲氧基‐7‐(哌啶‐1‐亚甲基)‐6H‐苯并呋喃[3,2‐c]苯并吡喃‐6‐酮(化合物S83)的制备
采用类似于实施例79的方法制备,不同之处在于以2,5‐二甲氧基‐苯乙酮代替邻甲氧基苯乙酮,其余所需原料,试剂以及制备方法与实施例79相同,得终产物。1H NMR(400MHz,CDCl3)δ8.85(br,1H),7.57–7.34(m,3H),7.15(d,J=8.7Hz,1H),6.96(dd,J=8.3,3.4Hz,1H),4.70(d,J=2.8Hz,2H),3.93(d,J=3.0Hz,3H),3.05–2.36(m,4H),1.85–1.42(m,6H).13C NMR(101MHz,CDCl3)δ160.6,158.4,157.3,156.3,149.4,148.0,122.7,120.3,118.3,116.4,114.9,112.7,110.9,106.3,103.2,58.4,55.9,53.6,25.9,23.9.HRMS(ESI)m/z:Calcd for C22H22NO5(M+H)+380.1492;Found 380.1507.
实施例84 8‐羟基‐3‐甲氧基‐(7‐(1‐哌啶基)亚甲基)‐6H‐苯并呋喃[3,2h]吡喃‐6‐酮(化合物S84)的制备
采用类似于实施例79的方法制备,不同之处在于以2,4‐二甲氧基‐苯乙酮代替邻甲氧基苯乙酮,其余所需原料,试剂以及制备方法与实施例79相同,得终产物。1H NMR(400MHz,MeOD)δ7.86(d,J=8.8Hz,1H),7.45(d,J=8.9Hz,1H),6.98(d,J=8.8Hz,1H),6.93(d,J=8.8Hz,2H),4.75(s,2H),3.90(s,3H),3.00(br,4H),1.81–1.73(m,4H),1.62(s,2H).13C NMR(101MHz,MeOD)δ164.4,162.7,160.3,157.0,156.0,149.9,124.5,123.7,115.9,114.2,113.4,111.8,106.0,104.0,101.6,56.3,53.9,24.9,23.4.HRMS(ESI)m/z:Calcd for C22H22NO5(M+H)+380.1492;Found 380.1494.
实施例85 3,8‐二羟基‐4,7‐二(1‐哌啶基)亚甲基)‐6H‐苯并呋喃并[3,2‐c]苯并吡喃‐6‐酮(化合物S85)的制备
采用类似于实施例79的方法制备,不同之处在于以4-羟基-3-甲基哌啶基-2-甲氧基苯乙酮代替邻甲氧基苯乙酮,其余所需原料,试剂以及制备方法与实施例79相同,得终产物。1H NMR(400MHz,MeOD)δ7.71(d,J=8.7Hz,1H),7.37(d,J=8.8Hz,1H),6.83(d,J=8.9Hz,1H),6.73(d,J=8.7Hz,1H),4.69(s,2H),4.11(s,2H),3.02–2.65(m,8H),1.76–1.47(m,12H).
实施例86 3,8-二羟基-7-(哌啶-1-亚甲基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S86)的制备
采用S84为原料,在三溴化硼,二氯甲烷做溶剂下,生成最终产物。1H NMR(400MHz,CDCl3/MeOD=3/1)δ7.77(d,J=8.6Hz,1H),7.45(d,J=8.9Hz,1H),7.02(d,J=8.8Hz,1H),6.89(d,J=8.6Hz,1H),6.82(s,1H),4.85(s,2H),3.15(br,4H),1.82(br,4H),1.62(br,2H).13C NMR(101MHz,CDCl3/MeOD=3/1)δ163.09(s),162.77(s),160.46(s),155.85(s),155.80(s),149.46(s),124.72(s),123.57(s),115.31(s),114.77(s),113.85(s),109.75(s),104.41(s),103.43(s),102.78(s),54.70(s),53.46(s),23.67(s),22.59(s).
实施例87 2,8-二羟基-7-(哌啶-1-亚甲基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S87)的制备
采用S83为原料,在三溴化硼,二氯甲烷做溶剂下,生成最终产物。1H NMR(400MHz,CDCl3/MeOD=2/1)δ7.58(d,J=8.9Hz,1H),7.36(d,J=2.5Hz,1H),7.32(d,J=9.0Hz,1H),7.13(dd,J=9.0,2.6Hz,1H),7.06(d,J=9.0Hz,1H),4.89(s,2H),3.19(br,4H),1.83(br,4H),1.66(br,2H).
实施例88 9-溴-8-羟基-7-(哌啶-1-亚甲基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S88)的制备
采用S79化合物作为原料,二氯甲烷做溶剂,滴加液溴(1.2eq),室温反应过夜,硫代硫酸钠淬灭,二氯甲烷萃取,无水硫酸钠干燥,减压浓缩,柱纯化,得最终产物。1H NMR(400MHz,MeOD)δ8.01(dd,J=7.8,1.2Hz,1H),7.79(s,1H),7.67–7.59(m,1H),7.49–7.37(m,3H),4.82(s,2H),2.81(br,4H),1.65(br,6H).13C NMR(101MHz,MeOD)δ161.35(s),159.03(s),156.59(s),153.62(s),148.28(s),132.60(s),125.24(s),122.58(s),122.25(s),117.30(s),115.40(s),113.43(s),112.51(s),111.94(s),105.82(s),58.56(s),53.35(s),25.23(s),23.56(s).
实施例89 8-羟基-9-甲氧基-7-(哌啶-1-亚甲基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S89)的制备
采用S79化合物作为原料,溶于DMF中,加入氯化亚铜,甲醇钠,回流5h,TLC纯化,得最终产物。1H NMR(400MHz,MeOD)δ7.97(d,J=7.6Hz,1H),7.59(t,J=7.6Hz,1H),7.49–7.37(m,2H),7.24(s,1H),4.86(s,2H),3.96(s,3H),3.07(br,3H),1.80(s,4H),1.62(br,2H).13C NMR(101MHz,MeOD)δ160.22(s),159.95(s),153.14(s),149.87(s),149.00(s),146.97(s),132.16(s),125.44(s),121.91(s),117.39(s),115.77(s),112.71(s),109.98(s),106.54(s),96.43(s),56.59(s),55.43(s),53.62(s),24.10(s),22.85(s).
实施例90 8-羟基-9-硝基-7-(哌啶-1-亚甲基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S90)的制备
采用S79化合物作为原料,溶于醋酸中,滴加硝酸,室温反应1h,反应毕,TLC纯化,得终产物。1H NMR(400MHz,CDCl3)δ8.24(s,1H),8.06(d,J=7.8Hz,1H),7.69(t,J=7.7Hz,1H),7.51(d,J=8.4Hz,1H),7.46(t,J=7.6Hz,1H),4.97(s,2H),2.93(br,4H),1.89–1.75(m,4H),1.62(br,2H).13C NMR(101MHz,CDCl3)δ165.06(s),162.08(s),159.02(s),154.14(s),143.95(s),136.42(s),133.86(s),129.82(s),125.58(s),122.92(s),117.51(s),114.08(s),112.05(s),110.29(s),104.72(s),57.00(s),52.76(s),23.59(s),22.48(s).
实施例91 8,9-二羟基-7-(哌啶-1-亚甲基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S91)的制备
采用S89化合物作为原料,二氯甲烷做溶剂,滴加BBr3,室温反应过夜,乙醇淬灭,二氯甲烷萃取,无水硫酸钠干燥,减压浓缩,柱纯化,得最终产物。1H NMR(400MHz,MeOD)δ8.01(d,J=7.8Hz,1H),7.67(t,J=7.6Hz,1H),7.57–7.42(m,2H),7.25(s,1H),4.91(s,2H),3.64(d,J=12.4Hz,2H),3.20(t,J=11.9Hz,2H),1.98(d,J=14.1Hz,2H),1.86–1.69(m,3H),1.62(t,J=12.8Hz,1H).13C NMR(101MHz,MeOD)δ161.16(s),160.72(s),154.22(s),151.09(s),147.58(s),146.84(s),133.12(s),126.43(s),122.65(s),118.16(s),116.50(s),113.55(s),109.00(s),107.95(s),100.92(s),54.26(s),53.93(s),23.93(s),22.79(s).
实施例92 10-溴-8-羟基-7-(哌啶-1-亚甲基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S92)的制备
采用类似于实施例79的方法制备,不同之处在于以溴代苯醌代替苯醌,其余所需原料,试剂以及制备方法与实施例79相同,得终产物。1H NMR(400MHz,MeOD)δ8.08(d,J=7.7Hz,1H),7.64(t,J=7.7Hz,1H),7.51–7.39(m,2H),7.18(s,1H),4.79(s,2H),2.90(br,4H),1.76(s,4H),1.59(br,2H).13C NMR(101MHz,MeOD)δ161.74(s),159.28(s),157.95(s),153.78(s),146.93(s),133.16(s),125.47(s),124.85(s),122.62(s),119.60(s),117.39(s),112.23(s),111.09(s),106.67(s),105.51(s),55.96(s),53.54(s),24.41(s),23.04(s).
实施例93 10-氯-8-羟基-7-(哌啶-1-亚甲基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S93)的制备
采用类似于实施例79的方法制备,不同之处在于以氯代苯醌代替苯醌,其余所需原料,试剂以及制备方法与实施例79相同,得终产物。1H NMR(400MHz,MeOD)δ8.06(d,J=7.6Hz,1H),7.62(t,J=7.9Hz,1H),7.50–7.37(m,2H),6.91(s,1H),4.68(s,2H),2.71(br,4H),1.80–1.47(m,6H).HRMS(ESI)m/z:Calcd for C21H19ClNO4(M+H)+384.0997,Found384.1014.
实施例94 8-羟基-10-甲基-7-(哌啶-1-亚甲基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S94)的制备
采用类似于实施例79的方法制备,不同之处在于以甲基苯醌代替苯醌,其余所需原料,试剂以及制备方法与实施例79相同,得终产物。1H NMR(400MHz,CDCl3)δ8.03(d,J=7.8Hz,1H),7.58(t,J=7.7Hz,1H),7.46(d,J=8.3Hz,1H),7.38(t,J=7.5Hz,1H),6.79(s,1H),4.65(s,2H),3.14–2.20(m,7H),1.86–1.40(br,6H).13C NMR(101MHz,CDCl3)δ160.3,158.4,157.0,153.3,148.5,131.6,124.4,122.1,121.8,121.4,117.5,117.0,112.6,112.1,106.3,58.2,53.5,25.8,23.9,14.9.HRMS(ESI)m/z:Calcd for364.1525(M+H)+C22H22NO4;Found 364.1543.
实施例95 10-叔丁基-8-羟基-7-(哌啶-1-亚甲基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S95)的制备
采用类似于实施例79的方法制备,不同之处在于以叔丁基苯醌代替苯醌,其余所需原料,试剂以及制备方法与实施例79相同,得终产物。1H NMR(400MHz,CDCl3/MeOD=6/1)δ8.06(dd,J=7.8,1.3Hz,1H),7.67–7.60(m,1H),7.51–7.42(m,2H),6.90(s,1H),4.68(s,2H),2.70(br,4H),1.69(br,4H),1.56(s,11H).13C NMR(101MHz,MeOD)δ160.49(s),159.27(s),156.92(s),153.61(s),148.24(s),135.33(s),132.20(s),125.06(s),123.30(s),122.05(s),117.22(s),114.40(s),112.85(s),112.21(s),106.10(s),58.39(s),53.86(s),34.64(s),30.06(s),26.05(s),24.12(s).
实施例96 8-羟基-9,10-二甲基-7-(哌啶-1-亚甲基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S96)的制备
采用类似于实施例79的方法制备,不同之处在于以二甲基苯醌代替苯醌,其余所需原料,试剂以及制备方法与实施例79相同,得终产物。1H NMR(400MHz,MeOD)δ7.97(dd,J=7.8,1.3Hz,1H),7.56–7.49(m,1H),7.39(d,J=8.1Hz,1H),7.34(t,J=7.8Hz,1H),4.56(s,2H),2.49–2.41(m,7H),2.23(s,3H),1.61(br,6H).13C NMR(101MHz,MeOD)δ159.90(s),159.12(s),155.11(s),153.24(s),149.00(s),131.63(s),124.70(s),124.66(s),121.88(s),120.05(s),119.26(s),116.99(s),112.80(s),111.22(s),106.32(s),58.28(s),53.60(s),25.93(s),24.06(s),12.12(s),11.96(s).
实施例97 8-羟基-7-(哌啶-1-亚甲基)苯并呋喃[3,2-c]喹啉-6(5H)-酮(化合物S97)的制备
97.1以邻溴苯乙酮为原料,甲苯中加入2.5eq的NaH,2.0eq的碳酸二乙酯,氮气保护下70℃加热回流20min,反应毕,待冷至室温加入冰水,加入冰醋酸至体系中性,乙酸乙酯(50mL×3)萃取,分出有机层,饱和食盐水10ml洗涤,无水硫酸钠干燥,减压蒸馏除去溶剂,粗品经柱层析(石油醚:乙酸乙酯=40:1)得化合物97‐1,邻溴苯甲酰乙酸乙酯;
97.2将邻溴苯甲酰乙酸乙酯,与5%的三氟甲磺酸铜溶解于甲苯中,氮气保护的条件下缓慢滴加0.6eq的1,4‐苯醌,加热回流10h,冷却至室温。NH4Cl淬灭,乙酸乙酯(50mL×3)萃取,分出有机层,饱和食盐水10ml洗涤,无水硫酸钠干燥,蒸去溶剂乙酸乙酯后所得粗产物用硅胶柱层析纯化(石油醚:乙酸乙酯=20:1)得化合物97‐2;
97.3化合物97‐2与Cu2O溶于NMP中,加入0.6eq的NH3·H2O密闭反应,反应7h后EtOH淬灭,并另加适量EtOH回流3h,反应毕,乙酸乙酯(50mL×3)萃取,分出有机层,饱和食盐水10ml洗涤,无水硫酸钠干燥,硅胶柱层析纯化(石油醚:乙酸乙酯=10:1)得得化合物97‐3;
97.4将化合物97‐3与5.0eq的CH2O,5.0eq的哌啶加入到乙醇溶剂中,氮气保护下加热回流3h,反应完毕,乙酸乙酯(50mL×3)萃取,分出有机层,饱和食盐水10ml洗涤,无水硫酸钠干燥,硅胶柱层析纯化(石油醚:乙酸乙酯=10:1)得终产物。1H NMR(400MHz,CDCl3/MeOD=10/1)δ7.99(d,J=8.0Hz,1H),7.47–7.40(m,1H),7.37–7.30(m,2H),7.22(t,J=7.2Hz,1H),6.83(dd,J=8.8,3.3Hz,1H),4.78(s,2H),2.52(br,4H),1.57(br,6H).13C NMR(101MHz,CDCl3/MeOD=10/1)δ160.59,159.87,156.37,149.55,137.69,130.66,123.49,122.84,121.76,115.80,115.71,114.87,111.88,111.03,110.87,59.07,53.61,25.81,23.96.
实施例98 8-羟基-7-(哌啶-1-亚甲基)苯并吡喃[4,3-b]吲哚-6(11H)-酮(化合物S98)的制备
采用类似于实施例25的方法制备,不同之处在于25.1中邻甲氧基苯甲酰乙酸乙酯代替苯甲酰乙酸乙酯,其余所需原料,试剂以及制备方法与实施例25相同,得终产物。1HNMR(400MHz,DMSO)δ8.27(br,1H),8.21(d,J=7.6Hz,1H),7.61(t,J=7.6Hz,1H),7.53–7.41(m,3H),6.93(d,J=8.6Hz,1H),4.79(s,2H),2.75(br,4H),1.61(br,4H),1.49(br,2H).13C NMR(101MHz,DMSO)δ158.34(s),154.50(s),152.26(s),142.29(s),132.15(s),130.70(s),124.54(s),124.21(s),122.51(s),116.68(s),115.11(s),112.87(s),112.75(s),111.48(s),99.89(s),56.12(s),52.74(s),24.54(s),22.96(s).
实施例99 8-羟基-3-甲氧基-7-(哌啶-1-亚甲基)苯并吡喃[4,3-b]吲哚-6(11H)-酮(化合物S99)的制备
采用类似于实施例25的方法制备,不同之处在于以2‐甲氧基‐4‐甲氧基苯乙酮代替邻甲氧基苯乙酮,其余所需原料,试剂以及制备方法与实施例25相同,得终产物。
1H NMR(400MHz,DMSO)δ13.26(s,1H),8.21(d,J=9.4Hz,1H),7.56(d,J=8.7Hz,1H),7.17–7.05(m,3H),4.95(s,2H),3.90(s,3H),1.86–1.44(m,7H).13C NMR(101MHz,MeOD)δ124.34,116.02,114.83,113.98,101.94,56.39,53.93,49.59,49.44,49.23,49.01,48.80,48.59,48.38,23.99,22.94.
实施例100 8-羟基-2-甲基-7-(哌啶-1-亚甲基)苯并吡喃[4,3-b]吲哚-6(11H)-酮(化合物S100)的制备
采用类似于实施例25的方法制备,不同之处在于以2‐甲氧基‐5‐甲基苯乙酮代替邻甲氧基苯乙酮,其余所需原料,试剂以及制备方法与实施例25相同,得终产物。
1H NMR(400MHz,MeOD)δ7.88(s,1H),7.55(d,J=8.8Hz,1H),7.39(dd,J=8.6,1.7Hz,1H),7.34(d,J=8.5Hz,1H),7.06(d,J=8.8Hz,1H),4.99(s,2H),3.61(t,J=6.1Hz,3H),3.12(d,J=13.0Hz,2H),1.98(d,J=17.2Hz,2H),1.80(t,J=16.5Hz,4H),1.56(d,J=8.3Hz,2H).13C NMR(101MHz,MeOD)δ161.15,152.92,150.10,143.27,134.07,132.28,131.49,124.87,121.44,116.18,114.79,113.68,111.87,105.74,99.83,52.34,51.92,22.20,21.04,19.76.
实施例101 3-溴-8-羟基-7-(哌啶-1-亚甲基)苯并吡喃[4,3-b]吲哚-6(11H)-酮(化合物S101)的制备
采用类似于实施例25的方法制备,不同之处在于以2‐甲氧基‐4‐溴苯乙酮代替邻甲氧基苯乙酮,其余所需原料,试剂以及制备方法与实施例25相同,得终产物。
1H NMR(400MHz,DMSO)δ13.53(s,1H),8.21(d,J=8.4Hz,1H),7.78(d,J=1.8Hz,1H),7.64(dd,J=8.4,1.8Hz,1H),7.57(d,J=8.8Hz,1H),7.11(d,J=8.8Hz,1H),4.90(s,2H),1.79–1.61(m,4H),1.59–1.44(m,2H).13C NMR(101MHz,MeOD)δ160.04,152.93,151.69,142.09,132.13,127.25,124.41,123.62,123.11,119.28,114.95,114.13,111.08,105.55,99.28,52.41,51.94,22.10,21.02,19.76.
实施例102 8-羟基-7-(哌啶-1-亚甲基)-6H-苯并[4,5]噻吩并[3,2-c]苯并吡喃-6-酮(化合物S102)的制备
采用类似于实施例36的方法制备,不同之处在于以2‐甲氧基苯乙酰甲酯代替苯乙酰甲酯,其余所需原料,试剂以及制备方法与实施例36相同,得终产物。1H NMR(400MHz,MeOD)δ7.80–7.71(m,1H),7.53(t,J=7.8Hz,1H),7.39–7.28(m,1H),7.24(d,J=8.9Hz,1H),4.96(s,1H),3.49(d,J=11.8Hz,1H),3.02(t,J=12.2Hz,1H),1.87(d,J=13.1Hz,1H),1.74(t,J=12.7Hz,1H),1.54–1.37(m,1H).13C NMR(101MHz,MeOD)δ158.98(s),157.58(s),155.23(s),150.86(s),137.07(s),132.41(s),130.26(s),125.94(s),125.37(s),124.30(s),118.56(s),116.81(s),116.79(s),116.53(s),110.48(s),53.11(s),52.95(s),23.07(s),21.78(s).
实施例103 8-羟基-7-(吡咯烷-1-亚甲基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S103)的制备
采用类似于实施例79的方法制备,不同之处在于以吡咯代替哌啶,其余所需原料,试剂以及制备方法与实施例79相同,得终产物。1H NMR(400MHz,MeOD)δ8.02(d,J=7.8Hz,1H),7.65(t,J=7.8Hz,1H),7.58(d,J=8.9Hz,1H),7.50-7.42(m,2H),7.10(d,J=8.9Hz,1H),5.03(s,2H),3.38(s,4H),2.11(s,4H).13C NMR(101MHz,MeOD)δ162.10(s),159.99(s),155.79(s),153.93(s),150.03(s),133.20(s),125.70(s),124.61(s),122.57(s),117.61(s),116.23(s),114.67(s),112.55(s),110.46(s),106.19(s),54.22(s),52.17(s),23.53(s).
实施例104 8-羟基-7-(4-甲基哌啶-1亚甲基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S104)的制备
采用类似于实施例79的方法制备,不同之处在于以对甲基哌啶代替哌啶,其余所需原料,试剂以及制备方法与实施例79相同,得终产物。1H NMR(400MHz,MeOD)δ7.96(d,J=7.7Hz,1H),7.56(t,J=7.5Hz,1H),7.47–7.28(m,3H),6.89(d,J=8.8Hz,1H),4.01(s,2H),2.98(d,J=10.5Hz,2H),2.29(t,J=10.3Hz,2H),1.66(d,J=13.0Hz,2H),1.44(br,1H),1.25(q,J=11.6Hz,2H),0.91(d,J=6.2Hz,3H).13C NMR(101MHz,MeOD)δ160.98(s),158.78(s),157.03(s),153.37(s),149.56(s),132.03(s),124.76(s),122.58(s),121.97(s),117.01(s),116.45(s),114.77(s),112.49(s),111.21(s),106.02(s),58.00(s),53.12(s),34.12(s),30.43(s),21.60(s).
实施例105 8-羟基-7-(3-甲基哌啶-1亚甲基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S105)的制备
采用类似于实施例79的方法制备,不同之处在于以间甲基哌啶代替哌啶,其余所需原料,试剂以及制备方法与实施例79相同,得终产物。1H NMR(400MHz,DMSO)δ8.05(d,J=8.0Hz,1H),7.72(t,J=7.3Hz,1H),7.60(dd,J=13.6,8.5Hz,2H),7.49(t,J=7.5Hz,1H),6.92(d,J=8.9Hz,1H),4.58(q,J=14.0Hz,2H),2.89(br,2H),2.14(t,J=11.0Hz,1H),1.87(t,J=10.6Hz,1H),1.68(br,3H),1.49(d,J=11.7Hz,1H),0.97(d,J=9.5Hz,1H),0.85(d,J=6.1Hz,3H).13C NMR(101MHz,DMSO)δ160.26(s),157.24(s),156.49(s),152.83(s),148.64(s),132.38(s),124.89(s),122.26(s),121.77(s),116.70(s),115.93(s),114.44(s),111.73(s),111.23(s),105.43(s),60.07(s),57.05(s),52.56(s),31.90(s),30.62(s),24.70(s),19.13(s).
实施例106 8-羟基-7-(2-甲基哌啶-1亚甲基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S106)的制备
采用类似于实施例79的方法制备,不同之处在于以邻甲基哌啶代替哌啶,其余所需原料,试剂以及制备方法与实施例79相同,得终产物。1H NMR(400MHz,DMSO)δ8.05(d,J=8.0Hz,1H),7.72(t,J=7.1Hz,1H),7.63–7.56(m,2H),7.50(t,J=7.5Hz,1H),6.88(d,J=8.9Hz,1H),4.71(dd,J=33.3,14.8Hz,2H),2.83(d,J=12.4Hz,1H),2.68(br,1H),2.34(t,J=Hz,1H),1.82–1.28(m,6H),1.16(d,J=6.1Hz,3H).13C NMR(101MHz,DMSO)δ160.20(s),157.31(s),156.75(s),152.80(s),148.57(s),132.36(s),124.89(s),121.86(s),121.75(s),116.69(s),116.03(s),114.95(s),111.73(s),110.97(s),105.40(s),55.36(s),53.71(s),50.38(s),32.98(s),25.11(s),21.86(s),16.93(s).
实施例107 1-(8-羟基-6-羰基-6H-苯并呋喃[3,2-c]苯并吡喃-7-亚甲基)吡咯烷-2-酮(化合物S107)的制备
采用类似于实施例79的方法制备,不同之处在于以吡咯烷酮代替哌啶,其余所需原料,试剂以及制备方法与实施例79相同,得终产物。1H NMR(400MHz,CDCl3)δ10.06(s,1H),8.04(d,J=7.7Hz,1H),7.63(t,J=7.8Hz,1H),7.51(dd,J=12.6,8.7Hz,2H),7.43(t,J=7.5Hz,1H),7.14(d,J=8.9Hz,1H),5.44(s,2H),3.65(t,J=7.1Hz,2H),2.45(t,J=8.2Hz,2H),2.07–1.92(m,2H).13C NMR(101MHz,CDCl3)δ177.95(s),161.40(s),158.76(s),155.36(s),153.54(s),149.66(s),132.31(s),124.94(s),124.01(s),122.15(s),118.61(s),117.22(s),115.90(s),112.85(s),112.58(s),106.01(s),48.26(s),39.61(s),30.59(s),18.03(s).
实施例108 1-(8-甲氧基-6-羰基-6H-苯并呋喃[3,2-c]苯并吡喃-7-亚甲基)吡咯烷-2-酮(化合物S108)的制备
采用实施例107的化合物,溶于二氯甲烷中在碘甲烷作用下生成终产物。1H NMR(400MHz,CDCl3)δ8.00(d,J=7.2Hz,1H),7.63–7.54(m,2H),7.49–7.35(m,2H),7.05(d,J=9.0Hz,1H),5.40(s,2H),3.88(s,3H),3.16(t,J=7.0Hz,2H),2.37(t,J=8.1Hz,2H),1.90–1.79(m,2H).13C NMR(101MHz,CDCl3)δ174.08(s),161.79(s),158.15(s),156.64(s),153.76(s),150.02(s),132.44(s),125.32(s),124.76(s),122.13(s),118.87(s),117.19(s),112.35(s),111.52(s),110.88(s),106.05(s),77.16(s),56.91(s),46.38(s),39.03(s),31.31(s),17.87(s).
实施例109 1-(8-羟基-(2-甲氧基乙氧基)-6-羰基-6H-苯并呋喃[3,2-c]苯并吡喃-7-亚甲基)吡咯烷-2-酮(化合物S109)的制备
采用实施例107的化合物,溶于二氯甲烷中在溴乙基甲醚作用下生成终产物。
1H NMR(400MHz,CDCl3)δ7.95(t,J=7.2Hz,1H),7.62–7.46(m,2H),7.44–7.31(m,2H),7.10–6.98(m,1H),5.43–5.32(m,2H),4.18–3.99(m,2H),3.85–3.69(m,2H),3.51–3.37(m,3H),3.19–3.06(m,2H),2.33(t,J=6.4Hz,2H),1.87–1.76(m,2H).13C NMR(101MHz,CDCl3)δ173.84(s),161.62(s),158.00(s),155.92(s),153.62(s),150.07(s),132.36(s),125.16(s),124.70(s),122.04(s),119.28(s),117.05(s),112.27(d,J=13.9Hz),111.50(s),105.94(s),71.20(s),69.33(s),59.21(s),46.22(s),39.03(s),31.16(s),17.76(s).
实施例110 1-(8-羟基-6-羰基-6H-苯并呋喃[3,2-c]苯并吡喃-7-亚甲基)哌啶-2-酮(化合物S110)的制备
采用类似于实施例79的方法制备,不同之处在于以环己内酰胺代替哌啶,其余所需原料,试剂以及制备方法与实施例79相同,得终产物。1H NMR(400MHz,CDCl3)δ8.04(dd,J=7.8,1.0Hz,1H),7.65–7.59(m,1H),7.54-7.47(m,2H),7.42(t,J=7.6Hz,1H),7.10(d,J=8.9Hz,1H),5.62(s,2H),3.47(t,J=5.2Hz,2H),2.46(t,J=6.4Hz,2H),1.81–1.63(m,4H).13C NMR(101MHz,CDCl3)δ172.86(s),161.45(s),158.79(s),155.59(s),153.44(s),149.38(s),132.30(s),124.91(s),124.55(s),122.13(s),117.95(s),117.15(s),115.22(s),112.90(s),112.51(s),105.96(s),47.54(s),43.30(s),31.94(s),22.82(s),20.62(s).
实施例111 1-(8-羟基-6-羰基-6H-苯并呋喃[3,2-c]苯并吡喃-7-亚甲基)环己亚胺-2-酮(化合物S111)的制备
采用类似于实施例79的方法制备,不同之处在于以环庚内酰胺代替哌啶,其余所需原料,试剂以及制备方法与实施例79相同,得终产物。1H NMR(400MHz,CDCl3)δ10.16(s,1H),8.03(d,J=7.7Hz,1H),7.62(t,J=7.5Hz,1H),7.49(t,J=10.0Hz,2H),7.42(t,J=7.4Hz,1H),7.09(d,J=8.9Hz,1H),5.54(s,2H),3.46(s,2H),2.60(s,2H),1.70(s,4H),1.60(s,2H).13C NMR(101MHz,CDCl3)δ178.09(s),160.28(s),157.76(s),154.45(s),152.26(s),148.29(s),131.14(s),123.77(s),122.96(s),120.97(s),116.51(s),116.01(s),114.36(s),111.57(s),111.36(s),104.70(s),47.49(s),42.58(s),35.37(s),28.73(s),26.27(s),22.20(s).
实施例112 1-(8-甲氧基-6-羰基-6H-苯并呋喃[3,2-c]苯并吡喃-7-亚甲基)哌啶-2-酮(化合物S112)的制备
采用类似于实施例108的方法制备,不同之处在于以S110为原料得终产物。1H NMR(400MHz,CDCl3)δ8.02(d,J=7.6Hz,1H),7.65–7.54(m,2H),7.47(d,J=8.3Hz,1H),7.40(t,J=7.5Hz,1H),7.06(d,J=8.9Hz,1H),5.60(s,2H),3.89(s,3H),3.16(t,J=5.3Hz,2H),2.40(t,J=5.9Hz,2H),1.77–1.62(m,4H).13C NMR(101MHz,CDCl3)δ169.15(s),161.78(s),158.22(s),156.82(s),153.82(s),150.10(s),132.37(s),125.97(s),124.70(s),122.12(s),120.15(s),117.23(s),112.49(s),111.27(s),111.00(s),106.38(s),56.93(s),46.92(s),42.92(s),32.72(s),23.45(s),21.53(s).
实施例113 1-(8-乙氧基-6-羰基-6H-苯并呋喃[3,2-c]苯并吡喃-7-亚甲基)哌啶-2-酮(化合物S113)的制备
采用类似于实施例112的方法制备,不同之处在于以碘乙烷代替碘甲烷,其余所需原料,试剂以及制备方法与实施例112相同,得终产物。1H NMR(400MHz,CDCl3)δ8.01(d,J=7.7Hz,1H),7.60(t,J=7.8Hz,1H),7.53(d,J=8.9Hz,1H),7.46(d,J=8.3Hz,1H),7.39(t,J=7.5Hz,1H),7.03(d,J=9.0Hz,1H),5.60(s,2H),4.07(q,J=6.9Hz,2H),3.15(t,J=5.7Hz,2H),2.40(t,J=6.4Hz,2H),1.76–1.62(m,4H),1.43(t,J=6.9Hz,3H).13C NMR(101MHz,CDCl3)δ168.90(s),161.65(s),158.20(s),156.11(s),153.75(s),149.97(s),132.30(s),125.89(s),124.67(s),122.09(s),120.16(s),117.17(s),112.47(s),111.71(s),111.18(s),106.36(s),65.09(s),46.82(s),42.91(s),32.77(s),23.43(s),21.56(s),15.16(s).
实施例114 1-(8-(2-甲氧基乙氧基)-6-羰基-6H-苯并呋喃[3,2-c]苯并吡喃-7-亚甲基)哌啶-2-酮(化合物S114)的制备
采用类似于实施例112的方法制备,不同之处在于以溴乙基甲醚代替碘甲烷,其余所需原料,试剂以及制备方法与实施例112相同,得终产物。1HNMR(400MHz,CDCl3)δ7.99(d,J=7.7Hz,1H),7.58(t,J=7.7Hz,1H),7.52(d,J=8.9Hz,1H),7.44(d,J=8.3Hz,1H),7.37(t,J=7.5Hz,1H),7.05(d,J=8.9Hz,1H),5.59(s,2H),4.13(t,J=4.7Hz,2H),3.78(t,J=4.8Hz,2H),3.44(s,3H),3.14(t,J=5.7Hz,2H),2.38(t,J=6.4Hz,2H),1.77–1.60(m,4H).13C NMR(101MHz,CDCl3)δ168.89(s),161.66(s),158.11(s),156.08(s),153.71(s),150.16(s),132.31(s),125.88(s),124.66(s),122.06(s),120.53(s),117.11(s),112.38(s),112.34(s),111.26(s),106.29(s),71.32(s),69.24(s),59.22(s),46.73(s),42.73(s),32.74(s),23.37(s),21.45(s).
实施例115 1-甲基(8-羟基-6-羰基-6H-苯并呋喃[3,2-c]苯并吡喃-7-亚甲基)-1-甲基哌啶-1-季铵盐(化合物S115)的制备
采用S79化合物作为原料,DMF作溶剂在钠氢,碘甲烷的作用下反应30分钟得终产物。1H NMR(400MHz,CDCl3)δ8.03(d,J=7.8Hz,1H),7.69(d,J=9.0Hz,1H),7.63(t,J=7.8Hz,1H),7.49(d,J=8.3Hz,1H),7.42(t,J=7.5Hz,1H),7.11(d,J=9.1Hz,1H),5.13(s,2H),4.04(s,3H),3.55(br,2H),2.94(br,2H),2.42(br,2H),1.78(br,4H).13C NMR(101MHz,CDCl3)δ161.08(s),158.02(s),155.91(s),152.79(s),148.94(s),131.69(s),125.05(s),123.96(s),121.26(s),116.37(s),113.30(s),111.21(s),109.74(s),109.27(s),105.26(s),55.67(s),52.14(s),51.16(s),21.19(s),20.91(s).
实施例116 1-乙基-1-(8-羟基-6-羰基-6H-苯并呋喃[3,2-c]苯并吡喃-7-亚甲基)-1-甲基哌啶-1-季铵盐(化合物S116)的制备
采用S79化合物作为原料,DMF作溶剂在钠氢,碘乙烷的作用下反应30分钟得终产物。1H NMR(400MHz,CDCl3)δ7.99(d,J=7.7Hz,1H),7.68–7.55(m,2H),7.46(d,J=8.4Hz,1H),7.39(t,J=7.4Hz,1H),7.06(d,J=9.1Hz,1H),5.08(s,2H),4.24(q,J=6.7Hz,2H),3.58(br,1H),2.95(br,1H),2.37(br,2H),1.77(br,4H),1.51(t,J=6.8Hz,3H).13C NMR(101MHz,CDCl3)δ161.82(s),159.14(s),156.17(s),153.87(s),149.99(s),132.55(s),126.26(s),124.89(s),122.28(s),117.43(s),114.32(s),112.38(s),111.09(s),111.06(s),106.83(s),65.07(s),53.18(s),52.07(s),22.30(s),21.99(s),15.05(s).
实施例117 1-(8-羟基-6-羰基-6H-苯并呋喃[3,2-c]苯并吡喃-7-亚甲基)-1-(2-甲氧基乙基)哌啶-1-季铵盐(化合物S117)的制备
采用S79化合物作为原料,DMF作溶剂在钠氢,溴乙基甲醚的作用下反应30分钟得终产物。1H NMR(400MHz,CDCl3)δ11.20(s,1H),8.03(dd,J=7.8,1.1Hz,1H),7.75–7.57(m,2H),7.49(d,J=8.1Hz,1H),7.44–7.37(m,1H),7.13(d,J=9.1Hz,1H),5.14(s,2H),4.40–4.32(m,2H),3.92–3.87(m,2H),3.62(s,2H),3.45(s,4H),2.97(s,2H),2.43(s,2H),1.79(s,6H).13C NMR(101MHz,CDCl3)δ162.05(s),159.17(s),156.29(s),153.95(s),150.28(s),132.69(s),126.26(s),125.00(s),122.37(s),117.52(s),114.41(s),112.41(s),111.72(s),111.58(s),106.75(s),71.34(s),68.80(s),59.10(s),53.45(s),52.40(s),22.36(s),22.12(s).
实施例118 8-羟基-7-(哌啶-1-羰基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S118)的制备
采用实施例79中5‐羟基‐2‐(2‐甲氧基苯基)苯并呋喃‐3‐羧酸乙酯中间体,其后续制备方法如下:
118‐1.将其溶于二氧六环中,加入水,亚氯酸钠、氨基磺酸,室温下搅拌半小时。TLC检测至反应完全后,加硫代硫酸钠溶液淬灭,用盐酸溶液调pH为弱酸性,加乙酸乙酯萃取,饱和氯化钠溶液洗去水,无水硫酸钠干燥,减压浓缩,得淡黄色固体118-1。
118-2.氮气保护下,将118-1、EDC·HCl、HOBT溶于DMF中,加吡啶、哌啶,室温下搅拌,过夜。TLC检测至反应完全后,加氯化铵溶液淬灭,乙酸乙酯萃取,有机相依次用5%的盐酸溶液、饱和碳酸氢钠溶液、饱和氯化钠溶液洗,无水硫酸钠干燥,减压浓缩,TLC纯化得118-2。
118-3.将化合物118‐2溶于DCM中,氮气保护,0℃冰水浴条件下缓慢滴加1mmol/mL的BBr3·DCM,滴加完毕室温搅拌5h,乙醇淬灭,另加5mL乙醇加热回流5h,减压浓缩除去溶剂,二氯甲烷(50mL×3)萃取,分离有机相减压浓缩,快速柱纯化(石油醚:乙酸乙酯=10:1)得终产物。1H NMR(400MHz,DMSO)δ9.83(s,1H),8.06(d,J=7.7Hz,1H),7.75–7.70(m,2H),7.57(d,J=8.3Hz,1H),7.50(t,J=7.5Hz,1H),7.07(d,J=9.0Hz,1H),3.77-3.72(m,1H),3.65–3.53(m,1H),3.21–3.02(m,2H),1.84–1.70(m,1H),1.62–1.48(m,3H),1.41–1.31(m,2H).13C NMR(101MHz,DMSO)δ163.88(s),160.28(s),155.68(s),153.13(s),150.82(s),148.68(s),132.58(s),124.94(s),121.91(s),120.39(s),117.10(s),116.98(s),115.37(s),112.22(s),111.81(s),104.89(s),47.00(s),41.50(s),25.41(s),24.54(s),24.24(s).
实施例119 8-甲氧基-7-(哌啶-1-羰基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S119)的制备
采用S118化合物作为原料,在碘甲烷作用下生成最终产物。1H NMR(400MHz,CDCl3)δ8.01(d,J=7.8Hz,1H),7.61(dd,J=8.0,4.4Hz,2H),7.47(d,J=8.4Hz,1H),7.39(t,J=7.6Hz,1H),7.08(d,J=9.1Hz,1H),3.91(s,5H),3.28–3.12(m,2H),2.00–1.89(m,1H),1.73–1.59(m,3H),1.53–1.39(m,2H).13C NMR(101MHz,CDCl3)δ165.04(s),161.45(s),156.75(s),154.02(s),153.18(s),150.46(s),132.41(s),124.65(s),122.10(s),121.46(s),119.86(s),117.55(s),112.43(s),111.99(s),110.83(s),105.59(s),56.99(s),48.03(s),42.53(s),26.03(s),25.10(s),24.87(s).
实施例120 N-(环丙基甲基)-8-羟基-6-羰基-6H-苯并呋喃[3,2-c]苯并吡喃-7-甲酰胺(化合物S120)的制备
采用类似于实施例118的方法制备,不同之处在于以环丙烷甲基代替118‐2的哌啶,其余所需原料,试剂以及制备方法与实施例118相同,得终产物。1H NMR(400MHz,CDCl3)δ13.42(s,1H),8.98(s,1H),8.09(d,J=7.9Hz,1H),7.68(dd,J=14.6,8.1Hz,2H),7.52(d,J=8.4Hz,1H),7.47(t,J=7.6Hz,1H),7.18(d,J=9.1Hz,1H),3.45(dd,J=7.0,5.3Hz,2H),1.21–1.13(m,1H),0.56(q,J=5.7Hz,2H),0.33(q,J=5.1Hz,2H).13C NMR(101MHz,CDCl3)δ168.89(s),161.83(s),161.33(s),159.74(s),153.04(s),149.43(s),132.99(s),125.28(s),122.44(s),119.45(s),119.34(s),117.10(s),116.97(s),112.19(s),109.91(s),105.65(s),45.44(s),10.24(s),3.87(s).
实施例121 8-羟基-9-(哌啶-1-亚甲基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S121)的制备
采用实施例118‐1化合物作为原料加入哌啶,醋酸,氰基硼氢化钠,室温下过夜。TLC检测至反应完全后,加乙酸乙酯萃取,饱和氯化钠溶液洗去水,无水硫酸钠干燥,减压浓缩,TLC纯化,接着溶于DCM中,氮气保护,0℃冰水浴条件下缓慢滴加1mmol/mL的BBr3·DCM,滴加完毕室温搅拌5h,乙醇淬灭,另加5mL乙醇加热回流5h,减压浓缩除去溶剂,二氯甲烷(50mL×3)萃取,分离有机相减压浓缩,快速柱纯化(石油醚:乙酸乙酯=10:1)得终产物。1HNMR(400MHz,MeOD)δ8.07(s,1H),8.01(d,J=7.6Hz,1H),7.64(t,J=7.8Hz,1H),7.51–7.40(m,3H),4.39(s,2H),3.49(br,2H),2.94(br,2H),1.93(br,6H).13C NMR(101MHz,MeOD)δ161.04(s),157.87(s),153.72(s),152.82(s),148.39(s),131.81(s),125.34(s),124.32(s),121.26(s),116.61(s),115.27(s),114.00(s),111.50(s),105.48(s),104.30(s),54.47(s),51.83(s),21.93(s),20.84(s).
实施例122 8-羟基-9-(哌啶-1-羰基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S122)的制备
采用实施例118的方法制备,得终产物。1H NMR(400MHz,DMSO)δ10.12(s,1H),8.04(d,J=7.7Hz,1H),7.73(t,J=7.8Hz,1H),7.66(s,1H),7.60(d,J=8.3Hz,1H),7.50(t,J=7.5Hz,1H),7.43(s,1H),3.61(br,2H),3.21(br,2H),1.55(br,6H).13C NMR(101MHz,DMSO)δ165.65(s),160.44(s),157.17(s),153.11(s),151.49(s),148.51(s),132.50(s),125.07(s),124.58(s),123.93(s),121.84(s),117.24(s),112.05(s),110.96(s),105.73(s),104.93(s),47.22(s),41.92(s),25.55(s),24.06(s).
实施例123 8-甲氧基-9-(哌啶-1-羰基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S123)的制备
采用实施例S122化合物作为原料加入碘甲烷室温过夜,得终产物。1H NMR(400MHz,CDCl3)δ7.98(dd,J=6.3,2.9Hz,2H),7.58(s,1H),7.52–7.45(m,3H),7.40(s,1H),4.40(q,J=7.1Hz,2H),3.92(s,3H),3.77(m,2H),3.21(d,J=4.5Hz,2H),1.67(s,6H),1.39(t,J=7.1Hz,3H).13C NMR(101MHz,CDCl3)δ167.18(s),163.99(s),162.12(s),153.03(s),148.36(s),130.52(s),129.69(s),129.64(s),128.58(s),128.19(s),124.85(s),110.39(s),109.00(s),103.75(s),60.84(s),56.18(s),48.20(s),42.83(s),26.48(s),25.79(s),24.77(s),14.32(s).
实施例124 8-(2-甲氧基乙氧基)-9-(哌啶-1-羰基)-6H-苯并呋喃[3,2-c]苯并吡喃-6-酮(化合物S124)的制备
采用类似于实施例123的方法制备,不同之处在于以溴乙基甲醚代替碘甲烷,其余所需原料,试剂以及制备方法与实施例124相同,得终产物。1H NMR(400MHz,CDCl3)δ8.02(d,J=7.8Hz,1H),7.66–7.57(m,2H),7.56(s,1H),7.50(d,J=8.4Hz,1H),7.41(t,J=7.5Hz,1H),4.35–4.14(m,2H),3.88–3.68(m,4H),3.43(s,3H),3.33–3.11(m,2H),1.66(br,6H).13CNMR(101MHz,CDCl3)δ166.59(s),161.13(s),158.21(s),153.73(s),152.97(s),150.05(s),132.28(s),126.60(s),124.92(s),124.75(s),122.07(s),117.66(s),112.68(s),111.20(s),105.93(s),104.07(s),70.94(s),68.81(s),59.21(s),48.17(s),42.89(s),26.16(s),25.72(s),24.75(s).
实施例125 7-叔丁基-5-羟基-2-(4-甲氧基)-N-甲基-4-(哌啶-1-亚甲基)苯并呋喃-3-甲酰胺(化合物S125)的制备
采用类似于实施例6和实施例19的方法制备,不同之处在于实施例6中以叔丁基苯醌代替苯醌,合成7-叔丁基-5-羟基-2-(4-甲氧基)苯并呋喃-3-羧酸乙酯后再采用类似于实施例19的方法,不同之处在于实施例19-2中以甲胺代替乙胺,其余所需原料,试剂以及制备方法与实施例6和19相同,得终产物。1H NMR(400MHz,CDCl3)δ7.71(d,J=8.8Hz,2H),6.97(d,J=8.8Hz,2H),6.73(s,1H),6.01(d,J=4.6Hz,1H),3.85(s,3H),3.79(s,2H),2.99(d,J=4.9Hz,3H),2.48(br,4H),1.62(br,4H),1.51(br,2H),1.49(s,9H).13C NMR(101MHz,CDCl3)δ167.75(s),160.40(s),154.73(s),152.07(s),146.10(s),134.37(s),128.09(s),126.53(s),122.68(s),114.46(s),112.07(s),111.71(s),109.50(s),56.97(s),55.50(s),53.97(s),34.31(s),29.95(s),27.15(s),26.01(s),24.10(s).
实施例126 7-叔丁基-5-羟基-2-(4-羟基)-N-甲基-4-(哌啶-1-亚甲基)苯并呋喃-3-甲酰胺(化合物S126)的制备
采用S125为原料,在三溴化硼,二氯甲烷做溶剂下,生成最终产物。1H NMR(400MHz,MeOD)δ7.58(d,J=8.7Hz,2H),6.93(d,J=8.7Hz,2H),6.88(s,1H),4.34(s,2H),3.20(br,4H),2.91(s,3H),1.87(br,4H),1.70(br,2H),1.52(s,9H).13C NMR(101MHz,MeOD)δ169.60(s),160.63(s),156.37(s),155.17(s),147.50(s),138.88(s),129.89(s),128.95(s),121.64(s),116.87(s),111.82(s),111.64(s),105.57(s),53.96(s),53.18(s),35.42(s),30.09(s),26.95(s),24.85(s),23.14(s).
实施例127 7-叔丁基-5-羟基-2-(3-甲氧基)-N-甲基-4-(哌啶-1-亚甲基)苯并呋喃-3-甲酰胺(化合物S127)的制备
采用类似于实施例126的方法制备,不同之处在于以3-甲氧基苯乙酰乙酸乙酯代替4-甲氧基苯乙酰乙酸乙酯,其余所需原料,试剂以及制备方法与实施例126相同,得终产物。1H NMR(400MHz,CDCl3)δ7.29(t,J=7.9Hz,1H),7.23–7.19(m,2H),7.07(s,1H),6.88(dd,J=8.1,1.6Hz,1H),4.05(s,2H),3.77(s,3H),3.02(br,4H),2.90(d,J=4.8Hz,3H),1.74(br,4H),1.42(br,2H),1.40(s,9H).13C NMR(101MHz,CDCl3)δ167.72(s),159.87(s),154.38(s),153.43(s),146.66(s),137.29(s),130.62(s),130.05(s),126.98(s),119.60(s),115.30(s),113.76(s),112.83(s),112.65(s),105.57(s),55.45(s),53.04(s),52.89(s),34.55(s),29.87(s),27.18(s),24.01(s),22.54(s).
实施例128 7-叔丁基-5-羟基-2-(3-羟基)-N-甲基-4-(哌啶-1-亚甲基)苯并呋喃-3-甲酰胺(化合物S128)的制备
采用S127为原料,在三溴化硼,二氯甲烷做溶剂下,生成最终产物。1H NMR(400MHz,MeOD)δ7.27(t,J=7.9Hz,1H),7.19–7.11(m,2H),6.88(s,1H),6.85(dd,J=8.1,1.3Hz,1H),4.26(s,2H),3.10(br,4H),2.88(s,3H),1.80(br,4H),1.63(br,2H),1.47(s,9H).13C NMR(101MHz,MeOD)δ169.25(s),159.12(s),155.28(s),147.64(s),138.97(s),131.61(s),131.10(s),128.72(s),119.22(s),117.98(s),114.75(s),113.59(s),112.35(s),105.83(s),54.04(s),53.26(s),35.42(s),30.10(s),27.07(s),24.84(s),23.12(s).
实施例129 7-叔丁基-5-羟基-2-(2-甲氧基)-N-甲基-4-(哌啶-1-亚甲基)苯并呋喃-3-甲酰胺(化合物S129)的制备
采用类似于实施例126的方法制备,不同之处在于以2-甲氧基苯乙酰乙酸乙酯代替4-甲氧基苯乙酰乙酸乙酯,其余所需原料,试剂以及制备方法与实施例126相同,得终产物。1H NMR(400MHz,CDCl3)δ7.60(d,J=7.6Hz,1H),7.46(t,J=7.9Hz,1H),7.28(s,1H),7.11(t,J=7.5Hz,1H),7.01(d,J=8.4Hz,1H),6.70(s,1H),4.34(s,2H),3.85(s,3H),3.32(m,2H),3.10–2.92(m,2H),2.85(d,J=4.8Hz,3H),2.03–1.57(m,6H),1.44(s,9H).13C NMR(101MHz,CDCl3)δ167.74(s),156.66(s),154.56(s),152.11(s),147.31(s),137.92(s),131.79(s),131.05(s),126.57(s),121.25(s),118.63(s),114.74(s),114.30(s),111.47(s),104.94(s),55.72(s),52.41(s),52.35(s),34.64(s),29.80(s),27.07(s),23.80(s),22.32(s).
实施例130 10-叔丁基-3,8-二羟基-7-(哌啶-1-亚甲基)-6H-苯并呋喃[3,2-c]苯丙吡喃-6-酮(化合物S130)的制备
采用类似于实施例86的方法制备,不同之处在于以叔丁基苯醌代替苯醌,其余所需原料,试剂以及制备方法与实施例86相同,得终产物。1H NMR(400MHz,MeOD)δ7.88(d,J=8.6Hz,1H),7.00(s,1H),6.95(d,J=8.7Hz,1H),6.90(d,J=1.6Hz,1H),4.90(s,2H),3.53(br,2H),3.04(br,2H),1.86(br,6H),1.53(s,9H).13C NMR(101MHz,MeOD)δ162.86(s),162.52(s),161.14(s),155.97(s),155.25(s),148.06(s),139.32(s),125.74(s),123.65(s),114.96(s),112.54(s),105.44(s),104.59(s),103.61(s),102.92(s),53.30(s),53.15(s),35.07(s),29.90(s),23.02(s),22.12(s).
实施例131 10-叔丁基-2,8-二羟基-7-(哌啶-1-亚甲基)-6H-苯并呋喃[3,2-c]苯丙吡喃-6-酮(化合物S131)的制备
采用类似于实施例86的方法制备,不同之处在于以叔丁基苯醌代替苯醌和2,5‐二甲氧基苯乙酸乙酯替代2,4‐二甲氧基苯乙酸乙酯,其余所需原料,试剂以及制备方法与实施例86相同,得终产物。1H NMR(400MHz,MeOD)δ7.41(d,J=2.7Hz,1H),7.34(d,J=9.0Hz,1H),7.15(dd,J=9.0,2.8Hz,1H),7.08(s,1H),4.96(s,2H),3.57(d,J=12.6Hz,2H),3.06(t,J=11.9Hz,2H),1.95(d,J=14.2Hz,2H),1.88–1.76(m,3H),1.52(s,10H).13C NMR(100MHz,MeOD)δ161.32(s),160.74(s),155.26(s),154.91(s),148.37(s),147.47(s),139.44(s),125.36(s),121.53(s),118.52(s),113.42(s),112.76(s),106.39(s),105.87(s),105.53(s),53.20(s),53.00(s),34.98(s),29.75(s),22.85(s),22.01(s).
试验实施例1
本发明提供结构通式(I)(II)(Ⅲ)(Ⅳ)类化合物对结核杆菌H37Rv的MIC90测试测试
1.1材料:本发明所述部分化合物
结核分枝杆菌H37Rv菌株(于Middlebrook 7H9肉汤培养液中培养)
1.2实验方法
本实验主要以微孔alamar Blue实验的步骤进行:将H37Rv菌株培养至对数生长期,培养液稀释至OD600=0.001,将100uL稀释后的培养液(约含104个菌落形成单位)注入单个微孔中,100uL的2倍稀释的化合物也注入对应微孔。96孔平板在37℃下培养7天,随后35uL的Alamar蓝/吐温80(2:1.5,V/V)混合溶液加入到各孔中并培养16小时。以在544ex/590em条件下被酶标仪检测并分析得出数据作为化合物90%抑制结核杆菌H37Rv的最低浓度MIC90。
试验实施例2
本发明提供部分结构通式(I)(II)(Ⅲ)(Ⅳ)类化合物的血清抑制滴定实验(下称SIT实验),用以表征其口服生物利用度和动物体内有效。
实验材料及试剂:六周大雌性BALB/c小鼠30只,0.5%羧甲基纤维素,1mL注射器若干,结核分枝杆菌H37Rv菌株(于Middlebrook 7H9肉汤培养液中培养),本发明中部分化合物(具体化合物见表5),异烟肼,alamar Blue试剂。
实验方法:将待测化合物用0.5%的羧甲基纤维素(CMC)制备为10mg/mL的均匀悬浮液。将小鼠分为xx组,每组3只,每组依小鼠质量按100mg/kg比例分别喂饲不同化合物,异烟肼同样以100mg/kg对一组小鼠喂饲以作阳性对照,0.5%羧甲基纤维素以100mg/kg喂饲作空白对照。60min后处死小鼠,收集小鼠的心脏血液,分离血清供下一步实验。将空白组及血清用不含吐温的Middlebrook 7H9肉汤培养液在96孔平板从1:2至1:64梯度稀释,将平板密封并于37℃培养7天。随后在每孔中加入32μL由吐温80配制为0.86%浓度的alamar Blue试剂,在37℃培育后用BMG酶标仪在544ex/590em条件下测定荧光强度,所得数据即为图1中的相对荧光单位(RFUs)。
试验实施例3
本发明中,所述苯并呋喃及Coumestans衍生物以结核杆菌pks13基因片段编码的聚酮合酶为作用靶点,本试验用于对pks13靶点的确认。
本试验采用全基因测序的方法,选取了化合物S7、S79、S84,对上述化合物引起基因突变的结核杆菌进行基因测序(见表6和表7)。
由表6和表7可知,结核杆菌的9个耐药突变体在四个位置上发生了突变(Rv1765c、Rv2015c、Rv3800c、Rv3921c),但6个仅在pks13基因位点发生了突变(A1667V、D1644G、N1640K、N1640S),由此可见,本发明苯并呋喃及Coumestans衍生物以结核杆菌pks13基因片段编码的聚酮合酶为作用靶点。
试验实施例4
本发明中,所述Coumestans衍生物S79和S84对人类细胞MRC-5cells、HFL-1cells、QSG-7701cells、HEK-293cells毒性的测试。
由表8可知,选取化合物S79和化合物S84分别对人类细胞MRC-5cells、HFL-1cells、QSG-7701cells、HEK-293cells进行细胞毒性检测发现,化合物79的IC50值>50μg/mL,说明化合物79对人类细胞没有毒性。化合物84对HFL-1cells、QSG-7701cells的IC50值分别为50.2±5.3和38.8±2.6,对MRC-5cells、HEK-293cells的IC50值>50μg/mL,说明化合物84对人类这四种细胞基本没有毒性。
本发明中,所述Coumestans衍生物S132、S57、S7、S79、S84、S81、S80、S82、S77对Vero细胞(非洲绿猴肾细胞)细胞毒和活性的对比检测(见表9)。SI值为IC50(Vero)/MIC(Mtb)的比值,S132、S57、S7、S79、S84、S81、S80、S82化合物SI值范围为8–32,但是S77化合物IC50和MIC是相等的。
试验实施例5
本发明中,所述Coumestans衍生物S132、S79、S84对人肝微粒体稳定性的测试(见表10)。
本发明提供的系列化合物对结核杆菌H37Rv MIC90测试的数据如下表5所示:
表5
由表5可知,通过对先导化合物的探究,构效关系的改造本发明的化合物对结核杆菌表现出了很好的活性,其中S79、S95、S94、S97化合物对结核杆菌H37Rv的MIC90达到0.0625‐0.125μg/mL,表现出了优异抗结核活性,部分化合物对结核杆菌H37Rv的MIC90值为0.5‐16μg/mL,但也有一些化合物丧失了对结核杆菌的活性MIC90≥64μg/mL(见表5),总之,本发明部分化合物表现出了优异的抗结核活性,有望发展成为新一代的抗结核药物。
本发明提供的部分化合物血清抑制滴定实验的相对荧光强度数据,如图1、2所示。其中,图1显示S7化合物在动物体内活性消失,S79和S84化合物在动物体内显示有很好的活性,表现出了较高的生物利用度(其中异烟肼为阳性化合物作对照)。图2中S132化合物无论是腹腔给药还是口服在动物体内都没有活性。
其中,图2所涉及的化合物S132结构表示如下:
表6
表7
表8
表9
a SI=IC50(Vero cells)/MIC(H37Rv)
表10
表10表示的是S132、S79、S84、Testosterone、Diclofenac、Propafenone对人肝微粒体稳定性数据,其中Testosterone、Diclofenac、Propafenone三个药物作为S132、S79、S84的对照。
本发明的保护内容不局限于以上实施例。在不背离发明构思的精神和范围下,本领域技术人员能够想到的变化和优点都被包括在本发明中,并且以所附的权利要求书为保护范围。
Claims (9)
4.一种药物组合物,其特征在于,所述药物组合物包括如权利要求1~3之任一项所述的苯并呋喃及香豆素类衍生物或其药学上可接受的盐,以及药学上可接受的载体。
5.如权利要求1~3之任一项所述的苯并呋喃及香豆素类衍生物或如权利要求4所述的药物组合物在制备结核分枝杆菌细胞壁合成抑制剂中的应用。
6.如权利要求1~3之任一项所述的苯并呋喃及香豆素类衍生物或如权利要求4所述的药物组合物在制备治疗与pks13基因片段编码的聚酮合酶作为靶点有关的疾病的药物中的应用。
7.如权利要求1~3之任一项所述的苯并呋喃及香豆素类衍生物或如权利要求4所述的药物组合物在制备预防和/或治疗肺结核疾病的药物中的应用。
8.如权利要求1~3之任一项所述的苯并呋喃及香豆素类衍生物或如权利要求4所述的药物组合物在制备治疗耐多药性肺结核疾病的药物中的应用。
9.如权利要求1~3之任一项所述的苯并呋喃及香豆素类衍生物或如权利要求4所述的药物组合物在制备抑制结核分枝杆菌的生长和繁殖的药物中的应用。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711387365.4A CN109942523B (zh) | 2017-12-20 | 2017-12-20 | 一类苯并呋喃及苯并呋喃香豆素衍生物及其制备方法和应用 |
PCT/CN2018/121968 WO2019120210A1 (zh) | 2017-12-20 | 2018-12-19 | 一类苯并呋喃及Coumestans衍生物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711387365.4A CN109942523B (zh) | 2017-12-20 | 2017-12-20 | 一类苯并呋喃及苯并呋喃香豆素衍生物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109942523A CN109942523A (zh) | 2019-06-28 |
CN109942523B true CN109942523B (zh) | 2023-06-09 |
Family
ID=66994436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711387365.4A Active CN109942523B (zh) | 2017-12-20 | 2017-12-20 | 一类苯并呋喃及苯并呋喃香豆素衍生物及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN109942523B (zh) |
WO (1) | WO2019120210A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111440190B (zh) * | 2020-05-18 | 2021-08-24 | 诸暨市人民医院 | 一种细菌抑制剂香豆素[3,4]并苯并噻吩类化合物的制备方法 |
CN112745284B (zh) * | 2020-12-28 | 2022-04-26 | 四川大学华西医院 | 一种天然查尔酮衍生物及其制备方法和用途 |
CN112979732B (zh) * | 2021-04-01 | 2022-09-09 | 清华大学 | 呋喃香豆素类化合物及其在结核分枝杆菌检测中的用途 |
CN114957232B (zh) * | 2021-05-28 | 2023-06-30 | 四川大学 | 一种苯并二氢恶嗪类化合物及其制备方法和抗结核的用途 |
CN113698375A (zh) * | 2021-09-23 | 2021-11-26 | 八叶草健康产业研究院(厦门)有限公司 | 一种4-环己亚胺甲基取代苯并呋喃衍生物的合成方法 |
CN114456136B (zh) * | 2022-01-27 | 2024-06-07 | 广西中医药大学 | 双靶点非甾体抗炎化合物及其制备方法与用途 |
CN114591215B (zh) * | 2022-03-09 | 2023-12-01 | 华东师范大学 | N-取代吲哚化合物及其在治疗结核病中的应用 |
CN118146234A (zh) * | 2022-11-30 | 2024-06-07 | 浙江我武翼方药业有限公司 | 6,5,7,6-四环衍生物、其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2269951A1 (en) * | 1974-05-07 | 1975-12-05 | Delalande Sa | 2H,4H-furo(2',3'-5-6)benzo(1,2-e)-1,3-oxazines - with analgesic, antiinflammatory cardiac analeptic, hypo- or hyper-tensive, and or spasmolytic activity |
CN104829569A (zh) * | 2015-05-12 | 2015-08-12 | 广州中医药大学 | 一种2-苯基-苯骈五元杂环类化合物及其衍生物的应用 |
WO2016112036A1 (en) * | 2015-01-05 | 2016-07-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Myc g-quadruplex stabilizing small molecules and their use |
WO2016172498A1 (en) * | 2015-04-22 | 2016-10-27 | The Texas A&M University System | Substituted benzofuran derivatives as novel antimycobacterial agents |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011507910A (ja) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
-
2017
- 2017-12-20 CN CN201711387365.4A patent/CN109942523B/zh active Active
-
2018
- 2018-12-19 WO PCT/CN2018/121968 patent/WO2019120210A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2269951A1 (en) * | 1974-05-07 | 1975-12-05 | Delalande Sa | 2H,4H-furo(2',3'-5-6)benzo(1,2-e)-1,3-oxazines - with analgesic, antiinflammatory cardiac analeptic, hypo- or hyper-tensive, and or spasmolytic activity |
WO2016112036A1 (en) * | 2015-01-05 | 2016-07-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Myc g-quadruplex stabilizing small molecules and their use |
WO2016172498A1 (en) * | 2015-04-22 | 2016-10-27 | The Texas A&M University System | Substituted benzofuran derivatives as novel antimycobacterial agents |
CN104829569A (zh) * | 2015-05-12 | 2015-08-12 | 广州中医药大学 | 一种2-苯基-苯骈五元杂环类化合物及其衍生物的应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2019120210A1 (zh) | 2019-06-27 |
CN109942523A (zh) | 2019-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109942523B (zh) | 一类苯并呋喃及苯并呋喃香豆素衍生物及其制备方法和应用 | |
CN113544128B (zh) | Kras-g12c抑制剂 | |
JP3992666B2 (ja) | カルボン酸誘導体 | |
EP0481676B1 (en) | Hydroxyquinolone derivatives | |
CN102803260B (zh) | 被取代的多环性氨基甲酰基吡啶酮衍生物 | |
CN110291065B (zh) | 一种新的异二氢吲哚衍生物、其药物组合物及应用 | |
JP6606278B2 (ja) | 2−アリールアミノピリジン、ピリミジン又はトリアジン誘導体及びその製造方法と使用 | |
KR100340372B1 (ko) | 치환된 3-(아미노알킬아미노)-1,2-벤즈이속사졸, 이의 제조방법 및 이를 포함하는 약제학적 조성물 | |
JP7294681B2 (ja) | カリウムチャネル調節剤としてのp-ジアミノベンゼン誘導体、その製造方法およびその医薬における使用 | |
CN110041253B (zh) | 吡啶类n-氧化衍生物及其制备方法和应用 | |
EP3027597A1 (en) | 1,7-naphthyridine derivatives | |
JPH0367071B2 (zh) | ||
AU639337B2 (en) | Dioxo-tetrahydroquinoline derivatives | |
ES2770676T3 (es) | Moduladores de quinolina enlazados a metileno de ROR-gamma-T | |
CN108689937B (zh) | 吲唑类化合物及其在制备ido抑制剂类药物上的用途 | |
CN104364240B (zh) | 一种用于预防或治疗分支杆菌疾病的药物 | |
CN111741946B (zh) | 吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用 | |
AU2003295171A1 (en) | Benzoxazocines and their use as monoamine-reuptake inhibitors | |
Yamato et al. | Synthesis and Antitumor Activity of Fused Quinoline Derivatives. II. Novel 4-and 7-Hydroxyindolo-[3, 2-b] quinolines | |
TWI525091B (zh) | 吡咯並喹啉基-吡咯啶-2,5-二酮組成物類及製備和使用彼等之方法 | |
HU187305B (en) | Process for producing condensed as-triazine derivatives | |
JP3907220B2 (ja) | 複素環含有化合物 | |
CN115466259B (zh) | 一种kras g12c抑制剂索托拉西布的制备方法 | |
CN115003673B (zh) | 一种二氢嘧啶类化合物、其制备方法及应用 | |
CN112004790A (zh) | 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |